US20050260758A1 - High efficiency peptide production in plant cells - Google Patents
High efficiency peptide production in plant cells Download PDFInfo
- Publication number
- US20050260758A1 US20050260758A1 US11/069,601 US6960105A US2005260758A1 US 20050260758 A1 US20050260758 A1 US 20050260758A1 US 6960105 A US6960105 A US 6960105A US 2005260758 A1 US2005260758 A1 US 2005260758A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- plant cell
- virus
- nucleic acid
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 485
- 238000004519 manufacturing process Methods 0.000 title abstract description 48
- 230000003612 virological effect Effects 0.000 claims abstract description 130
- 230000004927 fusion Effects 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 76
- 208000015181 infectious disease Diseases 0.000 claims abstract description 48
- 230000008569 process Effects 0.000 claims abstract description 47
- 230000002458 infectious effect Effects 0.000 claims abstract description 41
- 238000001727 in vivo Methods 0.000 claims abstract description 23
- 241000196324 Embryophyta Species 0.000 claims description 256
- 241000700605 Viruses Species 0.000 claims description 179
- 150000007523 nucleic acids Chemical class 0.000 claims description 121
- 102000039446 nucleic acids Human genes 0.000 claims description 100
- 108020004707 nucleic acids Proteins 0.000 claims description 100
- 230000014509 gene expression Effects 0.000 claims description 94
- 239000002245 particle Substances 0.000 claims description 80
- 230000000890 antigenic effect Effects 0.000 claims description 49
- 240000007594 Oryza sativa Species 0.000 claims description 37
- 235000007164 Oryza sativa Nutrition 0.000 claims description 37
- 244000061176 Nicotiana tabacum Species 0.000 claims description 34
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 34
- 108090000565 Capsid Proteins Proteins 0.000 claims description 30
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 28
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 11
- 108010067390 Viral Proteins Proteins 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 10
- 241000724328 Alfalfa mosaic virus Species 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 241000724254 Cowpea chlorotic mottle virus Species 0.000 claims description 7
- 241000723655 Cowpea mosaic virus Species 0.000 claims description 7
- 241000193738 Bacillus anthracis Species 0.000 claims description 5
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 5
- 241000209510 Liliopsida Species 0.000 claims description 4
- 229940065181 bacillus anthracis Drugs 0.000 claims description 4
- 241001233957 eudicotyledons Species 0.000 claims description 4
- 210000000234 capsid Anatomy 0.000 abstract description 192
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 147
- 239000013612 plasmid Substances 0.000 abstract description 39
- 102000037865 fusion proteins Human genes 0.000 abstract description 25
- 108020001507 fusion proteins Proteins 0.000 abstract description 25
- 238000004114 suspension culture Methods 0.000 abstract description 10
- 230000001976 improved effect Effects 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 269
- 108090000623 proteins and genes Proteins 0.000 description 90
- 102000004169 proteins and genes Human genes 0.000 description 75
- 235000018102 proteins Nutrition 0.000 description 73
- 101710132601 Capsid protein Proteins 0.000 description 55
- 101710094648 Coat protein Proteins 0.000 description 55
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 55
- 101710125418 Major capsid protein Proteins 0.000 description 55
- 101710141454 Nucleoprotein Proteins 0.000 description 55
- 101710083689 Probable capsid protein Proteins 0.000 description 55
- 150000001413 amino acids Chemical class 0.000 description 53
- 101000984489 Cowpea chlorotic mottle virus Capsid protein Proteins 0.000 description 50
- 101150023114 RNA1 gene Proteins 0.000 description 45
- 101100191561 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP3 gene Proteins 0.000 description 45
- 101150084101 RNA2 gene Proteins 0.000 description 44
- 101100353432 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP2 gene Proteins 0.000 description 44
- 239000013598 vector Substances 0.000 description 33
- 239000000047 product Substances 0.000 description 31
- 235000009566 rice Nutrition 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 230000009466 transformation Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 230000009261 transgenic effect Effects 0.000 description 20
- 239000000872 buffer Substances 0.000 description 18
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 230000001717 pathogenic effect Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000003053 toxin Substances 0.000 description 14
- 231100000765 toxin Toxicity 0.000 description 14
- 108700012359 toxins Proteins 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 13
- 239000000178 monomer Substances 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 241000894007 species Species 0.000 description 12
- 241000219977 Vigna Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 230000010354 integration Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 241000709992 Potato virus X Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 101710194807 Protective antigen Proteins 0.000 description 9
- -1 e.g.: amylins Substances 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 8
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000013256 coordination polymer Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 238000001742 protein purification Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001533462 Bromoviridae Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000961587 Secoviridae Species 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 241000723873 Tobacco mosaic virus Species 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 238000005462 in vivo assay Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000003488 releasing hormone Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000010415 tropism Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 241001515826 Cassava vein mosaic virus Species 0.000 description 5
- 241000701489 Cauliflower mosaic virus Species 0.000 description 5
- 241001515849 Satellite Viruses Species 0.000 description 5
- 241000710119 Sobemovirus Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108091036066 Three prime untranslated region Proteins 0.000 description 4
- 241001533336 Tombusviridae Species 0.000 description 4
- 102400000757 Ubiquitin Human genes 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000010726 Vigna sinensis Nutrition 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001524 infective effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 210000002706 plastid Anatomy 0.000 description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000004153 renaturation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241001115395 Caulimoviridae Species 0.000 description 3
- 241000702463 Geminiviridae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- 241000219843 Pisum Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000726445 Viroids Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000002599 biostatic effect Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229910010271 silicon carbide Inorganic materials 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 2
- 241000219193 Brassicaceae Species 0.000 description 2
- 241000724268 Bromovirus Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241001533413 Deltavirus Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000253097 Luteoviridae Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 241001336717 Nanoviridae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000723741 Nodaviridae Species 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241001112506 Ourmiavirus Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000710936 Partitiviridae Species 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 241001492409 Retro-transcribing viruses Species 0.000 description 2
- 101100084449 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP4 gene Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241001250139 Tobacco necrosis satellite virus-like Species 0.000 description 2
- 241001059845 Tymoviridae Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 102000018568 alpha-Defensin Human genes 0.000 description 2
- 108050007802 alpha-defensin Proteins 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940080469 phosphocellulose Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001814 protein method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012807 shake-flask culturing Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical class [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 2
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 125000003345 AMP group Chemical group 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 108010079677 Agatoxins Proteins 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 1
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- AUFACLFHBAGZEN-ZLUOBGJFSA-N Ala-Ser-Cys Chemical compound N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O AUFACLFHBAGZEN-ZLUOBGJFSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- ZXKNLCPUNZPFGY-LEWSCRJBSA-N Ala-Tyr-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N ZXKNLCPUNZPFGY-LEWSCRJBSA-N 0.000 description 1
- XSLGWYYNOSUMRM-ZKWXMUAHSA-N Ala-Val-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XSLGWYYNOSUMRM-ZKWXMUAHSA-N 0.000 description 1
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 241000724330 Alfamovirus Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 241000219318 Amaranthus Species 0.000 description 1
- 231100000729 Amatoxin Toxicity 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 101710120040 Antifungal peptide Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 108700040321 Arabidopsis SPP Proteins 0.000 description 1
- 108010045149 Archaeal Proteins Proteins 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
- MAISCYVJLBBRNU-DCAQKATOSA-N Arg-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N MAISCYVJLBBRNU-DCAQKATOSA-N 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- LRPZJPMQGKGHSG-XGEHTFHBSA-N Arg-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)O LRPZJPMQGKGHSG-XGEHTFHBSA-N 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- XSGBIBGAMKTHMY-WHFBIAKZSA-N Asn-Asp-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O XSGBIBGAMKTHMY-WHFBIAKZSA-N 0.000 description 1
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 1
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 1
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 1
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- ZQFRDAZBTSFGGW-SRVKXCTJSA-N Asp-Ser-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZQFRDAZBTSFGGW-SRVKXCTJSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- YWWJKULNWGRYAS-UOVSKDHASA-N CMP-3-deoxy-beta-D-manno-octulosonic acid Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)O[C@@]2(O[C@@H]([C@H](O)[C@H](O)C2)[C@H](O)CO)C(O)=O)O1 YWWJKULNWGRYAS-UOVSKDHASA-N 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 241000520666 Carmotetraviridae Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010004539 Chalcone isomerase Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- 108091092236 Chimeric RNA Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 101710089098 Cholecystokinins Proteins 0.000 description 1
- 241000219109 Citrullus Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 241000702669 Coltivirus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000723607 Comovirus Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 229930185483 Cortistatin Natural products 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 244000024469 Cucumis prophetarum Species 0.000 description 1
- 235000010071 Cucumis prophetarum Nutrition 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000208175 Daucus Species 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 241000615461 Dicistroviridae Species 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 235000003550 Dracunculus Nutrition 0.000 description 1
- 241000316827 Dracunculus <angiosperm> Species 0.000 description 1
- 241001319090 Dracunculus medinensis Species 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- 235000001942 Elaeis Nutrition 0.000 description 1
- 241000512897 Elaeis Species 0.000 description 1
- 241000243234 Encephalitozoon Species 0.000 description 1
- 241000596569 Encephalitozoon intestinalis Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241001126836 Enterocytozoon Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 241001312526 Euphyllophyta Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- KWUSGAIFNHQCBY-DCAQKATOSA-N Gln-Arg-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O KWUSGAIFNHQCBY-DCAQKATOSA-N 0.000 description 1
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 1
- STHSGOZLFLFGSS-SUSMZKCASA-N Gln-Thr-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STHSGOZLFLFGSS-SUSMZKCASA-N 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102100024977 Glutamine-tRNA ligase Human genes 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101710115777 Glycine-rich cell wall structural protein 2 Proteins 0.000 description 1
- 101710168683 Glycine-rich protein 1 Proteins 0.000 description 1
- 101710170453 Glycoprotein 55 Proteins 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- OQDLKDUVMTUPPG-AVGNSLFASA-N His-Leu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OQDLKDUVMTUPPG-AVGNSLFASA-N 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 241000209219 Hordeum Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241000724277 Ilarvirus Species 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 1
- OWSWUWDMSNXTNE-GMOBBJLQSA-N Ile-Pro-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N OWSWUWDMSNXTNE-GMOBBJLQSA-N 0.000 description 1
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 1
- GVEODXUBBFDBPW-MGHWNKPDSA-N Ile-Tyr-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 GVEODXUBBFDBPW-MGHWNKPDSA-N 0.000 description 1
- JCGMFFQQHJQASB-PYJNHQTQSA-N Ile-Val-His Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O JCGMFFQQHJQASB-PYJNHQTQSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 235000021506 Ipomoea Nutrition 0.000 description 1
- 241000207783 Ipomoea Species 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 241000567229 Isospora Species 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000219739 Lens Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- ARNIBBOXIAWUOP-MGHWNKPDSA-N Leu-Tyr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ARNIBBOXIAWUOP-MGHWNKPDSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 241000714210 Leviviridae Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 description 1
- YRWCPXOFBKTCFY-NUTKFTJISA-N Lys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N YRWCPXOFBKTCFY-NUTKFTJISA-N 0.000 description 1
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 1
- BIWVMACFGZFIEB-VFAJRCTISA-N Lys-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCCCN)N)O BIWVMACFGZFIEB-VFAJRCTISA-N 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- DBMLDOWSVHMQQN-XGEHTFHBSA-N Met-Ser-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DBMLDOWSVHMQQN-XGEHTFHBSA-N 0.000 description 1
- 241001295810 Microsporidium Species 0.000 description 1
- 241000702318 Microviridae Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 241000234295 Musa Species 0.000 description 1
- 241000234615 Musaceae Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 241000224436 Naegleria Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000723638 Nepovirus Species 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 241000207746 Nicotiana benthamiana Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- CKMNPXWFAZLBNK-QOFYEYOWSA-N OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O Chemical compound OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O CKMNPXWFAZLBNK-QOFYEYOWSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000243981 Onchocerca Species 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000209117 Panicum Species 0.000 description 1
- 235000006443 Panicum miliaceum subsp. miliaceum Nutrition 0.000 description 1
- 235000009037 Panicum miliaceum subsp. ruderale Nutrition 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 240000004370 Pastinaca sativa Species 0.000 description 1
- 101710091688 Patatin Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- 241000219833 Phaseolus Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- HHOOEUSPFGPZFP-QWRGUYRKSA-N Phe-Asn-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HHOOEUSPFGPZFP-QWRGUYRKSA-N 0.000 description 1
- MFQXSDWKUXTOPZ-DZKIICNBSA-N Phe-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N MFQXSDWKUXTOPZ-DZKIICNBSA-N 0.000 description 1
- GYEPCBNTTRORKW-PCBIJLKTSA-N Phe-Ile-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O GYEPCBNTTRORKW-PCBIJLKTSA-N 0.000 description 1
- PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- OQSGBXGNAFQGGS-CYDGBPFRSA-N Pro-Val-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OQSGBXGNAFQGGS-CYDGBPFRSA-N 0.000 description 1
- 108010007838 Prolactin Release-Inhibiting Factors Proteins 0.000 description 1
- 102000009087 Prolactin-Releasing Hormone Human genes 0.000 description 1
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 241001515850 Satellite Nucleic Acids Species 0.000 description 1
- 108010036758 SchistoFLRFamide Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- SWIQQMYVHIXPEK-FXQIFTODSA-N Ser-Cys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O SWIQQMYVHIXPEK-FXQIFTODSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002560 Solanum lycopersicum Nutrition 0.000 description 1
- 241001291298 Solanum schenckii Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000592344 Spermatophyta Species 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108700034501 Staphylococcus aureus auR Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 108010043934 Sucrose synthase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 241000701521 Tectiviridae Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000005488 Thioesterase Human genes 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 1
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 1
- WYLAVUAWOUVUCA-XVSYOHENSA-N Thr-Phe-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WYLAVUAWOUVUCA-XVSYOHENSA-N 0.000 description 1
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 description 1
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 241000724291 Tobacco streak virus Species 0.000 description 1
- 241000710141 Tombusvirus Species 0.000 description 1
- 241000710915 Totiviridae Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000592342 Tracheophyta Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 241001489145 Trichuris trichiura Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- OEVJGIHPQOXYFE-SRVKXCTJSA-N Tyr-Asn-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O OEVJGIHPQOXYFE-SRVKXCTJSA-N 0.000 description 1
- QKXAEWMHAAVVGS-KKUMJFAQSA-N Tyr-Pro-Glu Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O QKXAEWMHAAVVGS-KKUMJFAQSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 108010011107 Urotensins Proteins 0.000 description 1
- 102000026557 Urotensins Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- ZSZFTYVFQLUWBF-QXEWZRGKSA-N Val-Asp-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N ZSZFTYVFQLUWBF-QXEWZRGKSA-N 0.000 description 1
- YDPFWRVQHFWBKI-GVXVVHGQSA-N Val-Glu-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YDPFWRVQHFWBKI-GVXVVHGQSA-N 0.000 description 1
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- VVIZITNVZUAEMI-DLOVCJGASA-N Val-Val-Gln Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(N)=O VVIZITNVZUAEMI-DLOVCJGASA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000219873 Vicia Species 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229930190815 caerulein Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229930002869 chlorophyll b Natural products 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- OKGNKPYIPKMGLR-ZPCKCTIPSA-N gastrins Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 OKGNKPYIPKMGLR-ZPCKCTIPSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 108010051239 glutaminyl-tRNA synthetase Proteins 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 101150028555 ksi gene Proteins 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 108010083942 mannopine synthase Proteins 0.000 description 1
- 108010077372 mast cell degranulating peptide Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000010070 molecular adhesion Effects 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- JLTCWSBVQSZVLT-UHFFFAOYSA-N n-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxa Chemical compound NCCCCC(C(=O)NCC(N)=O)NC(=O)C1CCCN1C(=O)C1NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSC1.N1C(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 JLTCWSBVQSZVLT-UHFFFAOYSA-N 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 108010077051 polycysteine Proteins 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 101150028692 rcp gene Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 241001147420 ssDNA viruses Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 108020002982 thioesterase Proteins 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000000780 urotensin Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/14011—Bromoviridae
- C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/14011—Bromoviridae
- C12N2770/14023—Virus like particles [VLP]
Definitions
- the present invention provides an improved process for the production of recombinant peptides.
- the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures.
- the invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production.
- Bacterial, yeast, plant, insect, and mammalian cell expression systems are currently used to produce recombinant peptides, with varying degrees of success.
- One goal in creating expression systems for the production of heterologous peptides is to provide broad based, flexible, efficient, economic, and practical platforms and processes that can be utilized in commercial, therapeutic, and vaccine applications.
- bacteria are the most widely used expression system for the production of recombinant peptides because of their potential to produce abundant quantities of recombinant peptides.
- Bacteria generally do not glycosylate, acetylate, acylate, phosphorylate, or gamma-carboxylate eukaryotic proteins, and, therefore, are limited in their capacities to produce, in vivo, certain types of heterologous eukaryotic peptides that require post-translational modifications. Additional steps modifying the bacterially produced eukaryotic peptides are likely to increase the time and reduce the overall yield of peptide production, diluting many of the advantages of the bacterial host expression system. Therefore, alternative non-bacterial expression systems have been utilized to overcome the inherent limitations of bacterial expression systems.
- Whole plants offer the advantages of being relatively inexpensive to grow in vast quantities, with the potential for a great yield of the desired recombinant protein from the large biomass of the harvested transgenic or viral infected plants. As a result, whole plants have been developed as expression systems for commercial production of biopharmaceutical proteins intended for human or veterinary administration.
- One approach for improving peptide production in host cell expression systems is to make use of the properties of infectious recombinant viruses to produce recombinant peptides of interest.
- infectious viruses in plant host systems is particularly well known. See, for example, Porta & Lomonossoff, (2002) “Viruses as vectors for the expression of foreign sequences in plants,” Biotechnology and Genetic Enginering Reviews 19: 245-291.
- encapsidated viruses include a protein coat or “capsid” that is assembled to contain the viral nucleic acid.
- Many viruses have capsids that can be “self-assembled” from the individually expressed capsids, both within the cell the capsid is expressed in (“in vivo assembly”), and outside of the cell after isolation and purification (“in vitro assembly”).
- capsids are modified to contain a target recombinant peptide, generating a recombinant viral capsid-peptide fusion. The fusion peptide can then be expressed in a cell, and, ideally, assembled in vivo to form recombinant viral or virus-like particles.
- U.S. Pat. No. 5,874,087 to Lomonossoff & Johnson describes production of infectious plant viruses, in plant cells or whole plants, wherein the viral capsids are engineered to contain a biologically active peptide, such as a hormone, growth factor, or antigenic peptide.
- a virus selected from the genera Comovirus, Tombusvirus, Sobemovirus, and Nepovirus is engineered to contain the exogenous peptide encoding sequence and the entire engineered genome of the virus is expressed to produce the recombinant virus.
- the specification stresses that multiplication of the modified virus is a central part of the invention.
- U.S. Pat. No. 6,232,099 to Chapman et al. describes the use of infective, rod-shaped viruses to produce foreign proteins connected to viral capsid subunits in whole plants.
- Rod-shaped viruses also classified as helical viruses, such as potato virus X (PVX) have recombinant peptides of interest inserted into the genome of the virus to create recombinant viral capsid-peptide fusions.
- the recombinant, infective virus is then used to infect a plant cell of a whole plant, wherein, the virus actively replicates in the plant cell and further infects other cells, ultimately infecting the entire host plant.
- the recombinant viral capsid-peptide fusion is purified from the plant.
- Chapman et al. also teaches that a limited insertion size is tolerated by icosahedral viruses. Chapman et al. cite WO 92/18618, which limits the size of the recombinant peptide in an icosahedral virus for expression in a plant host cell to 26 amino acids in length, in supporting his assertion. Chapman et al. theorize that a larger peptide present in the internal insertion site in the capsid of icosahedral viruses may result in disruption of the geometry of the protein and/or its ability to successfully interact with other capsids leading to failure of the chimeric virus to assemble.
- U.S. Pat. No. 6,042,832 to Koprowski et al. describes fusion capsid proteins comprising a plant virus capsid protein fused to an antigenic polypeptide. The resultant particles are produced in whole plants.
- the present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture.
- the viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles.
- the present invention does not require the utilization of an infective viral agent; rather, non-infectious nucleic acid encoding a capsid-heterologous peptide fusion product is stably inserted into the genome of a plant cell, which can be cultured in a fermentation process to produce the peptide of interest. Such a process results in a less variable, and more stable host system for the expression of capsid fusion proteins containing heterologous peptides.
- infectious viruses containing capsid-heterologous peptide fusion proteins utilized to express heterologous peptides of interest in whole plants exhibit genetic instability in the whole plant that results in mutations in the recombinant capsid protein nucleic acid, and the expressed mutant capsid either cannot assemble into virus particles or contains a mutated target peptide.
- the present invention provides increased stability of the resultant heterologous peptide, with the additional benefits of precise control over growth conditions, batch to batch consistency, a high level of containment, and the ability to produce recombinant proteins in compliance with good manufacturing practices.
- the capsid-fusion protein products can form virus like particles within the cell.
- the virus like particle may result in the improved efficiency of achieving a high purity of the recovered peptide.
- the virus like particles produced in the cell typically are not capable of infecting the plant cell.
- the viral capsid sequence can be derived from both trophic and non-trophic viruses, wherein trophism is determined by the specific plant cell utilized as the expression host.
- the viral capsid protein is derived from a virus that exhibits a native or natural trophism towards the plant cell utilized to express the fusion product.
- the viral capsid protein is derived from a virus that does not exhibit a native or natural trophism towards the plant cell utilized to express the fusion product.
- the cell does not include artificially introduced viral proteins other than the desired capsid protein sequences utilized to produce the fusion product.
- the cell includes artificially introduced viral proteins or nucleic acids other than the desired capsid protein sequences utilized to produce the fusion product, wherein the additional viral proteins or nucleic acids do not confer infectivity to the nucleic acid sequences.
- the viral capsid is derived from a virus with a tropism to a different family of organisms than the plant cell expression host.
- the viral capsid is derived from a virus with a tropism to a different genus of organisms than the plant cell expression host.
- the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell utilized to express the fusion product.
- the capsid is derived from a rod shaped plant virus.
- the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus and Potato Virus X (PVX).
- the capsid protein is derived from an icosahedral virus.
- the capsid is derived from a plant icosahedral virus.
- the icosahedral capsid is derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
- the present invention also provides plant cells that include a non-infectious nucleic acid construct containing an expression cassette encoding for a fusion protein of a virus capsid and a recombinant peptide.
- the fusion peptide of the virus capsid and recombinant peptide is operably linked to a promoter and terminator that functions in plant cells.
- the nucleic acid is genomically integrated in the plant cell, wherein the integration results in the stable inheritance and expression of the nucleic acid encoding the capsid fusion protein from generation to generation.
- the capsid protein is derived from an icosahedral virus.
- the cell produces virus like particles or soluble cage structures.
- the plant cell is a Monocot or a Dicot. In a particular embodiment, the plant cell is Nicotiana tabacum . In an alternative embodiment, the plant cell is Oryza sativa .
- the recombinant peptide fused to the viral capsid protein is a therapeutic peptide useful for human or animal treatments. In one particular embodiment, the recombinant peptide is an antigenic peptide. In a particular embodiment, the antigenic peptide is a glycosylated antigenic peptide. In one embodiment, the plant cells or extracts containing capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal.
- the purified capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal.
- the heterologous peptide is an antimicrobial peptide.
- the recombinant peptide is a peptide that is toxic to the plant host cell when in free monomeric form.
- the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids in length.
- the recombinant peptide fused to the capsid contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In certain embodiments, the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid. In another embodiment, the individual monomers in the concatameric peptide are linked by cleavable linker regions. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the viral capsid.
- the recombinant peptide is inserted into at least one surface loop of an icosahedral viral capsid. In one embodiment, at least one monomer is inserted into more than one surface loops of a viral capsid protein. In still another embodiment, the recombinant peptide is inserted into at least one outer surface loop of the viral capsid. In an alternative embodiment, the recombinant peptide is inserted into at least one inner surface loop of the viral capsid.
- More than one loop of the virus like particle can be modified.
- the recombinant peptide is expressed on at least two surface loops of the virus-like particle.
- at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle.
- at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle.
- the recombinant peptides in the surface loops can have the same amino acid sequence.
- the amino acid sequence of the recombinant peptides in the surface loops differ.
- the cell includes at least one additional nucleic acid encoding either a wild-type capsid or different capsid-recombinant peptide fusion peptide, wherein the multiple capsids can be assembled in vivo to produce chimeric virus like particles.
- plant cells that include a fusion protein of a viral capsid and a recombinant peptide.
- the plant cell is a monocot.
- the plant cell is a dicot.
- the capsid-recombinant peptide fusion protein assembles in vivo to form a virus like particle.
- the plant cells containing the nucleic acid construct encoding the capsid protein-recombinant peptide fusion peptide is obtained by nuclear transformation. In one embodiment, the plant cell is obtained by plastid transformation. In still another embodiment, the plant cell is obtained by chloroplast transformation.
- the present invention further provides for non-infectious nucleic acid constructs containing an expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide.
- the expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide is operably linked to a promoter and terminator.
- the capsid is derived from a plant virus.
- the capsid is derived from an icosahedral plant virus.
- the capsid is an icosahedral viral capsid derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
- the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus capsid.
- the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cell. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cells, and at least one terminator that functions in plant cells. In one embodiment, a nucleic acid sequence encoding a selection marker operably linked to a promoter and a terminator sequence is included in the nucleic acid construct. In an alternative embodiment, a selection marker operably linked to a promoter and a termination sequence is provided on a separate nucleic acid construct. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences derived from the 3′ untranslated region (3′ UTR) of the viral RNA.
- 3′ UTR 3′ untranslated region
- the nucleic acid construct includes at least one encapsidation signal derived from the viral RNA.
- the non-infectious nucleic acid construct includes additional nucleic acid sequences derived from the viral RNA, wherein the additional sequences do not confer infectivity to the viral nucleic acids.
- the present invention provides a process for producing a recombinant peptide including:
- the process further includes: e) cleaving the fusion product to separate the recombinant peptide from the viral capsid protein. In still another embodiment, the process further provides: f) following step (e), isolating the recombinant peptide. See, for example, FIG. 1 .
- the plant cell is selected from the group consisting of Oryza sativa and Nicotiana tabacum.
- the nucleic acid encoding a recombinant peptide and a viral capsid protein is operably linked to a promoter sequence and a terminator sequence.
- the process includes co-expressing another nucleic acid encoding a wild-type capsid or a different capsid-recombinant peptide fusion peptide, wherein the capsids are assembled in vivo to produce chimeric virus like particles.
- an expression system for the production of recombinant peptides including:
- the nucleic acid encoding the fusion peptide can be operably linked to a promoter sequence and a terminator sequence. When expressed the fusion peptide can assemble into virus like particles within the cell.
- the promoter is a plant promoter.
- FIG. 1 illustrates a scheme for production of peptide monomers in Virus-Like Particles (VLP) in plant cells.
- a sequence encoding a desired target peptide (“I”) is inserted into a sequence encoding a viral coat protein (“CP”) constructing a gene encoding recombinant viral coat protein (“rCP”), which, as part of a vector, is transformed into the plant cell and expressed to form recombinant coat proteins (“rCP”).
- Optional cleavage sites (“*”) are also shown.
- a plant cell is transfected or transformed with a plant expression plasmid for with the rCP gene.
- rCP can assemble into VLPs in plant cells.
- FIG. 2 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNA1, RNA2, and one of the RNA3s transcribed from pDOW2124 (CCMV-RNA3-CP), pDOW2125 (CCMV-RNA3-CP63BamHI), pDOW2126 (CCMV-RNA3-CP102BamHI), pDOW2127 (CCMV-RNA3-CP114BamHI), pDOW2128 (CCMV-RNA3-CP129BamHI), and pDOW2129 (CCMV-RNA3-CP160BamHI).
- the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents Buffer only
- Lane 2 represents RNA1 and RNA2 only
- Lane 3 represents RNA1 and RNA2+wt RNA3 transcribed from pDOW2124
- Lane 4 represents RNA1 and RNA2+RNA3 transcribed from pDOW2125
- Lane 5 represents RNA1 and RNA2+RNA3 transcribed from pDOW2126
- Lane 6 represents RNA1 and RNA2+RNA3 transcribed from pDOW2127
- Lane 7 represents RNA1 and RNA2+RNA3 transcribed from pDOW2128
- Lane 8 represents RNA1 and RNA2+RNA3 transcribed from pDOW2129.
- FIG. 3 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNA1, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PA1, PA2, PA3, or PA4 at the position 63, 102, or 114.
- the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents a size marker
- Lane 2 represents Buffer only
- Lane 3 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 63
- Lane 4 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 63
- Lane 5 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 63
- Lane 6 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 63
- Lane 7 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 102
- Lane 8 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 102
- Lane 9 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 102
- Lane 10 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 102
- Lane 11 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP
- FIG. 4 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNA1, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PA1, PA2, PA3, or PA4 at the position 129 or 160.
- the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents a size marker
- Lane 2 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 129
- Lane 3 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 129
- Lane 4 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 129
- Lane 5 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 129
- Lane 6 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 160
- Lane 7 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 160
- Lane 8 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 160
- Lane 9 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 160
- Lane 10 represents RNA1+RNA2+wt RNA3
- Lane 11 represents Buffer only.
- FIG. 5 shows plasmid map of pDOW2160.
- FIG. 6 shows plasmid map of pDOW2161.
- FIG. 7 shows plasmid map of pDOW2162.
- FIG. 8 shows plasmid map of pDOW2163.
- FIG. 9 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163.
- the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents Buffer only
- Lane 2-6 represent RNA1+RNA2+wt RNA3 (control)
- Lane 7 represents pDOW2160
- Lane 8 represents pDOW2161
- Lane 9 represents pDOW2162
- Lane 10 represents pDOW2163.
- FIG. 10 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2169, pDOW2170, pDOW2171, and pDOW2172.
- the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents RNA1+RNA2+RNA3 (control)
- Lane 2 represents Buffer
- Lane 3 represents pDOW2169
- Lane 4 represents pDOW2170
- Lane 5 represents pDOW2171
- Lane 6 represents pDOW2172.
- FIG. 11 shows expression of chimeric CCMV CP in tobacco NT1 cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents Untransformed tobacco cells (negative control)
- Lane 2 represents Transgenic tobacco cells transformed with pDOW2160
- Lane 3 represents Transgenic tobacco cells transformed with pDOW2161
- Lane 4 represents Transgenic tobacco cells transformed with pDOW2162
- Lane 5 represents Transgenic tobacco cells transformed with pDOW2163.
- FIG. 12 shows expression of chimeric CCMV CP in rice cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents wt CCMV CP (positive control)
- Lane 2 represents Size ladder
- Lane 3 represents Non-transgenic rice cells (negative control)
- Lane 4 represents Transgenic rice cells transformed with pDOW2160
- Lane 5 represents wt CCMV CP (positive control)
- Lane 6 represents Size ladder
- Lane 7 represents Non-transgenic rice cells
- Lane 8 represents Transgenic rice cells transformed with pDOW2161
- Lane 9 represents wt CCMV CP (positive control)
- Lane 10 represents Size ladder
- Lane 11 represents Non-transgenic rice cells (negative control)
- Lane 12 represents Transgenic rice cells transformed with pDOW2162
- Lane 13 represents wt CCMV CP (positive control)
- Lane 14 represents Size ladder
- Lane 15 represents Non-transgenic rice cells (negative control)
- Lane 16 represents Transgenic rice cells transformed with pDOW2163.
- FIG. 13 shows detection of PCR products amplified from selected individual rice calli transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. 1.2% agarose gel stained with EtBr showing PCR products amplified from selected individual rice calli. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome.
- Lane 1 represents Rice calli 46-5
- Lane 2 represents Rice calli 46-11
- Lane 3 represents Rice calli 46-17
- Lane 4 represents Size Ladder
- Lane 5 represents Rice calli 47-6
- Lane 6 represents Rice calli 48-12
- Lane 7 represents Rice calli 48-18
- Lane 8 represents Rice calli 48-20
- Lane 9 represents Rice calli 49-11
- Lane 10 represents Rice calli 49-18
- Lane 11 represents Negative control (non-transgenic rice cells).
- FIG. 14 shows western blot analysis of chimeric CCMV VLPs purified from rice cells stably transformed with non-infectious plasmid pDOW2160 by PEG precipitation and ultra-filtration and detection of chimeric CP-PA1 fusion proteins in the purified VLP samples.
- the samples were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
- Lane 1 represents Size ladder
- Lane 2 represents Total cell lysate from rice suspension cells transgenic for CCMV CP-PA1 fusion
- Lane 3 represents First PEG supernatant
- Lane 4 represents First PEG pellet
- Lane 5 represents Second PEG pellet
- Lane 6 represents Second PEG supernatant.
- FIG. 15 shows diagram of production process of chimeric VLPs in plant suspension cells by fermentation.
- the present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture.
- the viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles.
- the present invention further provides plant cells and nucleic acid constructs for use in the process.
- the invention provides plant cells, capable of propagation in suspension plant cell cultures, with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide.
- the fusion peptide can be operably linked to a promoter sequence and a termination sequence.
- the expression in the plant cell of the fusion peptide produces virus like particles or soluble cage structures.
- the invention also provides nucleic acid constructs capable of integrating into the genome of the plant cell and encoding the fusion peptide of a viral capsid and a recombinant peptide, which can in one embodiment, be a therapeutic peptide useful for human and animal treatments.
- the invention also provides a process for producing a recombinant peptide in a suspension plant cell culture by providing: a nucleic acid capable of genomic integration in a plant cell containing an expression cassette encoding a fusion peptide of a recombinant peptide and a viral capsid operably linked to a promoter sequence and a termination sequence; expressing the nucleic acid in the plant cell in a suspension plant cell culture, wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and isolating the virus like particles.
- infectious means the ability of a virus particle to transfer its nucleic acid to a host or introduction of a viral nucleic acid into a host, wherein the viral nucleic acid is replicated, viral proteins are translated, and new viral particles capable of further transfer of nucleic acid to a host are assembled.
- non-infectious means the inability of a virus-derived nucleic acid to replicate in a host after introduction into a host, wherein the viral proteins are translated, and new virus like particles assembled that are not capable of initiating viral infection process in a host.
- peptide as used herein is not limited to any particular molecular weight, and can also include proteins or polypeptides.
- the present invention provides plant cells that include a non-infectious nucleic acid construct capable of genomic integration and encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence.
- the cells can be utilized in a process for producing recombinant peptides.
- the plant cells can be derived by transforming the native plant cell with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence, wherein the nucleic acid construct is stably integrated into the host cell's genome. Stable transformation depends on the integration of the foreign DNA into the genome.
- the foreign DNA can be integrated into the nuclear or plastid genome of the plant.
- the nucleic acid construct can be randomly inserted into the genome of the plant, or can be directed to a particular region of the genome through homologous recombination.
- the plant cell can be obtained by any means known in the art, including nuclear transformation, plastid transformation, and chloroplast transformation. See, for example, U.S. Pat. No. 6,218,145; EP 012345149; WO 0121782; U.S. Pat. No. 6,515,206; WO 99/10513; U.S. Pat. No. 5,693,507; WO 02055651; WO 0170939; U.S. Pat. No. 6,472,586; WO 02057466; U.S. Pat. No. 5,057,422; WO 0120974 Staub, J. M. and Maliga, P, (1992) “Long regions of homologous DNA are incorporated into the tobacco plastid genome by transformation,” Plant Cell 4: 39-45.
- the invention provides plant cells for use in a process for producing peptides by expression of the peptide fused to a viral capsid from a non-infectious plasmid stably integrated into the host genome.
- the expression can result in the formation of at least one virus like particle (VLP) in the cell.
- VLP virus like particle
- Viruses can be classified into those with helical symmetry or icosahedral symmetry.
- Generally recognized capsid morphologies include: icosahedral (including icosahedral proper, isometric, quasi-isometric, and geminate or “twinned”), polyhedral (including spherical, ovoid, and lemon-shaped), bacilliform (including rhabdo- or bullet-shaped, and fusiform or cigar-shaped), and helical (including rod, cylindrical, and filamentous); any of which may be tailed and/or may contain surface projections, such as spikes or knobs.
- the amino acid sequence of the capsid is selected from the capsids of viruses classified as having any morphology.
- the capsid is derived from a rod shaped virus.
- the capsid is derived from a rod shaped plant virus.
- the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus (TMV) and Potato Virus X (PVX).
- TMV consists of a single plus-sense genomic RNA (6.5 kb) encapsidated with a unique coat protein (17.5 kDa) which results in rod-shaped particles (300 nm).
- Potato Virus X are filamentous, non enveloped; usually flexuous viruses with a clear modal length of 515 nm and 13 nm wide (Brandes, 1964). The capsid structure forms a basic helix with a pitch of 3.4 nm (Varma et al., 1968).
- the capsid has an icosahedral morphology.
- the capsid amino acid sequence will be selected from the capsids of entities that are icosahedral proper.
- the capsid amino acid sequence will be selected from the capsids of icosahedral viruses.
- the capsid amino acid sequence will be selected from the capsids of icosahedral plant viruses.
- the viral capsid will be derived from an icosahedral virus not infectious to plants.
- the virus is a virus infectious to mammals.
- viral capsids of icosahedral viruses are composed of numerous protein sub-units arranged in icosahedral (cubic) symmetry.
- Native icosahedral capsids can be built up, for example, with 3 subunits forming each triangular face of a capsid, resulting in 60 subunits forming a complete capsid.
- Representative of this small viral structure is e.g. bacteriophage ⁇ X174.
- Many icosahedral virus capsids contain more than 60 subunits.
- Many capsids of icosahedral viruses contain an antiparallel, eight-stranded beta-barrel folding motif.
- the motif has a wedge-shaped block with four beta strands (designated BIDG) on one side and four (designated CHEF) on the other.
- BIDG beta strands
- CHEF CHEF
- Enveloped viruses can exit an infected cell without its total destruction by extrusion (budding) of the particle through the membrane, during which the particle becomes coated in a lipid envelope derived from the cell membrane (See, e.g.: A J Cann (ed.) (2001) Principles of Molecular Virology (Academic Press); A Granoff and R G Webster (eds.) (1999) Encyclopedia of Virology (Academic Press); D L D Caspar (1980) Biophys. J. 32:103; D L D Caspar and A Klug (1962) Cold Spring Harbor Symp. Quant. Biol. 27:1; J Grimes et al. (1988) Nature 395:470; J E Johnson (1996) Proc. Nat'l Acad. Sci. USA 93:27; and J Johnson and J Speir (1997) J. Mol. Biol. 269:665).
- Viral taxonomies recognize the following taxa of encapsidated-particle entities:
- the amino acid sequence of the capsid may be selected from the capsids of any members of any of these taxa.
- Amino acid sequences for capsids of the members of these taxa may be obtained from sources, including, but not limited to, e.g.: the on-line “Nucleotide” (Genbank), “Protein,” and “Structure” sections of the PubMed search facility offered by the NCBI at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi.
- the capsid amino acid sequence will be selected from taxa members that are specific for at least one of the following hosts: bacteria, fingi including yeasts, plants, protists including algae, invertebrate animals, vertebrate animals, and humans. In one embodiment, the capsid amino acid sequence will be selected from members of any one of the following taxa: Group I, Group II, Group III, Group IV, Group V, Group VII, Viroids, and Satellite Viruses. In one embodiment, the capsid amino acid sequence will be selected from members of any one of these seven taxa that are specific for at least one of the six above-described host types.
- the capsid amino acid sequence will be selected from members of any one of Group II, Group III, Group IV, Group VII, and Satellite Viruses; or from any one of Group II, Group IV, Group VII, and Satellite Viruses.
- the viral capsid is selected from Group IV or Group VII.
- the viral capsid sequence can be derived from a virus not tropic to the cell.
- the cell does not include viral proteins from the particular selected virus other than the desired icosahedral capsids.
- the viral capsid is derived from a virus with a tropism to a different family of organisms than the cell.
- the viral capsid is derived from a virus with a tropism to a different genus of organisms than the cell.
- the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell.
- the viral capsid is selected from a virus of Group IV.
- the viral capsid is selected from rod-shaped plant viruses. In a more particular embodiment, the viral capsid is selected from the group consisting of Tobacco Mosaic Virus and Potato Virus X.
- the viral capsid is selected form an icosahedral virus.
- the icosahedral virus can be selected from a member of any of the Papillomaviridae, Totiviridae, Dicistroviridae, Hepadnaviridae, Togaviridiae, Polyomaviridiae, Nodaviridae, Tectiviridae, Leviviridae, Microviridae, Sipoviridae, Nodaviridae, Picornoviridae, Parvoviridae, Calciviridae, Tetraviridae, and Satellite viruses.
- the sequence will be selected from members of any one of the taxa that are specific for at least one plant host.
- the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Bunyaviridae, Reoviridae, Rhabdoviridae, Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa.
- the icosahedral plant virus species is a plant-infectious virus species that is or is a member of any of the Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa.
- the icosahedral plant virus species is a plant infectious virus species that is or is a member of any of the Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae.
- the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae.
- the icosahedral plant virus species will be a plant-infectious virus species that is a member of the Comoviridae or Bromoviridae family.
- the viral capsid is derived from a Cowpea Mosaic Virus or a Cowpea Chlorotic Mottle Virus.
- the viral capsid is derived from a species of the Bromoviridae taxa.
- the capsid is derived from an Ilarvirus or an Alfamovirus.
- the capsid is derived from a Tobacco streak virus, or an Alfalfa mosaic virus (AMV) (including AMV 1 or AMV 2).
- the viral capsid of the invention is non-infective in the host cells described.
- a virus like particle (VLP) or cage structure is formed in the host cell during or after expression of the viral capsid.
- the VLP or cage structure also includes the peptide of interest, and in a particular embodiment, the peptide of interest is expressed on the surface of the VLP.
- the expression system typically does not contain additional viral proteins that allow infectivity of the virus.
- the expression system includes a host cell and a vector which codes for one or more viral capsids and an operably linked peptide of interest.
- the vector typically does not include additional viral proteins.
- the invention is derived from the discovery that viral capsids form to a greater extent in certain host cells and allow for more efficient recovery of recombinant peptide.
- the VLP or cage structure is a multimeric assembly of capsids, including from three to about 1,000 capsids. In one embodiment, the VLP or cage structure includes at least 30, at least 50, at least 60, at least 90 or at least 120 capsids. In another embodiment, each VLP or cage structure includes at least 150 capsids, at least 160, at least 170, or at least 180 capsids.
- the VLP is expressed as an icosahedral structure.
- the VLP is expressed in the same geometry as the native virus that the capsid sequence is derived of. In a separate embodiment, however, the VLP does not have the identical geometry of the native virus.
- the structure is produced in a particle formed of multiple capsids but not forming a native-type VLP.
- a cage structure of as few as 3 viral capsids can be formed.
- cage structures of about 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, or 60 capsids can be formed.
- At least one of the capsids includes at least one peptide of interest.
- the peptide is expressed within at least one internal loop, or in at least one external surface loop of the VLP.
- More than one loop of the viral capsid can be modified.
- the recombinant peptide is expressed on at least two surface loops of the virus-like particle.
- at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle.
- at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle.
- the recombinant peptides in the surface loops can have the same amino acid sequence.
- the amino acid sequence of the recombinant peptides in the surface loops differs.
- the host cell can be modified to improve assembly of the VLP.
- the host cell can, for example, be modified to include chaperone proteins that promote the formation of VLPs from expressed viral capsids.
- the host cell is modified to include a repressor protein to more efficiently regulate the expression of the capsid to promote regulated formation of the VLPs.
- the nucleic acid sequence encoding the viral capsid or proteins can also be additionally modified to alter the formation of VLPs (see e.g. Brumfield, et al. (2004) J. Gen. Virol. 85: 1049-1053). For example, these modifications are designed to alter the interior, exterior or the interface between adjacent subunits in the assembled protein cage.
- mutagenic primers can be used to: (i) alter the interior surface charge of the viral nucleic acid binding region by replacing basic residues (e.g.
- K, R in the N terminus with acidic glutamic acids (Douglas et al., 2002b); (ii) delete interior residues from the N terminus (in CCMV, usually residues 4-37); (iii) insert a cDNA encoding an 11 amino acid peptide cell-targeting sequence (Graf et al., 1987) into a surface exposed loop; and (iv) modify interactions between viral subunits by altering the metal binding sites (in CCMV, residues 81/148 mutant).
- the peptides operably linked to a viral capsid sequence contain at least two amino acids. In another embodiment, the peptides are at least three, at least four, at least five, or at least six amino acids in length. In a separate embodiment, the peptides are at least seven amino acids long. The peptides can also be at least eight, at least nine, at least ten, at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 45, 50, 60, 65, 75, 85, 95, 96, 99 or more amino acids long. In one embodiment, the peptides encoded are at least 25 kD.
- the peptide will contain from 2 to about 300 amino acids, or about 5 to about 250 amino acids, or about 5 to about 200 amino acids, or about 5 to about 150 amino acids, or about 5 to about 100 amino acids. In another embodiment, the peptide contains or about 10 to about 140 amino acids, or about 10 to about 120 amino acids, or about 10 to about 100 amino acids.
- the peptides or proteins operably linked to a viral capsid sequence will contain about 500 amino acids. In one embodiment, the peptide will contain less than 500 amino acids. In another embodiment, the peptide will contain up to about 300 amino acids, or up to about 250, or up to about 200, or up to about 180, or up to about 160, or up to about 150, or up to about 140, or up to about 120, or up to about 110, or up to about 100, or up to about 90, or up to about 80, or up to about 70, or up to about 60, or up to about 50, or up to about 40 or up to about 30 amino acids.
- the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids.
- the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In certain embodiments, the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid. In another embodiment, the individual monomers in the concatameric peptide are linked by cleavable linker regions. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus-like particle. In one embodiment, at least one monomer is inserted in a surface loop of the virus-like particle.
- the peptides of interest that are fused to the viral capsids can be a heterologous protein that is not derived from the virus and, optionally, that is not derived from the same species as the cell.
- the peptides of interest that are fused to the viral capsids can be functional peptides; structural peptides; antigenic peptides, toxic peptides, antimicrobial peptides, fragments thereof; precursors thereof, combinations of any of the foregoing; and/or concatamers of any of the foregoing.
- the recombinant peptide is a therapeutic peptide useful for human and animal treatments, including antigenic peptides used in a vaccine strategy.
- the antigenic peptide is glycosylated in vivo.
- Functional peptides include, but are not limited to, e.g.: bio-active peptides (i.e. peptides that exert, elicit, or otherwise result in the initiation, enhancement, prolongation, attenuation, termination, or prevention of a biological function or activity in or of a biological entity, e.g., an organism, cell, culture, tissue, organ, or organelle); catalytic peptides; microstructure- and nanostructure-active peptides (i.e.
- peptides that form part of engineered micro- or nanostructures in which, or in conjunction with which, they perform an activity, e.g., motion, energy transduction); and stimulant peptides (e.g., peptide flavorings, colorants, odorants, pheromones, attractants, deterrents, and repellants).
- stimulant peptides e.g., peptide flavorings, colorants, odorants, pheromones, attractants, deterrents, and repellants.
- Bio-active peptides include, but are not limited to, e.g.: immunoactive peptides (e.g., antigenic peptides, allergenic peptides, peptide immunoregulators, peptide immunomodulators); signaling and signal transduction peptides (e.g., peptide hormones, cytokines, and neurotransmitters; receptors; agonist and antagonist peptides; peptide targeting and secretion signal peptides); and bio-inhibitory peptides (e.g., toxic, biocidal, or biostatic peptides, such as peptide toxins and antimicrobial peptides).
- immunoactive peptides e.g., antigenic peptides, allergenic peptides, peptide immunoregulators, peptide immunomodulators
- signaling and signal transduction peptides e.g., peptide hormones, cytokines, and neurotransmitters; receptors; agonist and antagonist peptide
- Structural peptides include, but are not limited to, e.g.: peptide aptamers; folding peptides (e.g., peptides promoting or inducing formation or retention of a physical conformation in another molecule); adhesion-promoting peptides (e.g., adhesive peptides, cell-adhesion-promoting peptides); interfacial peptides (e.g., peptide surfactants and emulsifiers); microstructure and nanostructure-architectural peptides (i.e.
- pre-activation peptides e.g., leader peptides of pre-, pro-, and pre-pro-proteins and -peptides; inteins.
- Catalytic Peptides include, e.g., apo B RNA-editing cytidine deaminase peptides; catalytic peptides of glutaminyl-tRNA synthetases; catalytic peptides of aspartate transcarbamoylases; plant Type 1 ribosome-inactivating peptides; viral catalytic peptides such as, e.g., the foot-and-mouth disease virus [FMDV-2A] catalytic peptide; matrix metalloproteinase peptides; and catalytic metallo-oligopeptides.
- FMDV-2A foot-and-mouth disease virus
- the peptide can also be a peptide epitope, hapten, or a related peptide (e.g., antigenic viral peptide; virus related peptide, e.g., HIV-related peptide, hepatitis-related peptide; antibody idiotypic domain; cell surface peptide; antigenic human, animal, protist, plant, fungal, bacterial, and/or archaeal peptide; allergenic peptide and allergen desensitizing peptide).
- a related peptide e.g., antigenic viral peptide; virus related peptide, e.g., HIV-related peptide, hepatitis-related peptide; antibody idiotypic domain; cell surface peptide; antigenic human, animal, protist, plant, fungal, bacterial, and/or archaeal peptide; allergenic peptide and allergen desensitizing peptide.
- the peptide can also be a peptide immunoregulators or immunomodulators (e.g., interferons, interleukins, peptide immunodepressants and immunopotentiators); an antibody peptides (e.g., single chain antibodies; single chain antibody fragments and constructs, e.g., single chain Fv molecules; antibody light chain molecules, antibody heavy chain molecules, domain-deleted antibody light or heavy chain molecules; single chain antibody domains and molecules, e.g., a CH1, CH1-3, CH3, CH1-4, CH4, VHCH1, CL, CDR1, or FR1-CDR1-FR2 domain; paratopic peptides; microantibodies); another binding peptide (e.g., peptide aptamers, intracellular and cell surface receptor proteins, receptor fragments; anti-tumor necrosis factor peptides).
- an antibody peptides e.g., single chain antibodies; single chain antibody fragments and constructs, e.g., single chain Fv molecules
- the peptide can also be an enzyme substrate peptide or an enzyme inhibitor peptide (e.g., caspase substrates and inhibitors, protein kinase substrates and inhibitors, fluorescence-resonance-energy transfer-peptide enzyme substrates).
- an enzyme substrate peptide e.g., caspase substrates and inhibitors, protein kinase substrates and inhibitors, fluorescence-resonance-energy transfer-peptide enzyme substrates.
- the peptide can also be a cell surface receptor peptide ligand, agonist, and antagonist (e.g., caeruleins, dynorphins, orexins, pituitary adenylate cyclase activating peptides, tumor necrosis factor peptides; synthetic peptide ligands, agonists, and antagonists); a peptide hormone (e.g., endocrine, paracrine, and autocrine hormones, including, e.g.: amylins, angiotensins, bradykinins, calcitonins, cardioexcitatory neuropeptides, casomorphins, cholecystokinins, corticotropins and corticotropin-related peptides, differentiation factors, endorphins, endothelins, enkephalins, erythropoietins, exendins, follicle-stimulating hormones, galan
- ocytocins parathyroid hormones, pleiotrophins, prolactins, relaxins, secretins, serotonins, sleep-inducing peptides, somatomedins, thymopoietins, thyroid stimulating hormones, thyrotropins, urotensins, vasoactive intestinal peptides, vasopressins); a peptide cytokine, chemokine, virokine, and viroceptor hormone releasing and release-inhibiting peptide (e.g., corticotropin-releasing hormones, cortistatins, follicle-stimulating-hormone-releasing factors, gastric inhibitory peptides, gastrin releasing peptides, gonadotropin-releasing hormones, growth hormone releasing hormones, luteinizing hormone-releasing hormones, melanotropin-releasing hormones, melanotropin-release inhibiting factors; nocistatins,
- a peptide toxin contains no D-amino acids.
- Toxin precursor peptides can be those that contain no D-amino acids and/or that have not been converted by posttranslational modification into a native toxin structure, such as, e.g., by action of a D configuration inducing agent (e.g., a peptide isomerase(s) or epimeras(e) or racemase(s) or transaminase(s)) that is capable of introducing a D-configuration in an amino acid(s), and/or by-action of a cyclizing agent (e.g., a peptide thioesterase, or a peptide ligase such as a trans-splicing protein or intein) that is capable of form a cyclic peptide structure.
- a D configuration inducing agent e.g., a peptide isomerase(s) or epimeras(e) or racemase(
- Toxin peptide portions can be the linear or pre-cyclized oligo- and poly-peptide portions of peptide-containing toxins.
- peptide toxins include, e.g., agatoxins, amatoxins, charybdotoxins, chlorotoxins, conotoxins, dendrotoxins, insectotoxins, margatoxins, mast cell degranulating peptides, saporins, sarafotoxins; and bacterial exotoxins such as, e.g., anthrax toxins, botulism toxins, diphtheria toxins, and tetanus toxins.
- the peptide can also be a metabolism- and digestion-related peptide (e.g., cholecystokinin-pancreozymin peptides, peptide yy, pancreatic peptides, motilins); a cell adhesion modulating or mediating peptide, extracellular matrix peptide (e.g., adhesins, selectins, laminins); a neuroprotectant or myelination-promoting peptide; an aggregation inhibitory peptide (e.g., cell or platelet aggregation inhibitor peptides, amyloid formation or deposition inhibitor peptides); a joining peptide (e.g., cardiovascular joining neuropeptides, iga joining peptides); or a miscellaneous peptide (e.g., agouti-related peptides, amyloid peptides, bone-related peptides, cell-permeable peptides, conantokins, contryphan
- the peptide can also be post-translationally modified in vivo.
- the peptide may be, singularly or in combination, glycosylated, acetylated, acylated, phosphorylated, or gamma-carboxylated.
- the peptide of interest is exogenous to the selected viral capsid.
- Peptides may be either native or synthetic in sequence (and their coding sequences may be either native or synthetic nucleotide sequences).
- native, modified native, and entirely artificial sequences of amino acids are encompassed.
- the sequences of the nucleic acid molecules encoding these amino acid sequences likewise may be native, modified native, or entirely artificial nucleic acid sequences, and may be the result of, e.g., one or more rational or random mutation and/or recombination and/or synthesis and/or selection process employed (i.e. applied by human agency) to obtain the nucleic acid molecules.
- the coding sequence can be a native coding sequence for the target peptide, if available, but will more typically be a coding sequence that has been selected, improved, or optimized for use in the selected expression host cell: for example, by synthesizing the gene to reflect the codon use preference of a host species.
- the host species is Nicotiana tabacum , and the codon preference of Nicotiana tabacum is taken into account when designing both the signal sequence and the peptide sequence.
- the host species is Oryza sativa , and the codon preference of Oryza sativa is taken into account when designing both the signal sequence and the peptide sequence
- an antigenic peptide is produced through expression with a viral capsid.
- the antigenic peptide can be selected from those that are antigenic peptides of human or animal pathogenic agents, including infectious agents, parasites, cancer cells, and other pathogenic agents.
- pathogenic agents also include the virulence factors and pathogenesis factors, e.g., exotoxins, endotoxins, et al., of those agents.
- the pathogenic agents may exhibit any level of virulence, i.e. they may be, e.g., virulent, avirulent, pseudo-virulent, semi-virulent, and so forth.
- the antigenic peptide will contain an epitopic amino acid sequence from the pathogenic agent(s).
- the epitopic amino acid sequence will include that of at least a portion of a surface peptide of at least one such agent.
- the capsid-recombinant peptide virus like particles can be used as a vaccine in a human or animal application.
- More than one antigenic peptide may be selected, in which case the resulting virus-like particles can present multiple different antigenic peptides.
- the various antigenic peptides will all be selected from a plurality of epitopes from the same pathogenic agent.
- the various antigenic peptides selected will all be selected from a plurality of closely related pathogenic agents, for example, different strains, subspecies, biovars, pathovars, serovars, or genovars of the same species or different species of the same genus.
- the pathogenic agent(s) will belong to at least one of the following groups: Bacteria and Mycoplasma agents including, but not limited to, pathogenic: Bacillus spp., e.g., Bacillus anthracis; Bartonella spp., e.g., B. quintana; Brucella spp.; Burkholderia spp., e.g., B. pseudomallei; Campylobacter spp.; Clostridium spp., e.g., C. tetani, C. botulinum; Coxiella spp., e.g., C.
- Bacillus spp. e.g., Bacillus anthracis
- Bartonella spp. e.g., B. quintana
- Brucella spp. e.g., Burkholderia spp., e.g., B. pseudomallei
- Edwardsiella spp. e.g., E. tarda
- Enterobacter spp. e.g., E. cloacae
- Enterococcus spp. e.g., E. faecalis, E. faecium
- Escherichia spp. e.g., E. coli
- Francisella spp. e.g., F. tularensis
- Haemophilus spp. e.g., H. influenzae
- Klebsiella spp. e.g., K. pneumoniae
- Legionella spp. Listeria spp., e.g., L.
- Meningococci and Gonococci e.g., Neisseria spp.; Moraxella spp.; Mycobacterium spp., e.g., M. leprae, M. tuberculosis ; Pneumococci, e.g., Diplococcus pneumoniae; Pseudomonas spp., e.g., P. aeruginosa; Rickettsia spp., e.g., R. prowazekii, R. rickettsii, R. typhi; Salmonella spp., e.g., S.
- Staphylococcus spp. e.g., S. aureus
- Streptococcus spp. including Group A Streptococci and hemolytic Streptococci, e.g., S. pneumoniae, S. pyogenes; Streptomyces spp.; Shigella spp.; Vibrio spp., e.g., V. cholerae ; and Yersinia spp., e.g., Y. pestis, Y. enterocolitica .
- Fungus and Yeast agents including, but not limited to, pathogenic: Alternaria spp.; Aspergillus spp.; Blastomyces spp., e.g., B. dermatiditis; Candida spp., e.g., C. albicans; Cladosporium spp.; Coccidiodes spp., e.g., C. immitis; Cryptococcus spp., e.g., C. neoformans; Histoplasma spp., e.g., H. capsulatum ; and Sporothrix spp., e.g., S. schenckii.
- the pathogenic agent(s) will be from a protist agent including, but not limited to, pathogenic: Amoebae, including Acanthamoeba spp., Amoeba spp., Naegleria spp., Entamoeba spp., e.g., E. histolytica; Cryptosporidium spp., e.g., C. parvum; Cyclospora spp.; Encephalitozoon spp., e.g., E. intestinalis; Enterocytozoon spp.; Giardia spp., e.g., G.
- pathogenic Amoebae, including Acanthamoeba spp., Amoeba spp., Naegleria spp., Entamoeba spp., e.g., E. histolytica
- Cryptosporidium spp. e.g., C
- Plasmodium spp. e.g., P. falciparum, P. malariae, P. ovate, P. vivax; Toxoplasma spp., e.g., T. gondii ; and Trypanosoma spp., e.g., T. brucei.
- the pathogenic agent(s) will be from a parasitic agent (e.g., helminthic parasites) including, but not limited to, pathogenic: Ascaris spp., e.g. A. lumbricoides; Dracunculus spp., e.g., D. medinensis; Onchocerca spp., e.g., O. volvulus; Schistosoma spp.; Trichinella spp., e.g., T. spiralis ; and Trichuris spp., e.g., T. trichiura.
- a parasitic agent e.g., helminthic parasites
- the pathogenic agent(s) will be from a viral agent including, but not limited to, pathogenic: Adenoviruses; Arenaviruses, e.g., Lassa Fever viruses; Astroviruses; Bunyaviruses, e.g., Hantaviruses, Rift Valley Fever viruses; Coronaviruses, Deltaviruses; Cytomegaloviruses, Epstein-Barr viruses, Herpes viruses, Varicella viruses; Filoviruses, e.g., Ebola viruses, Marburg viruses; Flaviruses, e.g., Dengue viruses, West Nile Fever viruses, Yellow Fever viruses; Hepatitis viruses; Influenzaviruses; Lentiviruses, T-Cell Lymphotropic viruses, other leukemia viruses; Norwalk viruses; Papillomaviruses, other tumor viruses; Paramyxoviruses, e.g., Measles viruses, Mumps viruses, Parainfluenzaviruses
- the antigenic peptide is selected from the group consisting of a Canine parvovirus peptide, Bacillus anthracis protective antigen (PA) antigenic peptide, and an Eastern Equine Encephalitis virus antigenic peptide.
- the antigenic peptide is the Bacillus antracis -derived peptide with the amino acid sequence selected from PA1 (SEQ. ID. NO. 1), PA2 (SEQ. ID. NO. 2), PA3 (SEQ. ID. NO. 3), or PA4 (SEQ. ID. NO. 4).
- the recombinant peptide is a peptide that is toxic to the host cell when in free monomeric form.
- the peptide of interest expressed in conjunction with a viral capsid will be a host cell toxic peptide.
- a host cell toxic peptide indicates a bio-inhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed, or to other cells in the cell culture or organism of which the host cell is a member, or to cells of the organism or species providing the host cells.
- the host-cell-toxic peptide will be a bioinhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed.
- Some examples of host-cell-toxic peptides include, but are not limited to: peptide toxins, anti-microbial peptides, and other antibiotic peptides.
- the recombinant peptide is a peptide that is an antimicrobial peptide.
- Anti-Microbial Peptides include, e.g., anti-bacterial peptides such as, e.g., magainins, betadefensins, some alpha-defensins; cathelicidins; histatins; anti-fungal peptides; antiprotozoal peptides; synthetic AMPs; peptide antibiotics or the linear or pre-cyclized oligo- or poly-peptide portions thereof; other antibiotic peptides (e.g., anthelmintic peptides, hemolytic peptides, tumoricidal peptides); and anti-viral peptides (e.g., some alpha-defensins; virucidal peptides; peptides that inhibit viral infection).
- the antimicrobial peptide is selected from the group consisting of D2A21 antimicrobial peptides such
- the cell used as a host for the expression of the viral capsid or viral capsid fusion peptide (also referred to as “host cell”) of the invention will be one in which the expression of viral capsid does not allow replication or infection of the cell.
- the viral capsid will be derived from a virus that does not infect the specific species of cell that the host cell is derived from.
- the viral capsid is derived from an icosahedral plant virus and is expressed in a host cell of a plant species that is not the native trophic host of the virus.
- the viral species infects mammals and the expression system includes a plant host cell.
- the virus is a trophic virus of the particular plant species utilized as a host cell for expressing the capsid-recombinant peptide fusion.
- the plant host cell may be any plant cell from the Tracheophyta, Euphyllophyta,spermatophyta , or Angiospermophyta .
- the plant cell is a Monocot, including, but not limited to, members of, e.g.: Arecaceae , e.g., Cocos spp., Elaeis spp.; Dioscoreaceae , e.g., Dioscorea spp.; Gramineae ( Poaceae ), e.g., Avena spp., Hordeum spp., Oryza spp., Panicum spp., Triticum spp., Zea spp.; and Musaceae , e.g., Musa spp.
- Arecaceae e.g., Cocos spp., Elaeis spp.
- Dioscoreaceae e.g., Dioscore
- the plant cell is a member of the Dicots, including, but not limited to, e.g.: Amaranthaceae , e.g., Amaranthus spp., Beta spp., Chenopodium spp.; Apiaceae ( Umbelliferae ), e.g., Daucus spp., Pastinaca spp.; Brassicaceae ( Cruciferae ), e.g., Arabidopsis spp., Brassica spp.; Compositae , e.g., Helianthus spp.; Convolvulaceae , e.g., Ipomoea spp.; Cucurbitaceae , e.g., Citrullus spp., Cucumis spp., Cucurbita spp.; Euphorbiaceae; Leguminosae ( Fabaceae ), e.g, Glycine spp
- the host cell is selected from the group consisting of Aradiposis thialiana, Taxus cuspidate, Catharanthus roseus, Nicotiana tabacum, Oryza sativa, Lycopersicum esculentum , and Glycine max.
- the present invention further provides non-infectious nucleic acid constructs capable of stably integrating into the host cell's genome and encoding a fusion peptide of a capsid and a recombinant peptide.
- the fusion peptide can be operably linked to a promoter sequence and a termination sequence.
- a nucleic acid construct for use in transforming plant host cells including a) a nucleic acid sequence encoding a recombinant peptide, and b) a nucleic acid sequence encoding a viral capsid is provided, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein is stably inserted into the genome of the plant host cell, wherein it is expressed in the plant cell.
- the vector can include sequence for multiple capsids, or for multiple peptides of interest. In one embodiment, the vector can include at least two different capsid-peptide coding sequences. In one embodiment, the coding sequences are linked to the same promoter. In certain embodiments, the coding sequences are separated by an internal ribosomal binding site. In other embodiments, the coding sequences are linked by a linker sequence that allows the formation of virus like particles in the cell. In another embodiment, the coding sequences are linked to different promoters. These promoters may be constitutive or driven by the same or different induction conditions. In another embodiment, multiple vectors capable of insertion into the genome and encoding different capsid-peptide combinations are provided. The multiple vectors can include promoters that are constitutive or driven by the same induction conditions, or by different induction conditions. In one embodiment, the viral capsid is derived from an icosahedral viral capsid.
- the coding sequence for a peptide of interest can be inserted into the coding sequence for a viral capsid or capsid in a predetermined site.
- the peptide can also be inserted at a non-predetermined site and cells screened for production of VLPs.
- the peptide is inserted into the capsid coding sequence so as to be expressed as a loop during formation of a VLP.
- one peptide coding sequence is included in the vector, however in other embodiments, multiple sequences are included.
- the multiple sequences can be in the form of concatamers, for example concatamers linked by cleavable linker sequences.
- Peptides may be inserted at more than one insertion site in a capsid.
- peptides may be inserted in more than one surface loop motif of a capsid; peptides may also be inserted at multiple sites within a given loop motif.
- the individual functional and/or structural peptide(s) of the insert(s), and/or the entire peptide insert(s), may be separated by cleavage sites, i.e. sites at which an agent that cleaves or hydrolyzes protein can act to separate the peptide(s) from the remainder of the capsid structure or assemblage.
- the peptide can be inserted at the amino terminus of the capsid.
- the peptide can be linked to the capsid through one or more linker sequences, including the cleavable linkers described above.
- the peptide can be inserted at the carboxy terminus of the capsid.
- the peptide can also be linked to the carboxy terminus through one or more linkers, which can be cleavable by chemical or enzymatic hydrolysis.
- peptide sequences are linked at both the amino and carboxy termini, or at one terminus and at at least one internal location, such as a location that is expressed on the surface of the capsid in its three dimensional conformation.
- the peptide can be inserted into the capsid from a Cowpea Chlorotic Mosaic Virus.
- the peptide can be inserted at amino acid 129 of the CCMV coat protein.
- the peptide sequence can be inserted at amino acid 63, 102, 114, 129, or 160 of the CCMV coat protein.
- the peptide sequence can be inserted at amino acids 60, 61, 62 or 63 of the CCMV coat protein.
- the peptide can be inserted at both amino acids 129 and amino acids 60-63 of the CCMV protein.
- the present invention provides a nucleic acid construct including a) a nucleic acid encoding an antigenic peptide, and b) a nucleic acid encoding a viral capsid, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein when expressed in a cell.
- a nucleic acid construct including a) a nucleic acid encoding an antigenic peptide, and b) a nucleic acid encoding a viral capsid, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein when expressed in a cell.
- Other capsids and recombinant peptides useful in constructing the nucleic acid construct are disclosed above.
- the nucleic acid construct includes a promoter sequence operably attached to the nucleic acid sequence encoding the capsid-recombinant peptide fusion peptide.
- An operable attachment or linkage refers to any configuration in which the transcriptional and any translational regulatory elements are covalently attached to the described sequence so that by action of the host cell, the regulatory elements can direct the expression of the sequence of interest.
- the nucleic acid construct encoding the capsid fusion product can be inserted in frame with a host cell native promoter utilizing a gene trapping strategy.
- the promoter initiates transcription and is generally positioned 1-100 nucleotides upstream of the transcription start site. Ideally, a promoter will be strong enough to allow for a large amount of recombinant peptide accumulation.
- tissue-specific promoters such as corn sucrose synthetase 1 (Yang et al., 1990), corn alcohol dehydrogenase 1 (Vogel et al., 1989), corn light harvesting complex (Simpson, 1986), corn heat shock protein (Odell et al., 1985), pea small subunit RuBP carboxylase (Poulsen et al., 1986; Cashmore et al., 1983), Ti plasmid mannopine synthase (Langridge et al., 1989), Ti plasmid nopaline synthase (Langridge et al., 1989), petunia chalcone isomerase (Van Tunen et al., 1988), bean glycine rich protein 1 (Keller et al., 1989), CaMV 35 s transcript (Odell et al., 1985) and Potato patatin (Wenzler et al., 1989).
- tissue-specific promoters such as corn sucrose
- Preferred promoters are the cauliflower mosaic virus (CaMV 35 S) promoter, the rice alpha-amylase RAmy3D promoter, and the S-E9 small subunit RuBP carboxylase promoter.
- CaMV 35 S cauliflower mosaic virus
- RAmy3D rice alpha-amylase RAmy3D promoter
- S-E9 small subunit RuBP carboxylase promoter a variety of plant gene promoters that are regulated in response to environmental, hormonal, chemical, and/or developmental signals can be used for expression of an operably linked gene in plant cells, including promoters regulated by (1) heat (Callis et al., Plant Physiol.
- a promoter having the nucleotide sequence of a promoter native to the selected plant host cell can also be used to control expression of the transgene encoding the target peptide. Tandem promoters may also be used in which more than one promoter is covalently attached to another, whether the same or different in sequence.
- a promoter having the nucleotide sequence derived from a virus can also be used to direct expression of the transgene encoding the target peptide.
- nucleic acid constructs include, but are not limited to, for example, transcriptional enhancer sequences, translational enhancer sequences, other promoters, activators, translational start and stop signals, transcription terminators, cistronic regulators, polycistronic regulators, tag sequences, such as nucleotide sequence “tags” and “tag” peptide coding sequences, which facilitates identification, separation, purification, or isolation of an expressed peptide, including His-tag, Flag-tag, T7-tag, S-tag, HSV-tag, B-tag, Strep-tag, polyarginine, polycysteine, polyphenylalanine, polyaspartic acid, (Ala-Trp-Trp-Pro) n , thioredoxin, beta-galactosidase, chloramphenicol acetyltransferase, cyclomaltodextrin gluconotransferase, CTP:C
- the nucleic acid construct further comprises a tag sequence adjacent to the coding sequence for the recombinant peptide of interest, or linked to a coding sequence for a viral capsid.
- this tag sequence allows for purification of the protein.
- the tag sequence can be an affinity tag, such as a hexa-histidine affinity tag.
- the affinity tag can be a glutathione-S-transferase molecule.
- the tag can also be a fluorescent molecule, such as YFP or GFP, or analogs of such fluorescent proteins.
- the tag can also be a portion of an antibody molecule, or a known antigen or ligand for a known binding partner useful for purification.
- the present invention can include, in addition to the capsid-recombinant peptide coding sequence, the following regulatory elements operably linked thereto: a promoter, a transcription terminator, translational start and stop signals.
- the nucleic acid construct includes additional nucleic acid sequences derived from the 3′ untranslated region (3′ UTR) of the viral genomic nucleic acid sequence utilized to derive the viral capsid protein.
- the 3′UTR contains sequences that play a role in regulation of translation or capsid formation in the wild type virus.
- the 3′UTR sequences are upstream pseudoknot domains (UPD). See, for example, Leathers et al. (1993) “A phylogenetically conserved sequence within viral 3′ untranslated RNA pseudoknots regulates translation,” Mol. Cell Biol. 13(9): 5331-5347.
- the 3′UTR are derived from the 3′UTR of the viral capsid encoding region of the viral genome. In a more particular embodiment, the 3′UTR is derived from the cowpea chlorotic mosaic virus RNA3 3′ untranslated region. In one embodiment, the 3′UTR sequence includes an encapsidation signal.
- the nucleic acid construct includes at least one encapsidation signal derived from a viral nucleic acid sequence.
- the encapsidation signal can be derived from 5′UTR, 3′UTR, or internal sequence of the viral genomic sequence.
- the nucleic acid construct is encapsidated in the VLP.
- the non-infectious nucleic acid construct also includes other sequences derived from the viral or non-viral nucleic acid sequence other than the viral capsid protein sequence.
- Useful expression vectors for use in plant cells in stably integrating into the host cell genome and expressing capsid-recombinant peptide fusion peptides are constructed by inserting a structural DNA sequence encoding a desired target peptide fused with a capsid peptide together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
- the vector may also comprise one or more phenotypic selectable or screenable markers to allow for selection of host cells. Alternatively, the selectable or screenable markers can be provided on a separate plasmid.
- a wide variety of vectors and/or carriers are known in the art as useful for transforming a target plant host cell with recombinant capsid-encoding nucleic acid for expression, and any of these may be used for expressing the genes according to the present invention. See, e.g., U Goderis I J et al., “A set of modular plant transformation vectors allowing flexible insertion of up to six expression units,” Plant Mol. Biol. 50(1):17-27 (2002); A H Christensen & P H Quail, “Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants,” Transgenic Res.
- plasmids transposons, genomic DNA, genomic RNA, plant artificial chromosomes, and other nucleic acid vectors may be used.
- examples of some vectors that may be used include, but are not limited to, pRT101, pRT101-MCS, pRT104, pRT104.24LS, pRT104.N-myc, pRT104.C-myc, pRT104.N-3HA, pRT104-N3HAdAsp, pRT104.N-6HA, pRT104-N6HAdAsp, pRT104.C-3HA, pRT104-GST, pRT104 NES(A2), pRT103-3HA, pRTd35S-Luci( ⁇ ), pRTd35S-Luci-NES, pRTd35S-GFP, pRTd35S-GFP.SacI, pRTdS GFP.BglII, pRTd35S-Ds-Red,
- the vector is pIL-Tab.
- the vector is pIL-Tab encoding for the coat protein from Cowpea Chlorotic Mosaic Virus (CCMV).
- CCMV Cowpea Chlorotic Mosaic Virus
- the vector is pIL-Tab, and the heterologous peptide is selected from the group consisting of PA1, PA2, PA3 or PA4.
- the vector is selected from the group consisting of pDOW2160 (Seq. ID. No. 5), pDOW 2161 (Seq. ID. No. 6), pDOW2162 (Seq. ID. No. 7), pDOW2163 (Seq. ID. No.
- carriers may be used, such as liposomes, dendrimers, cationic polymers, and cationic polymer-lipid complexes, all of which have been employed in widely published methods for delivery of nucleic acids to cells or protoplasts.
- carriers such as liposomes, dendrimers, cationic polymers, and cationic polymer-lipid complexes, all of which have been employed in widely published methods for delivery of nucleic acids to cells or protoplasts.
- naked DNA or naked RNA may be delivered to the plant host.
- the vector, carrier, or naked nucleic acid may be directly transformed into a plant cell or protoplast by any method known effective therefore in the art.
- any of the following methods may be used to transform the plant target host with the recombinant capsid-encoding nucleic acid: Agrobacterium spp.; microparticle bombardment as described by V. Vasil et al., Bio/Technology 9, 743 (1991); electroporation of protoplasts as described, for example, for lettuce by M C Chupeau et al., Bio/Technology 7, 503 (1989); surface abrasion using, e.g., silicon carbide whiskers, glass, or carborundum; liposome fusion with protoplasts as described, for example, by A.
- the present invention also provides a process for producing a recombinant peptide.
- the process includes:
- the fusion peptide is operably linked to a promoter sequence and a terminator sequence.
- the process further comprises: e) cleaving the recombinant peptide from the viral capsid protein.
- the process further comprises: f) isolating the recombinant peptide from step e. See, for example, FIG. 1 .
- Peptides may be expressed as single-copy peptide inserts within a capsid peptide (i.e. expressed as individual inserts from recombinant capsid peptide coding sequences that are mono-cistronic for the peptide) or may be expressed as di-, tri-, or multi-copy peptide inserts (i.e. expressed as concatemeric inserts from recombinant capsid peptide coding sequences that are poly-cistronic for the peptide; the concatemeric insert(s) may contain multiple copies of the same exogenous peptide of interest or may contain copies of different exogenous peptides of interest). Concatemers may be homo- or hetero-concatemers.
- the isolated virus like particle can be administered to a human or animal in a vaccine strategy.
- the nucleic acid construct can be co-expressed with another nucleic acid encoding a wild type capsid.
- the co-expressed capsid/capsid-recombinant peptide fusion particles assemble in vivo to form a chimeric virus like particle.
- the chimeric VLP is a virus like particle including capsids or capsid-peptide fusions encoded by at least two different nucleic acid constructs.
- the nucleic acid construct can be co-expressed with another nucleic acid encoding a different capsid-recombinant peptide fusion particle.
- the co-expressed capsid fusion particles will assemble in vivo to form a chimeric virus like particle.
- a second nucleic acid which is designed to express a different peptide, such as a chaperone protein, can be expressed concomitantly with the nucleic acid encoding the fusion peptide.
- the expressed viral capsid-heterologous peptide fusion product is expressed in soluble form in the cell.
- the expressed viral capsid-recombinant heterologous fusion product is assembled into VLPs in the cell.
- a portion of the expressed viral capsid-heterologous peptide fusion product of interest is formed in an insoluble aggregate in the cell.
- the peptide of interest can be renatured from the insoluble aggregate.
- the process further provides: e) cleaving the fusion product to separate the recombinant peptide from the capsid.
- a cleavable linkage sequence can be included between the viral protein and the recombinant peptide.
- agents that can cleave such sequences include, but are not limited to chemical reagents such as acids (HCl, formic acid), CNBr, hydroxylamine (for asparagine-glycine), 2-Nitro-5-thiocyanobenzoate, O-Iodosobenzoate, and enzymatic agents, such as endopeptidases, endoproteases, trypsin, clostripain, and Staphylococcal protease.
- chemical reagents such as acids (HCl, formic acid), CNBr, hydroxylamine (for asparagine-glycine), 2-Nitro-5-thiocyanobenzoate, O-Iodosobenzoate, and enzymatic agents, such as endopeptidases, endoproteases, trypsin, clostripain, and St
- Cleavable linkage sequences are well known in the art.
- any cleavable linkage sequence recognized by cleavage agents including dipeptide cleavage sequences such as Asp-Pro, can be utilized.
- the process of the invention optimally leads to the increased production of desired capsid-fusion products in a plant host cell in the desired sequence and conformation.
- the increased production alternatively can be an increased level of desired peptide per gram of protein produced, per gram of host protein, or as a percentage of total recombinant peptide produced.
- the increased production can also be an increased level of recoverable peptide, such as soluble protein, produced per gram of recombinant or per gram of host cell protein.
- the increased production can also be any combination of increased total level and increased active or soluble level of protein.
- the improved expression of recombinant protein can be through expression of the protein as a capsid fusion protein and subsequently inserted in VLPs.
- at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, or at least 180 copies of a peptide of interest are expressed in each VLP.
- the VLPs can be produced and recovered from the cytoplasm, periplasm or extracellular medium of the host cell.
- the peptide can be insoluble in the cell.
- the soluble or insoluble peptide is produced in a particle formed of multiple capsids but not forming a native-type VLP.
- a cage structure of as few as 3 viral capsids can be formed.
- the capsid structure includes more than one copy of a peptide of interest and in certain embodiments, includes at least ten, at least 20, or at least 30 copies.
- the peptide is formed in the vacuole of the plant cell.
- the peptide or viral capsid sequence can also include one or more targeting sequences or sequences to assist purification. These can be an affinity tag. These can also be targeting sequences directing the assembly of capsids into a VLP.
- Transformation of the plant host cells with the vector(s) may be performed using any transformation methodology known in the art, and the plant host cells may be transformed as intact cells or as protoplasts. Exemplary transformation methodologies have been described above.
- the term “fermentation” includes both embodiments in which literal fermentation is employed and embodiments in which other, non-fermentative culture modes are employed. Fermentation may be performed at any scale. Any method generally known in the art may be utilized in fermentation. See, for example, Hellwig et al. (2004) “Plant cell cultures for the production of recombinant proteins,” Nature Biotech 22(11): 1415-1422; Sajc et al. (2000) “Bioreactors for plant engineering: an outlook for further research,” Biochem Engin. J. 4:89-99.
- the fermentation medium may be selected from among any viable plant cell culture media.
- additives to the medium can include, for example, PVP, BSA, NaCl, BrefeldinA, reducing manganese, pluronic antifoam, polyethylene glycol, gelatin, protease inhibitors, redox co-factors, and dimethylsulfoxide.
- the expression system according to the present invention can be cultured in any fermentation format.
- batch, fed-batch, semi-continuous, and continuous fermentation modes may be employed herein.
- the expression systems according to the present invention are useful for transgene expression at any scale (i.e. volume) of fermentation.
- any scale i.e. volume
- the fermentation volume will be at or above 1 Liter.
- the fermentation volume will be at or above 5 Liters, 10 Liters, 15 Liters, 20 Liters, 25 Liters, 50 Liters, 75 Liters, 100 Liters, 200 Liters, 500 Liters, 1,000 Liters, 2,000 Liters, 5,000 Liters, 10,000 Liters or 50,000 Liters.
- growth, culturing, and/or fermentation of the transformed host cells is performed within a temperature range permitting survival of the host cells, preferably a temperature within the range of about 4° C. to about 55° C., inclusive.
- Plant cell expressions systems according to the present invention can provide a cell density or comparable packed wet cell density of about from about 20 g/L (2% packed cell volume) to more than 550 g/L (55% packed cell volume).
- the packed cell volume is between 2% to about 60%.
- the packed cell volume is 2%, 5%, 10%, 15%, 20%, 25%, 35%, 40%, 50%, 55%, 60%, 70%, or 85%.
- the invention provides a process for improving the recovery of peptides of interest by protection of the peptide during expression through linkage and co-expression with a viral capsid.
- the viral capsid fusion forms a VLP, which can be readily separated from the cell lysate.
- proteins of this invention may be isolated and purified to substantial purity by standard techniques well known in the art, including, but not limited to, PEG precipitation, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, detergent solubilization, selective precipitation with such substances as column chromatography, immunopurification methods, and others.
- proteins having established molecular adhesion properties can be reversibly fused to a ligand.
- the protein can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form.
- the fused protein can then be removed by enzymatic or other activity.
- protein can be purified using immunoaffinity columns or Ni-NTA columns.
- General techniques are further described in, for example, R. Scopes, Protein Purification: Principles and Practice, Springer-Verlag: N.Y. (1982); Deutscher, Guide to Protein Purification, Academic Press (1990); U.S. Pat. No. 4,511,503; S. Roe, Protein Purification Techniques: A Practical Approach (Practical Approach Series), Oxford Press (2001); D. Bollag, et al., Protein Methods, Wiley-Lisa, Inc.
- Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence.
- appropriate segments e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence.
- VLPs can be isolated and purified to substantial purity by standard techniques well known in the art.
- Techniques for isolation of VLPs include, in addition to those described above, precipitation techniques such as polyethylene glycol or salt precipitation. Separation techniques include anion or cation exchange chromatography, size exclusion chromatograph, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, immunopurification methods, centrifugation, ultracentrifugation, density gradient centrifugation (for example, on a sucrose or on a cesium chloride (CsCl) gradient), ultrafiltration through a size exclusion filter, and any other protein isolation methods known in the art.
- precipitation techniques such as polyethylene glycol or salt precipitation.
- Separation techniques include anion or cation exchange chromatography, size exclusion chromatograph, phosphocellulose chromatography, hydrophobic interaction
- the invention can also improve recovery of active recombinant peptides.
- Levels of active protein can be measured, for example, by measuring the interaction between an identified and a parent peptide, peptide variant, segment-substituted peptide and/or residue-substituted peptide by any convenient in vitro or in vivo assay.
- in vitro assays can be used to determine any detectable interaction between an identified protein and a peptide of interest, e.g. between enzyme and substrate, between hormone and hormone receptor, between antibody and antigen, etc.
- detection can include the measurement of calorimetric changes, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion processes, etc.
- In vivo assays include, but are not limited to, assays to detect physiological effects, e.g. weight gain, change in electrolyte balance, change in blood clotting time, changes in clot dissolution and the induction of antigenic response.
- any in vivo assay can be used so long as a variable parameter exists so as to detect a change in the interaction between the identified and the peptide of interest. See, for example, U.S. Pat. No. 5,834,250.
- Detection of the expressed protein is achieved by methods known in the art and includes, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.
- An initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest.
- One such example can be ammonium sulfate.
- Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations.
- a typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most hydrophobic of proteins.
- the precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest.
- the precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration.
- Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.
- the molecular weight of a recombinant protein can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes).
- the protein mixture can be ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest.
- the retentate of the ultrafiltration can then be ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest.
- the recombinant protein will pass through the membrane into the filtrate.
- the filtrate can then be chromatographed.
- Recombinant proteins can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands.
- antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).
- Insoluble protein can be renatured or refolded to generate secondary and tertiary protein structure conformation. Protein refolding steps can be used, as necessary, in completing configuration of the recombinant product. Refolding and renaturation can be accomplished using an agent that is known in the art to promote dissociation/association of proteins. For example, the protein can be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea.
- Recombinant protein can also be renatured, for example, by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.
- PBS phosphate-buffered saline
- the protein can be refolded while immobilized on a column, such as the Ni NTA column by using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, and 20 mM Tris/HCl pH 7.4, containing protease inhibitors.
- the renaturation can be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM immidazole.
- Immidazole can be removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl.
- the purified protein can be stored at room temperature, 4° C. or frozen at ⁇ 20° C. to ⁇ 80° C.
- Active proteins can have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native peptide that the sequence is derived from.
- the substrate specificity (k cat /K m ) is optionally substantially similar to the native peptide. Typically, k cat /K m will be at least 30%, 40%, or 50%, that of the native peptide; and more preferably at least 60%, 70%, 80%, or 90%.
- the activity of a recombinant peptide produced in accordance with the present invention by can be measured by any protein specific conventional or standard in vitro or in vivo assay known in the art.
- the activity of the plant cell host produced recombinant peptide can be compared with the activity of the corresponding native protein to determine whether the recombinant protein exhibits substantially similar or equivalent activity to the activity generally observed in the native peptide under the same or similar physiological conditions.
- the activity of the recombinant protein can be compared with a previously established native peptide standard activity.
- the activity of the recombinant peptide can be determined in a simultaneous, or substantially simultaneous, comparative assay with the native peptide.
- an in vitro assays can be used to determine any detectable interaction between a recombinant peptide and a target, e.g. between an expressed enzyme and substrate, between expressed hormone and hormone receptor, between expressed antibody and antigen, etc.
- Such detection can include the measurement of colorimetric changes, proliferation changes, cell death, cell repelling, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion methods, phosphorylation abilities, antibody specificity assays such as ELISA assays, etc.
- in vivo assays include, but are not limited to, assays to detect physiological effects of the plant host cell produced peptide in comparison to physiological effects of the native peptide, e.g. antigenic response.
- any in vitro or in vivo assay can be used to determine the active nature of the recombinant peptide that allows for a comparative analysis to the native peptide so long as such activity is assayable.
- the peptides produced in the present invention can be assayed for the ability to stimulate or inhibit interaction between the peptide and a molecule that normally interacts with the peptide, e.g. a substrate or a component of the signal pathway that the native protein normally interacts.
- a molecule that normally interacts with the peptide e.g. a substrate or a component of the signal pathway that the native protein normally interacts.
- Such assays can typically include the steps of combining the protein with a substrate molecule under conditions that allow the peptide to interact with the target molecule, and detect the biochemical consequence of the interaction with the protein and the target molecule.
- CCMV cowpea chlorotic mottle virus
- CCMV is a member of the bromovirus group of the Bromoviridae.
- Bromoviruses are 25-28 nm diameter icosahedral viruses with a four-component, positive sense, single-stranded RNA genome.
- RNA1 and RNA2 code for replicase enzymes.
- RNA3 codes for a protein involved in viral movement within plant hosts.
- RNA4 (a subgenomic RNA derived from RNA 3), i.e. sgRNA4, codes for the 20 kDa coat protein (CP) (SEQ ID NO:13) (Table 1).
- Each CCMV particle contains 180 copies of the CCMV CP.
- An exemplary DNA sequence encoding the CCMV CP is shown in SEQ ID NO:14 (Table 2). TABLE 1 Wild type CCMV coat protein encoded by sgRNA4 (Seq. ID No.
- CCMV coat proteins can be genetically modified to carry heterologous peptides without interfering with their ability to form particles.
- a number of suitable insertion sites have been identified.
- a total of up to 180 copies of a heterologous peptide unit (whether as individual peptide units or in concatameric units) can be inserted into the CCMV particle at a single insertion site in the CCMV CP. Insertion sites identified within CCMV CP to date can accommodate peptides of various lengths.
- PCR reactions were performed using a PTC225 thermocycler (MJ Research, South San Francisco, Calif., USA) according to the following protocol: TABLE 3 PCR protocol Reaction Mix (100 ⁇ L total volume) Thermocycling Steps 10 ⁇ L 10 ⁇ PT HIFI buffer * Step 1 1 Cycle 2 min. 94° C. 4 ⁇ L 50 mM MgSO 4 * Step 2 35 Cycles 30 sec. 94° C. 2 ⁇ L 10 mM dNTPs * 30 sec. 55° C. 0.25 ng Each Primer 1 min. 68° C. 1-5 ng Template DNA Step 3 1 Cycle 10 min. 70° C. 1 ⁇ L PT HIFI Taq DNA Polymerase * Step 4 1 Cycle Maintain 4° C. Remainder Distilled De-ionized H 2 O (ddH 2 O) * (from Invitrogen Corp, Carlsbad, CA, USA, hereinafter “Invitrogen”)
- Bacillus anthracis antigenic peptides were performed in whole plants, using cowpea chlorotic mottle virus (CCMV) with capsid proteins (CP) engineered to contain one of four different antigenic peptides.
- CCMV cowpea chlorotic mottle virus
- CP capsid proteins
- DNA having the nucleotide sequence of CCMV RNA 1 and DNA having the nucleotide sequence of CCMV RNA 2 were each separately subcloned in the cloning vector pUC19 downstream from, and under the control of, a T7 promoter and upstream from a unique Xba I site. This produced plasmids pDOW2122 (CCMV RNA1) and pDOW2123 (CCMV RNA2).
- SOE splicing-by-overlap-extension
- Each PA DNA fragment was restricted with BamHI restriction enzyme and independently inserted into the coat protein at one of the five different engineered restriction enzyme cleavage sites in the CCMV coat protein coding sequence: BamHI at codon 63, BamHI at codon 102, BamHI at codon 114, BamHI at codon 129, and BamHI at codon 160.
- PA1 SEQ ID NO: 1 encoded by SEQ ID NO: 15
- PA2 SEQ ID NO: 2, encoded by SEQ ID NO: 16
- PA3 SEQ ID NO: 3, encoded by SEQ ID NO:17
- PA4 SEQ ID NO:4, encoded by SEQ ID NO: 18
- PA1 Nucleic Acid Sequence 5′-agt aat tct cgt aag aaa cgt tct acc tct gct ggc cct acc (SEQ ID NO: 15) gtg cct gat cgt gat aat gat ggc aft cct gat-3′ Amino Acid Sequence Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro (SEQ ID NO: 1) Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro Asp PA2 Nucleic Acid Sequence 5′-agt cct gaa gct cgt cat cct ctc gtg gct gcg tat cct att (SEQ ID NO: 16) gtg cat gtt gat atg gaa aat aft atc ctc
- pDOW2125 pUC-CCMV RNA3-CP63BamHI
- pDOW2126 pUC-CCMV-RNA3-102BamHI
- pDOW2127 pUC-CCMV-RNA3-CP114BamHI
- pDOW2128 pUC-CCMV-RNA3-CP129BamHI
- pDOW2129 pUC-CCMV-RNA3-CP160BamHI
- Plasmids pDOW2135 (pUC-CCMV-RNA3-CP63BamHI-PA1), pDOW2139 (pUC-CCMV-RNA3-CP102BamHI-PA1), pDOW2143 (pUC-CCMV-RNA3-CP114BamHI-PA1), pDOW2147 (pUC-CCMV-RNA3-CP129BamHI-PA1), and pDOW2151 (pUC-CCMV-RNA3-CP160BamHI-PA1) are examples of chimeric RNA3 having a PA1 insert at position 63, 102, 114, 129, and 160.
- RNA3 construct was separately sub-cloned in the cloning vector pUC19 downstream from and under the control of a T7 promoter, and upstream from a unique Xba I site.
- RNA transcription kit from Ambion, Inc., Austin, Tex., USA. This produced 24 different RNA varieties: one for RNA1, one for RNA2, 20 for chimeric RNA3, and two for RNA3 controls.
- RNA1, RNA2, RNA3 or chimeric RNA3s containing a PA insert were used to infect cowpea plants.
- Cowpea plants were sprouted from Cowpea California Blackeye #5 seeds (Ferry-Morse Seed Co. KY). Sprouts were transplanted singly into 6 inch pots with Miracle-Gro potting mix (Miracle-Gro Lawn Products OH). Cowpea plants were infected at 2-leaf stage (approximately 7 days post germination). A dusting of Carborundum powder 400grit (Fisher Scientific cat.409-21-2) was applied onto one leaf of each plant.
- RNA cocktail mixes were applied onto the carborundum layer. Leaves were abraded by gentle rubbing with a gloved finger. Infections were established 7-14 days post inoculation.
- cDNAs were further amplified by PCR using primers CCMVRNA4.F (SEQ ID NO:20) (5′-CTG CAG ATG TCT ACA GTC GGA ACA GG-3′) and CCMVRNA4.R.
- the reactions were purified and sequenced with CCMV-CP-F1 primer, (SEQ ID NO: 21) (5′-AAC CCA TCG CTT CAG GCC AA-3′). Sequences were analyzed with Sequencher software version 4.0.5 (Gene Codes Corporation).
- the coat protein contained a small, unrecognized nucleotide insert (5′-CGTATTTCTGATCCTCTC-3′) that was translated as RISDPL instead of the PA1 insert amino acid sequence.
- the inserted nucleotide sequence kept the rest of the coat protein in frame. It has been determined that the engineered CCMV RNA3 is unstable upon expression in the whole plant, easily undergoes recombinations, and that the whole plant system is not useful for production of epitopes on chimeric CCMV virus particles.
- CCMV-peptide-encoding constructs were performed in plant cell suspension culture. Nicotiana tabacum NT1 cells were transfected by electroporation with RNA transcripts of CCMV RNA 3 coding for the chimeric CCMV coat proteins and CCMV RNA 1 and 2 coding for the replicase genes. Wild-type CCMV coat protein-encoding RNA 3 and engineered CCMV coat protein-encoding RNA 3 containing the appropriate BamHI restriction site but no inserts were used as controls.
- RNA1, RNA2, and one of the RNA3s were transformed into tobacco cells by electroporation.
- Murashige & Skoog basal salt (Phyto Technology Laboratories KS cat.M524), 100 mg Myo-Inositol (Sigma cat.I-3011), 1 ml of 1 mg/ml solution of Thiamine HCl (Sigma cat. T-3902), 180 mg Potassium Phosphate Monobasic KH 2 PO 4 (Sigma cat. P-8416), 30 g Sucrose (Sigma cat.S-5390), and 200 ⁇ l 2,4-D solution of 10 mg/ml (Sigma cat. D-7299) were mixed in a small amount of water. Purified water was added to the solution to bring volume up to 1 liter. The pH was adjusted to 5.8, and the solution was autoclaved.
- 0.4M mannitol, and 0.02M MES were mixed in a small amount of water. Purified water was added to bring volume up to 500 ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize, and the solution was stored at 4° C. Prior to use, 1% cellulysin (Calbiochem cat.219466) and 0.3% Macerase Pectinase (Calbiochem cat.441201) was added to solution, and the solution was shaken until cellylysin and Macerase Pectinase were dissolved.
- Tobacco cell line NT 1 was partially digested prior to electroporation as following.
- a robust cell line was maintained by sub-culturing weekly, cells were grown in NTI media at 24° C. or 28° C. with gentle shaking, and three days before digestion, 5 ml of cell suspension was sub-cultured into 50 ml of NTI media and incubated at 28° C. Cells were spun down in Soml tubes for 5 minutes at 800 rpm. The enzyme solution was prepared, and cells were washed in the mannitol wash solution (approx. 40 ml). Cells were spun for 5 minutes at 800 rpm, and 3 volumes of enzyme solution were added to the cells.
- Cells were resuspended by inversion; transferred into 10 cm petri dishes by pouring, and the dish was shaken very slowly at room temperature while wrapped in aluminum foil for 60-120 minutes. The cells were then transferred back into 50 ml plastic tubes; and spun for 5 minutes at 800 rpm. Cells were washed with 40 ml mannitol wash solution and spun again, washed with electroporation buffer, and spun. Three volumes of electroporation buffer (total volume is usually 20 ml) were added to the cells; and the cells were stored at 4° C. wrapped in aluminum foil.
- RNA transcript 1 ml of digested cells were aliquoted into electroporation cuvettes (4 mm gap). 2 ⁇ g each RNA transcript—CCMV RNA1, RNA2, and Chimeric RNA3—were added to the cuvettes and placed on ice for 5 minutes. 10 ml of NTI plating media were added (NTI+0.4M mannitol) to each Petri dish. The cells were electroporated at 500 ⁇ F, 250V, and the cuvettes were placed back on ice. The cells were then transferred into Petri dishes, and incubate at room temperature in darkness with no shaking. The cells were then collected for analysis at 48 hours post transfection.
- chimeric coat protein was analyzed by Western blot using anti-CCMV coat protein polyclonal antibody. Also, RNA was extracted from each of the cultures and the chimeric CCMV RNA4 was reverse transcribed into cDNA, which was then amplified by PCR. The PCR products were sequenced as described in Example 1. All samples were positive on the western blot except for the negative control that was transfected with only RNA1 and 2.
- the chimeric coat proteins Compared to control CCMV capsid proteins, the chimeric coat proteins had greater size and slower mobility on the gel indicating that the chimeric coat proteins contained PA inserts. This was verified by sequencing of the viral RNA progeny. Results demonstrated that 19 out of 20 chimeric constructs expressed the chimeric CCMV coat protein properly without mutation in the desired antigen peptide. The results indicate that chimeric CCMV RNA3s expressed in suspension cells are stable.
- FIG. 2 shows the expression of CCMV CP in cells transfected with CCMV RNA1, RNA2, and RNA3 transcribed from pDOW2125 (CCMV63BamHI), pDOW2126 (CCMV102BamHI), pDOW2127 (CCMV114BamHI), pDOW2128 (CCMV129BamHI) and pDOW2129 (CCMV160BamHI).
- CCMV63BamHI pDOW2125
- pDOW2126 CCMV102BamHI
- pDOW2127 CCMV114BamHI
- pDOW2128 CCMV129BamHI
- pDOW2129 CCMV160BamHI
- FIG. 3 and FIG. 4 show the expression of chimeric CCMV CP in cells transfected with CCMV RNA1, RNA2, and chimeric RNA3 containing CP with the four PA peptide inserts in the position 63, 102, 114, 129, and 160.
- FIG. 3 and FIG. 4 show the expression of chimeric CCMV CP in cells transfected with CCMV RNA1, RNA2, and chimeric RNA3 containing CP with the four PA peptide inserts in the position 63, 102, 114, 129, and 160.
- FIG. 3 demonstrates that the fusion protein of CCMV CP with PA1, PA2, PA3, or PA4 peptide that has been inserted at the position 63, 102, or 114, is expressed in the tobacco plant cells with the exception of PA2 peptide that has been inserted into the CCMP CP at the position 63.
- FIG. 4 demonstrates that the fusion protein of CCMV CP with PA1, PA2, PA3, or PA4 peptide that has been inserted at the position 129 or 160, is expressed in the tobacco plant cells.
- Plasmid pIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were XbaI and EcoRI. This plasmid contains the Cassava Vein Mosaic Virus promoter upstream of the XbaI site and a Nos terminator downstream of the EcoRI site. The vector was prepared by digestion with XbaI and EcoRI and dephosphorylated before litigation with the inserts.
- CCMV CP-PA fusions were amplified by PCR out of pDOW2147 (PUC-CCMV-RNA3-CP129BamHI-PA1), pDOW2148 (pUC-CCMV-RNA3-CP129BamHI-PA2), pDOW2149 (pUC-CCMV-RNA3-CP 129BamHI-PA3), pDOW2150 (pUC-CCMV-RNA3-CP 129BamHI-PA4) using primers CCMV-CP-XbaI (SEQ ID NO:22) and CCMV-CP-EcoRI (SEQ ID NO: 23) to create pDOW2160 (pIL-Tab-CCMV129BamHI-PA1) (SEQ ID NO: 5), pDOW2161 (pIL-Tab-CCMV129BamHI-PA2) (SEQ ID NO:6), pDOW2162 (pIL-Tab-CCMV129BamHI-PA3) (SEQ ID NO:7),
- Plant cells were transfected with 10%g of plasmid pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Plant cell transfection was performed as in Example 2.
- FIG. 9 shows the expression of chimeric CCMV CP in cells transfected with pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Compared to the control (CCMV coat protein with no insert), all four chimeric coat proteins showed slower mobility indicative of having PA inserts.
- Plasmid pIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were XbaI and EcoRI. This plasmid contains the Cassava Vein Mosaic Virus promoter upstream of the XbaI site and a Nos terminator downstream of the EcoRI site. The vector was prepared by digestion with XbaI and EcoRI and depshophorylated before litigation with the inserts.
- CCMV CP-PA fusions containing the 3′UTR of RNA3 were amplified by PCR out of pDOW2147, pDOW2148, pDOW2149, and pDOW2150 using primers CCMV-CP-XbaI and CCMV-CP-EcoRI-3′UTR (SEQ ID NO: 24) to create pDOW2169 (pIL-Tab-CP129BamHI-PA1-3′UTR) (SEQ ID NO: 9), pDOW2170 (pIL-Tab-CP129BamHI-PA2-3′UTR) (SEQ ID NO:
- Plant cells were transfected with 10%g of plasmid pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Plant cell transfection was performed as in Example 2.
- FIG. 10 shows the expression of chimeric CCMV CP in cells transfected with pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Compared to the control (CCMV coat protein with no insert), all four chimeric coat proteins showed slower mobility indicative of having PA inserts.
- Tobacco cell line NT1 was maintained by subculturing weekly. Cells were grown in NTI media at 24° C. or 28° C. with gentle shaking. Three days before transformation, 5 ml of cell suspension was subcultured into 50 ml of NTI media and incubated at 28° C.
- Plasmids pDOW2160, pDOW2161, pDOW2162, pDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter (pBBV) were used for NT1 tobacco cells transformation by micro-particle bombardment.
- the plasmid ratio used was 1:6 pBBV:pDOW2160, pBBV:pDOW2161, pBBV:pDOW2162, or pBBV:pDOW2163. Total of 5 ug of plasmid DNAs were sufficient for 6 bombardments.
- Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
- Bombarded cells were transferred on non-selective NT1 media agar plates for 4 hours before transferring to NT1 media agar plate with 25 ug/ml of Glufosinate-ammonium (Sigma cat#45520).
- FIG. 11 shows the expression of chimeric CCMV CP in cells stably transformed with pDOW2160, pDOW2161, pDOW2162, and pDOW2163.
- the CP fusion was detected by polyclonal antibodies for CCMV. Expression of all four chimeric coat protein transgenes was detected.
- Plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter were used for rice cells transformation by microparticle bombardment.
- the plasmid ratio used was 1:6 pBBV:pDOW2160, pBBV:pDOW2161, pBBV:pDOW2162, or pBBV:pDOW2163. Total of 5 ug of plasmid DNAs were sufficient for 6 bombardments.
- Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
- Bombarded cells were transferred to NB media agar plates with 25 ug/ml of Glufosinate-ammonium (Sigma cat#45520) for selection.
- calli that had white fluffy cell growth were selected for analysis by western blotting to test for the expression of CP fusions and PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome.
- FIG. 12 shows the expression of chimeric CCMV CP in cells stably transformed with pDOW2160, pDOW2161, pDOW2162, and pDOW2163 as detected by polyclonal antibodies to CCMV. Expression of all four chimeric coat protein transgenes was detected.
- Approximately 50-100 mg of fresh rice callus was placed into a 1.5 ml tube. The tissue was frozen in liquid N 2 for immediate DNA extraction or placed in ⁇ 80° C. freezer for storage. Prior to DNA extraction the tissue was manually disrupted by grinding with a micropestle. The sample was placed on ice and the genomic DNA was extracted as described in Qiagen DNeasy Plant Mini Kit manual.
- the Access Quick Master Mix 2 ⁇ (Promega cat#A1720) was used to set up the PCR reaction as follows: Master mix 25 ul CCMV-F (10 mM) primer, SEQ ID NO: 25 1 ul Nos-term-R (10 mM) primer, SEQ ID NO: 26 1 ul Genomic DNA 1 ul water 22 ul Total 50 ul
- the following PCR cycle has been used to amplify the promoter-CP fusion gene-terminator cassette from the genomic DNA: 1 cycle 95° C. 2 min 35 cycles of 95° C. 30 sec 55° C. 30 sec 70° C. 2 min 1 cycle 70° C. 5 min 4° C. hold
- FIG. 13 shows a PCR products amplified from selected individual rice calli. The samples that contained a PCR product of predicted size were scored as positive for stable transformation and integration of the chimeric CP transgene into the plant genome.
- Transgenic calli expressing chimeric CCMV CPs were transferred to liquid NB media to create a cell suspension culture suitable for scale up fermentation. Cells were grown in NB media at 28° C. with gentle shaking and subcultured weekly.
- Chimeric VLPs were precipitated by lysis of shake-flask culture samples, followed by PEG (polyethylene glycol)-treatment of the resulting cell lysates and ultrafiltration, according to the following protocol:
- FIG. 14 shows that the chimeric CCMV VLPs were recovered from cells stably transformed with pDOW2160. Chimeric CP-PA1 fusion proteins were detected in the resuspended PEC pellets but not the supernatant indicating the chimeric CP assembled into VLPs.
- the resuspended samples were centrifuged for 10 min at 15,000 ⁇ G at 4° C., the supernatant was recovered and subjected to the second round of PEG precipitation.
- PEG8000 was added to final concentration of 15% and stirred at 4° C. for 2 hours.
- the solution was then centrifuged at 15,000 ⁇ G for 10 mins and the pellet was resuspended in small volume of virus buffer.
- the resuspended VLP solution was loaded on to Centricon Plus-20 with 300K molecular weight cut-off and spun at 4,000 ⁇ G for 5 mins.
- the concentrated VLP sample was then analyzed by western blotting with polyclonal anti-CCMV antibodies (see FIG. 14 ). Chimeric CP-PA1 fusion proteins were detected in the resuspended and size-filtered second PEG pellets, but not in the supernatant, indicating the chimeric CP assembled into VLPs.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional patent application Ser. No. 60/548,744, filed Feb. 27, 2004, entitled “High Efficiency Peptide Production in Plant Cells.”
- This application is under a United States Government contract with the National Institutes of Health, National Institute of Allergy and Infectious Disease (NIAID), Cooperative Agreement No. 1-U01-AI054641-01.
- The present invention provides an improved process for the production of recombinant peptides. In particular, the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures. The invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production.
- Bacterial, yeast, plant, insect, and mammalian cell expression systems are currently used to produce recombinant peptides, with varying degrees of success. One goal in creating expression systems for the production of heterologous peptides is to provide broad based, flexible, efficient, economic, and practical platforms and processes that can be utilized in commercial, therapeutic, and vaccine applications. For example, for the production of certain peptides, it would be ideal to have an expression system capable of producing, in an efficient and inexpensive manner, large quantities of final, desirable products in vivo in order to eliminate or reduce downstream reassembly costs.
- Currently, bacteria are the most widely used expression system for the production of recombinant peptides because of their potential to produce abundant quantities of recombinant peptides. Bacteria generally do not glycosylate, acetylate, acylate, phosphorylate, or gamma-carboxylate eukaryotic proteins, and, therefore, are limited in their capacities to produce, in vivo, certain types of heterologous eukaryotic peptides that require post-translational modifications. Additional steps modifying the bacterially produced eukaryotic peptides are likely to increase the time and reduce the overall yield of peptide production, diluting many of the advantages of the bacterial host expression system. Therefore, alternative non-bacterial expression systems have been utilized to overcome the inherent limitations of bacterial expression systems.
- One particular host expression systems analyzed for their ability to produce heterologous peptides has been whole plants and plant cell suspension cultures. The safe and inexpensive culture of plants provides an improved alternative host for the cost effective production of certain peptides. This alternative is particularly attractive where the protein is complex, requires glycosylation, needs to be free of human or animal infectious viruses, and bacterial toxins.
- Whole plants offer the advantages of being relatively inexpensive to grow in vast quantities, with the potential for a great yield of the desired recombinant protein from the large biomass of the harvested transgenic or viral infected plants. As a result, whole plants have been developed as expression systems for commercial production of biopharmaceutical proteins intended for human or veterinary administration.
- Significant time and resources have been spent on trying to improve the cost of production and yield of heterologous proteins in non-bacterial systems in order to take advantage of the inherent abilities of these systems. While progress has been made in both of these areas, additional processes and platforms for the production of heterologous peptides in non-bacterial expression systems would be beneficial.
- Viruses and Virus Like Particles
- One approach for improving peptide production in host cell expression systems is to make use of the properties of infectious recombinant viruses to produce recombinant peptides of interest. The use of infectious viruses in plant host systems is particularly well known. See, for example, Porta & Lomonossoff, (2002) “Viruses as vectors for the expression of foreign sequences in plants,” Biotechnology and Genetic Enginering Reviews 19: 245-291.
- Recent strategies have focused on the production of heterologous peptides in virus like particle (VLP) structures. In general, encapsidated viruses include a protein coat or “capsid” that is assembled to contain the viral nucleic acid. Many viruses have capsids that can be “self-assembled” from the individually expressed capsids, both within the cell the capsid is expressed in (“in vivo assembly”), and outside of the cell after isolation and purification (“in vitro assembly”). Ideally, capsids are modified to contain a target recombinant peptide, generating a recombinant viral capsid-peptide fusion. The fusion peptide can then be expressed in a cell, and, ideally, assembled in vivo to form recombinant viral or virus-like particles.
- The production of heterologous proteins via virus capsid fusion proteins assembled into VLPs in plants has been met with varying success. See, for example, C Marusic et al., J. Virol. 75(18):8434-39 (September 2001) (use of infectious helical potato virus X in whole Nicotiana benthamiana to express virus capsids terminally fused to an antigenic, six amino acid HIV peptide, with in vivo formation of the recombinant virus particles); FR Brennan et al., Vaccine 17(15-16):1846-57 (9 Apr. 1999) (use of infectious cowpea mosaic virus or helical potato virus X capsids terminally fused to an antigenic, Staphylococcus aureus peptide, with in vivo formation of recombinant virus particles expression in whole cowpea plants (Vigna uniquiculata)); C Porta et al., Intervirology 39(1-2):79-84 (1996) (describing an infectious cowpea mosaic virus expressing a chimeric coat protein including an antigenic HIV sequence in whole plants).
- U.S. Pat. No. 5,874,087 to Lomonossoff & Johnson describes production of infectious plant viruses, in plant cells or whole plants, wherein the viral capsids are engineered to contain a biologically active peptide, such as a hormone, growth factor, or antigenic peptide. A virus selected from the genera Comovirus, Tombusvirus, Sobemovirus, and Nepovirus is engineered to contain the exogenous peptide encoding sequence and the entire engineered genome of the virus is expressed to produce the recombinant virus. The specification stresses that multiplication of the modified virus is a central part of the invention.
- U.S. Pat. No. 6,232,099 to Chapman et al. describes the use of infective, rod-shaped viruses to produce foreign proteins connected to viral capsid subunits in whole plants. Rod-shaped viruses, also classified as helical viruses, such as potato virus X (PVX) have recombinant peptides of interest inserted into the genome of the virus to create recombinant viral capsid-peptide fusions. The recombinant, infective virus is then used to infect a plant cell of a whole plant, wherein, the virus actively replicates in the plant cell and further infects other cells, ultimately infecting the entire host plant. Ultimately, the recombinant viral capsid-peptide fusion is purified from the plant.
- Chapman et al. also teaches that a limited insertion size is tolerated by icosahedral viruses. Chapman et al. cite WO 92/18618, which limits the size of the recombinant peptide in an icosahedral virus for expression in a plant host cell to 26 amino acids in length, in supporting his assertion. Chapman et al. theorize that a larger peptide present in the internal insertion site in the capsid of icosahedral viruses may result in disruption of the geometry of the protein and/or its ability to successfully interact with other capsids leading to failure of the chimeric virus to assemble.
- U.S. Pat. No. 6,042,832 to Koprowski et al. describes fusion capsid proteins comprising a plant virus capsid protein fused to an antigenic polypeptide. The resultant particles are produced in whole plants.
- The utilization of infectious recombinant viruses to produce heterologous proteins in capsid fusion proteins is not, however, without its drawbacks. One particularly troubling aspect is the ability of these viruses to mutate in vivo, resulting in capsid proteins that are essentially wild type revertants without the fused heterologous protein of interest, or mutated, non-desirable recombination capsid fusion protein products. See, or example, Porta & Lomonossoff (1996) “Use of viral replicons for the expression of genes in plants,” Molecular Biotechnology 5:209-221; Dolja et al. (1993) “Spontaneous mutagenesis of a plant potyvirus genome after insertion of a foreign gene,” J. Virol. 67(10):5968-5975; Dawson et al. (2001) “Assessment of recombinants that arise from the use of a TMV-based transient expression vector,” Virol. 284(2):182-189 (describing the deletion of the foreign inserted gene in inoculated whole plants). The lack of stability of these viral vectors in whole plants potentially reduces the yield of overall protein product, and may lead to inconsistencies and irregularities in the capsid-fusion product. Such irregularities may be particularly troublesome wherein the integrity of the protein product is essential for a particular desired physio-chemical characteristic in the peptide.
- As a result of the inherent instability of infectious recombinant viruses in plants, there is still a need in the field of commercial recombinant protein production for an efficient peptide production system that offers plant-system-type benefits.
- In addition, the use of whole plants for the production of recombinant peptides also presents potential problems. For instance, long development times, batch to batch variations in product yield, containment issues, the difficulty of applying good manufacturing practice to the early stages of production, the possibility of contamination with agrochemicals and fertilizers, as well as the impact of pests, disease and variable cultivation conditions due to microclimate and soil differences all result in a potential inconsistent host system for the production of recombinant peptides.
- Therefore, it is an object of the present invention to provide a stable and consistent plant cell expression system for the production of virus like particles containing capsid fusion proteins.
- It is another object of the present invention to provide plant cells for use as host cells in a stable expression system for the production of virus like particles containing capsid fusion proteins.
- It is still another object of the present invention to provide processes for the improved production of virus like particles containing capsid fusion proteins in plant cells, including plant cell suspension cultures.
- It is yet another object of the present invention to provide novel constructs and nucleic acids for use in plant cell expression system for the production of virus like particles containing capsid fusion proteins.
- The present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture. The viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles. The present invention does not require the utilization of an infective viral agent; rather, non-infectious nucleic acid encoding a capsid-heterologous peptide fusion product is stably inserted into the genome of a plant cell, which can be cultured in a fermentation process to produce the peptide of interest. Such a process results in a less variable, and more stable host system for the expression of capsid fusion proteins containing heterologous peptides.
- It has been discovered that infectious viruses containing capsid-heterologous peptide fusion proteins utilized to express heterologous peptides of interest in whole plants exhibit genetic instability in the whole plant that results in mutations in the recombinant capsid protein nucleic acid, and the expressed mutant capsid either cannot assemble into virus particles or contains a mutated target peptide. The present invention provides increased stability of the resultant heterologous peptide, with the additional benefits of precise control over growth conditions, batch to batch consistency, a high level of containment, and the ability to produce recombinant proteins in compliance with good manufacturing practices.
- The capsid-fusion protein products can form virus like particles within the cell. The virus like particle may result in the improved efficiency of achieving a high purity of the recovered peptide. The virus like particles produced in the cell typically are not capable of infecting the plant cell. The viral capsid sequence can be derived from both trophic and non-trophic viruses, wherein trophism is determined by the specific plant cell utilized as the expression host. In one embodiment, the viral capsid protein is derived from a virus that exhibits a native or natural trophism towards the plant cell utilized to express the fusion product. In one embodiment, the viral capsid protein is derived from a virus that does not exhibit a native or natural trophism towards the plant cell utilized to express the fusion product. In one embodiment, the cell does not include artificially introduced viral proteins other than the desired capsid protein sequences utilized to produce the fusion product. In another embodiment, the cell includes artificially introduced viral proteins or nucleic acids other than the desired capsid protein sequences utilized to produce the fusion product, wherein the additional viral proteins or nucleic acids do not confer infectivity to the nucleic acid sequences. In one embodiment, the viral capsid is derived from a virus with a tropism to a different family of organisms than the plant cell expression host. In another embodiment, the viral capsid is derived from a virus with a tropism to a different genus of organisms than the plant cell expression host. In another embodiment, the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell utilized to express the fusion product. In one embodiment of the present invention, the capsid is derived from a rod shaped plant virus. In a particular embodiment, the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus and Potato Virus X (PVX). In one embodiment of the present invention, the capsid protein is derived from an icosahedral virus. In a particular embodiment, the capsid is derived from a plant icosahedral virus. In a more particular embodiment, the icosahedral capsid is derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
- The present invention also provides plant cells that include a non-infectious nucleic acid construct containing an expression cassette encoding for a fusion protein of a virus capsid and a recombinant peptide. The fusion peptide of the virus capsid and recombinant peptide is operably linked to a promoter and terminator that functions in plant cells. In one specific embodiment, the nucleic acid is genomically integrated in the plant cell, wherein the integration results in the stable inheritance and expression of the nucleic acid encoding the capsid fusion protein from generation to generation. In one specific embodiment of the present invention, the capsid protein is derived from an icosahedral virus. In one embodiment the cell produces virus like particles or soluble cage structures. In one embodiment, the plant cell is a Monocot or a Dicot. In a particular embodiment, the plant cell is Nicotiana tabacum. In an alternative embodiment, the plant cell is Oryza sativa. In one embodiment of the present invention, the recombinant peptide fused to the viral capsid protein is a therapeutic peptide useful for human or animal treatments. In one particular embodiment, the recombinant peptide is an antigenic peptide. In a particular embodiment, the antigenic peptide is a glycosylated antigenic peptide. In one embodiment, the plant cells or extracts containing capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal. In an alternative embodiment, the purified capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal. In one embodiment, the heterologous peptide is an antimicrobial peptide. In another particular embodiment, the recombinant peptide is a peptide that is toxic to the plant host cell when in free monomeric form. In one embodiment, the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids in length.
- In one embodiment of the present invention, the recombinant peptide fused to the capsid contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In certain embodiments, the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid. In another embodiment, the individual monomers in the concatameric peptide are linked by cleavable linker regions. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the viral capsid. In one embodiment, the recombinant peptide is inserted into at least one surface loop of an icosahedral viral capsid. In one embodiment, at least one monomer is inserted into more than one surface loops of a viral capsid protein. In still another embodiment, the recombinant peptide is inserted into at least one outer surface loop of the viral capsid. In an alternative embodiment, the recombinant peptide is inserted into at least one inner surface loop of the viral capsid.
- More than one loop of the virus like particle can be modified. In one particular embodiment, the recombinant peptide is expressed on at least two surface loops of the virus-like particle. In another embodiment, at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle. In another embodiment, at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle. The recombinant peptides in the surface loops can have the same amino acid sequence. In separate embodiments, the amino acid sequence of the recombinant peptides in the surface loops differ.
- In still another embodiment, the cell includes at least one additional nucleic acid encoding either a wild-type capsid or different capsid-recombinant peptide fusion peptide, wherein the multiple capsids can be assembled in vivo to produce chimeric virus like particles.
- In one aspect of the present invention, plant cells are provided that include a fusion protein of a viral capsid and a recombinant peptide. In one specific embodiment of the present invention, the plant cell is a monocot. In an alternative embodiment, the plant cell is a dicot. In one embodiment, the capsid-recombinant peptide fusion protein assembles in vivo to form a virus like particle.
- In one embodiment of the present invention, the plant cells containing the nucleic acid construct encoding the capsid protein-recombinant peptide fusion peptide is obtained by nuclear transformation. In one embodiment, the plant cell is obtained by plastid transformation. In still another embodiment, the plant cell is obtained by chloroplast transformation.
- The present invention further provides for non-infectious nucleic acid constructs containing an expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide. In one embodiment of the present invention, the expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide is operably linked to a promoter and terminator. In one embodiment of the present invention, the capsid is derived from a plant virus. In one embodiment of the present invention, the capsid is derived from an icosahedral plant virus. In a particular embodiment, the capsid is an icosahedral viral capsid derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
- In one embodiment of the present invention, the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus capsid.
- In another embodiment, the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cell. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cells, and at least one terminator that functions in plant cells. In one embodiment, a nucleic acid sequence encoding a selection marker operably linked to a promoter and a terminator sequence is included in the nucleic acid construct. In an alternative embodiment, a selection marker operably linked to a promoter and a termination sequence is provided on a separate nucleic acid construct. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences derived from the 3′ untranslated region (3′ UTR) of the viral RNA. In still another embodiment, the nucleic acid construct includes at least one encapsidation signal derived from the viral RNA. In still another embodiment, the non-infectious nucleic acid construct includes additional nucleic acid sequences derived from the viral RNA, wherein the additional sequences do not confer infectivity to the viral nucleic acids.
- In one aspect, the present invention provides a process for producing a recombinant peptide including:
-
- a) providing a plant cell;
- b) providing a non-infectious nucleic acid encoding a fusion peptide, wherein the fusion is of at least one heterologous peptide and at least one viral capsid protein;
- c) transforming the plant cell, wherein the nucleic acid is subsequently integrated into the genome of the plant cell;
- d) expressing the nucleic acid in the plant cell, wherein the plant cells are grown in a suspension plant cell culture in a fermentation process;
- e) wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and
- f) isolating the virus like particles.
- In one embodiment, the process further includes: e) cleaving the fusion product to separate the recombinant peptide from the viral capsid protein. In still another embodiment, the process further provides: f) following step (e), isolating the recombinant peptide. See, for example,
FIG. 1 . In one embodiment of the present invention, the plant cell is selected from the group consisting of Oryza sativa and Nicotiana tabacum. - The nucleic acid encoding a recombinant peptide and a viral capsid protein is operably linked to a promoter sequence and a terminator sequence.
- In one embodiment, the process includes co-expressing another nucleic acid encoding a wild-type capsid or a different capsid-recombinant peptide fusion peptide, wherein the capsids are assembled in vivo to produce chimeric virus like particles.
- In another aspect of the present invention, an expression system for the production of recombinant peptides is provided including:
-
- a) a plant cell capable of being propagated in a plant cell medium;
- b) a non-infectious nucleic acid encoding a fusion peptide; wherein the fusion peptide comprises at least one recombinant peptide, and at least one viral capsid, and wherein the nucleic acid is capable of genomic integration and expression in the plant cell; and
- c) a growth medium.
- The nucleic acid encoding the fusion peptide can be operably linked to a promoter sequence and a terminator sequence. When expressed the fusion peptide can assemble into virus like particles within the cell. In one embodiment, the promoter is a plant promoter.
-
FIG. 1 illustrates a scheme for production of peptide monomers in Virus-Like Particles (VLP) in plant cells. A sequence encoding a desired target peptide (“I”) is inserted into a sequence encoding a viral coat protein (“CP”) constructing a gene encoding recombinant viral coat protein (“rCP”), which, as part of a vector, is transformed into the plant cell and expressed to form recombinant coat proteins (“rCP”). Optional cleavage sites (“*”) are also shown. A plant cell is transfected or transformed with a plant expression plasmid for with the rCP gene. rCP can assemble into VLPs in plant cells. The peptide insert is displayed on VLP surfaces. Chimeric VLPs can be purified from the plant cells, and the desired target peptides can optionally be cleaved off the purified VLPs and purified. -
FIG. 2 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNA1, RNA2, and one of the RNA3s transcribed from pDOW2124 (CCMV-RNA3-CP), pDOW2125 (CCMV-RNA3-CP63BamHI), pDOW2126 (CCMV-RNA3-CP102BamHI), pDOW2127 (CCMV-RNA3-CP114BamHI), pDOW2128 (CCMV-RNA3-CP129BamHI), and pDOW2129 (CCMV-RNA3-CP160BamHI). The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents Buffer only,Lane 2 represents RNA1 and RNA2 only,Lane 3 represents RNA1 and RNA2+wt RNA3 transcribed from pDOW2124,Lane 4 represents RNA1 and RNA2+RNA3 transcribed from pDOW2125,Lane 5 represents RNA1 and RNA2+RNA3 transcribed from pDOW2126,Lane 6 represents RNA1 and RNA2+RNA3 transcribed from pDOW2127,Lane 7 represents RNA1 and RNA2+RNA3 transcribed from pDOW2128,Lane 8 represents RNA1 and RNA2+RNA3 transcribed from pDOW2129. -
FIG. 3 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNA1, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PA1, PA2, PA3, or PA4 at the position 63, 102, or 114. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents a size marker,Lane 2 represents Buffer only,Lane 3 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 63,Lane 4 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 63,Lane 5 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 63,Lane 6 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 63,Lane 7 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 102,Lane 8 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 102,Lane 9 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 102,Lane 10 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 102,Lane 11 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 114,Lane 12 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 114,Lane 13 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 114, andLane 14 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 114. -
FIG. 4 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNA1, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PA1, PA2, PA3, or PA4 at the position 129 or 160. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents a size marker,Lane 2 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 129,Lane 3 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 129,Lane 4 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 129,Lane 5 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 129,Lane 6 represents RNA1+RNA2+chimeric RNA3 with PA1 in CP at position 160,Lane 7 represents RNA1+RNA2+chimeric RNA3 with PA2 in CP at position 160,Lane 8 represents RNA1+RNA2+chimeric RNA3 with PA3 in CP at position 160,Lane 9 represents RNA1+RNA2+chimeric RNA3 with PA4 in CP at position 160,Lane 10 represents RNA1+RNA2+wt RNA3, andLane 11 represents Buffer only. -
FIG. 5 shows plasmid map of pDOW2160. -
FIG. 6 shows plasmid map of pDOW2161. -
FIG. 7 shows plasmid map of pDOW2162. -
FIG. 8 shows plasmid map of pDOW2163. -
FIG. 9 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents Buffer only, Lane 2-6 represent RNA1+RNA2+wt RNA3 (control),Lane 7 represents pDOW2160,Lane 8 represents pDOW2161,Lane 9 represents pDOW2162, andLane 10 represents pDOW2163. -
FIG. 10 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2169, pDOW2170, pDOW2171, and pDOW2172. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents RNA1+RNA2+RNA3 (control),Lane 2 represents Buffer,Lane 3 represents pDOW2169,Lane 4 represents pDOW2170,Lane 5 represents pDOW2171, andLane 6 represents pDOW2172. -
FIG. 11 shows expression of chimeric CCMV CP in tobacco NT1 cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents Untransformed tobacco cells (negative control),Lane 2 represents Transgenic tobacco cells transformed with pDOW2160,Lane 3 represents Transgenic tobacco cells transformed with pDOW2161,Lane 4 represents Transgenic tobacco cells transformed with pDOW2162, andLane 5 represents Transgenic tobacco cells transformed with pDOW2163. -
FIG. 12 shows expression of chimeric CCMV CP in rice cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents wt CCMV CP (positive control),Lane 2 represents Size ladder,Lane 3 represents Non-transgenic rice cells (negative control),Lane 4 represents Transgenic rice cells transformed with pDOW2160,Lane 5 represents wt CCMV CP (positive control),Lane 6 represents Size ladder,Lane 7 represents Non-transgenic rice cells,Lane 8 represents Transgenic rice cells transformed with pDOW2161,Lane 9 represents wt CCMV CP (positive control),Lane 10 represents Size ladder,Lane 11 represents Non-transgenic rice cells (negative control),Lane 12 represents Transgenic rice cells transformed with pDOW2162,Lane 13 represents wt CCMV CP (positive control),Lane 14 represents Size ladder,Lane 15 represents Non-transgenic rice cells (negative control), andLane 16 represents Transgenic rice cells transformed with pDOW2163. -
FIG. 13 shows detection of PCR products amplified from selected individual rice calli transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. 1.2% agarose gel stained with EtBr showing PCR products amplified from selected individual rice calli. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome.Lane 1 represents Rice calli 46-5,Lane 2 represents Rice calli 46-11,Lane 3 represents Rice calli 46-17,Lane 4 represents Size Ladder,Lane 5 represents Rice calli 47-6,Lane 6 represents Rice calli 48-12,Lane 7 represents Rice calli 48-18,Lane 8 represents Rice calli 48-20,Lane 9 represents Rice calli 49-11,Lane 10 represents Rice calli 49-18, andLane 11 represents Negative control (non-transgenic rice cells). -
FIG. 14 shows western blot analysis of chimeric CCMV VLPs purified from rice cells stably transformed with non-infectious plasmid pDOW2160 by PEG precipitation and ultra-filtration and detection of chimeric CP-PA1 fusion proteins in the purified VLP samples. The samples were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.Lane 1 represents Size ladder,Lane 2 represents Total cell lysate from rice suspension cells transgenic for CCMV CP-PA1 fusion,Lane 3 represents First PEG supernatant,Lane 4 represents First PEG pellet,Lane 5 represents Second PEG pellet, andLane 6 represents Second PEG supernatant. -
FIG. 15 shows diagram of production process of chimeric VLPs in plant suspension cells by fermentation. - The present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture. The viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles. The present invention further provides plant cells and nucleic acid constructs for use in the process. Specifically, the invention provides plant cells, capable of propagation in suspension plant cell cultures, with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide. The fusion peptide can be operably linked to a promoter sequence and a termination sequence. In one embodiment, the expression in the plant cell of the fusion peptide produces virus like particles or soluble cage structures. The invention also provides nucleic acid constructs capable of integrating into the genome of the plant cell and encoding the fusion peptide of a viral capsid and a recombinant peptide, which can in one embodiment, be a therapeutic peptide useful for human and animal treatments.
- The invention also provides a process for producing a recombinant peptide in a suspension plant cell culture by providing: a nucleic acid capable of genomic integration in a plant cell containing an expression cassette encoding a fusion peptide of a recombinant peptide and a viral capsid operably linked to a promoter sequence and a termination sequence; expressing the nucleic acid in the plant cell in a suspension plant cell culture, wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and isolating the virus like particles.
- The term “infectious” as used herein means the ability of a virus particle to transfer its nucleic acid to a host or introduction of a viral nucleic acid into a host, wherein the viral nucleic acid is replicated, viral proteins are translated, and new viral particles capable of further transfer of nucleic acid to a host are assembled. The term “non-infectious” as used herein means the inability of a virus-derived nucleic acid to replicate in a host after introduction into a host, wherein the viral proteins are translated, and new virus like particles assembled that are not capable of initiating viral infection process in a host. The term “peptide” as used herein is not limited to any particular molecular weight, and can also include proteins or polypeptides.
- The present invention provides plant cells that include a non-infectious nucleic acid construct capable of genomic integration and encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence. The cells can be utilized in a process for producing recombinant peptides.
- The plant cells can be derived by transforming the native plant cell with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence, wherein the nucleic acid construct is stably integrated into the host cell's genome. Stable transformation depends on the integration of the foreign DNA into the genome. The foreign DNA can be integrated into the nuclear or plastid genome of the plant. The nucleic acid construct can be randomly inserted into the genome of the plant, or can be directed to a particular region of the genome through homologous recombination. The plant cell can be obtained by any means known in the art, including nuclear transformation, plastid transformation, and chloroplast transformation. See, for example, U.S. Pat. No. 6,218,145; EP 012345149; WO 0121782; U.S. Pat. No. 6,515,206; WO 99/10513; U.S. Pat. No. 5,693,507; WO 02055651; WO 0170939; U.S. Pat. No. 6,472,586; WO 02057466; U.S. Pat. No. 5,057,422; WO 0120974 Staub, J. M. and Maliga, P, (1992) “Long regions of homologous DNA are incorporated into the tobacco plastid genome by transformation,” Plant Cell 4: 39-45.
- Viral Capsids
- In one embodiment, the invention provides plant cells for use in a process for producing peptides by expression of the peptide fused to a viral capsid from a non-infectious plasmid stably integrated into the host genome. The expression can result in the formation of at least one virus like particle (VLP) in the cell.
- Viruses can be classified into those with helical symmetry or icosahedral symmetry. Generally recognized capsid morphologies include: icosahedral (including icosahedral proper, isometric, quasi-isometric, and geminate or “twinned”), polyhedral (including spherical, ovoid, and lemon-shaped), bacilliform (including rhabdo- or bullet-shaped, and fusiform or cigar-shaped), and helical (including rod, cylindrical, and filamentous); any of which may be tailed and/or may contain surface projections, such as spikes or knobs.
- Morphology
- In one embodiment of the invention, the amino acid sequence of the capsid is selected from the capsids of viruses classified as having any morphology. In one embodiment, the capsid is derived from a rod shaped virus. In a particular embodiment, the capsid is derived from a rod shaped plant virus. In a more particular embodiment, the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus (TMV) and Potato Virus X (PVX). TMV consists of a single plus-sense genomic RNA (6.5 kb) encapsidated with a unique coat protein (17.5 kDa) which results in rod-shaped particles (300 nm). Potato Virus X are filamentous, non enveloped; usually flexuous viruses with a clear modal length of 515 nm and 13 nm wide (Brandes, 1964). The capsid structure forms a basic helix with a pitch of 3.4 nm (Varma et al., 1968).
- In one embodiment, the capsid has an icosahedral morphology. In one embodiment, the capsid amino acid sequence will be selected from the capsids of entities that are icosahedral proper. In another embodiment, the capsid amino acid sequence will be selected from the capsids of icosahedral viruses. In one particular embodiment, the capsid amino acid sequence will be selected from the capsids of icosahedral plant viruses. However, in another embodiment, the viral capsid will be derived from an icosahedral virus not infectious to plants. For example, in one embodiment, the virus is a virus infectious to mammals.
- Generally, viral capsids of icosahedral viruses are composed of numerous protein sub-units arranged in icosahedral (cubic) symmetry. Native icosahedral capsids can be built up, for example, with 3 subunits forming each triangular face of a capsid, resulting in 60 subunits forming a complete capsid. Representative of this small viral structure is e.g. bacteriophage ØX174. Many icosahedral virus capsids contain more than 60 subunits. Many capsids of icosahedral viruses contain an antiparallel, eight-stranded beta-barrel folding motif. The motif has a wedge-shaped block with four beta strands (designated BIDG) on one side and four (designated CHEF) on the other. There are also two conserved alpha-helices (designated A and B), one is between betaC and betaD, the other between betaE and betaF.
- Enveloped viruses can exit an infected cell without its total destruction by extrusion (budding) of the particle through the membrane, during which the particle becomes coated in a lipid envelope derived from the cell membrane (See, e.g.: A J Cann (ed.) (2001) Principles of Molecular Virology (Academic Press); A Granoff and R G Webster (eds.) (1999) Encyclopedia of Virology (Academic Press); D L D Caspar (1980) Biophys. J. 32:103; D L D Caspar and A Klug (1962) Cold Spring Harbor Symp. Quant. Biol. 27:1; J Grimes et al. (1988) Nature 395:470; J E Johnson (1996) Proc. Nat'l Acad. Sci. USA 93:27; and J Johnson and J Speir (1997) J. Mol. Biol. 269:665).
- Viruses
- Viral taxonomies recognize the following taxa of encapsidated-particle entities:
-
- Group I Viruses, i.e. the dsDNA viruses;
- Group II Viruses, i.e. the ssDNA viruses;
- Group III Viruses, i.e. the dsRNA viruses;
- Group IV Viruses, i.e. the ssRNA (+)-stranded viruses with no DNA stage;
- Group V Viruses, i.e. the ssRNA (−)-stranded viruses;
- Group VI Viruses, i.e. the RNA retroid viruses, which are ssRNA reverse transcribing viruses;
- Group VII Viruses, i.e. the DNA retroid viruses, which are dsDNA reverse transcribing viruses;
- Deltaviruses;
- Viroids; and
- Satellite phages and Satellite viruses, excluding Satellite nucleic acids and Prions.
- Members of these taxa are well known to one of ordinary skill in the art and are reviewed in: H. V. Van Regenmortel et al. (eds.), Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses (2000) (Academic Press/Elsevier, Burlington Mass., USA); the Virus Taxonomy web-page of the University of Leicester (UK) Microbiology & Immunology Department at http://wwwmicro.msb.le.ac.uk/3035/Virusgroups.html; and the on-line “Virus” and “Viroid” sections of the Taxonomy Browser of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine of the National Institutes of Health of the US Department of Health & Human Services (Washington, D.C., USA) at http://www.ncbi.nlm.nih.gov/Taxonomy/tax.html.
- The amino acid sequence of the capsid may be selected from the capsids of any members of any of these taxa. Amino acid sequences for capsids of the members of these taxa may be obtained from sources, including, but not limited to, e.g.: the on-line “Nucleotide” (Genbank), “Protein,” and “Structure” sections of the PubMed search facility offered by the NCBI at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi.
- In one embodiment, the capsid amino acid sequence will be selected from taxa members that are specific for at least one of the following hosts: bacteria, fingi including yeasts, plants, protists including algae, invertebrate animals, vertebrate animals, and humans. In one embodiment, the capsid amino acid sequence will be selected from members of any one of the following taxa: Group I, Group II, Group III, Group IV, Group V, Group VII, Viroids, and Satellite Viruses. In one embodiment, the capsid amino acid sequence will be selected from members of any one of these seven taxa that are specific for at least one of the six above-described host types. In a more specific embodiment, the capsid amino acid sequence will be selected from members of any one of Group II, Group III, Group IV, Group VII, and Satellite Viruses; or from any one of Group II, Group IV, Group VII, and Satellite Viruses. In another embodiment, the viral capsid is selected from Group IV or Group VII.
- The viral capsid sequence can be derived from a virus not tropic to the cell. In one embodiment, the cell does not include viral proteins from the particular selected virus other than the desired icosahedral capsids. In one embodiment, the viral capsid is derived from a virus with a tropism to a different family of organisms than the cell. In another embodiment, the viral capsid is derived from a virus with a tropism to a different genus of organisms than the cell. In another embodiment, the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell.
- In a specific embodiment, the viral capsid is selected from a virus of Group IV.
- In one embodiment, the viral capsid is selected from rod-shaped plant viruses. In a more particular embodiment, the viral capsid is selected from the group consisting of Tobacco Mosaic Virus and Potato Virus X.
- In one embodiment, the viral capsid is selected form an icosahedral virus. The icosahedral virus can be selected from a member of any of the Papillomaviridae, Totiviridae, Dicistroviridae, Hepadnaviridae, Togaviridiae, Polyomaviridiae, Nodaviridae, Tectiviridae, Leviviridae, Microviridae, Sipoviridae, Nodaviridae, Picornoviridae, Parvoviridae, Calciviridae, Tetraviridae, and Satellite viruses.
- In a particular embodiment, the sequence will be selected from members of any one of the taxa that are specific for at least one plant host. In one embodiment the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Bunyaviridae, Reoviridae, Rhabdoviridae, Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa. In one embodiment, the icosahedral plant virus species is a plant-infectious virus species that is or is a member of any of the Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa. In specific embodiments, the icosahedral plant virus species is a plant infectious virus species that is or is a member of any of the Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae. In more particular embodiments, the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae. In more particular embodiments, the icosahedral plant virus species will be a plant-infectious virus species that is a member of the Comoviridae or Bromoviridae family. In a particular embodiment the viral capsid is derived from a Cowpea Mosaic Virus or a Cowpea Chlorotic Mottle Virus. In another embodiment, the viral capsid is derived from a species of the Bromoviridae taxa. In a specific embodiment, the capsid is derived from an Ilarvirus or an Alfamovirus. In a more specific embodiment, the capsid is derived from a Tobacco streak virus, or an Alfalfa mosaic virus (AMV) (including
AMV 1 or AMV 2). - VLP
- The viral capsid of the invention is non-infective in the host cells described. In one embodiment, a virus like particle (VLP) or cage structure is formed in the host cell during or after expression of the viral capsid. In one embodiment, the VLP or cage structure also includes the peptide of interest, and in a particular embodiment, the peptide of interest is expressed on the surface of the VLP. The expression system typically does not contain additional viral proteins that allow infectivity of the virus. In a typical embodiment, the expression system includes a host cell and a vector which codes for one or more viral capsids and an operably linked peptide of interest. The vector typically does not include additional viral proteins. The invention is derived from the discovery that viral capsids form to a greater extent in certain host cells and allow for more efficient recovery of recombinant peptide.
- In one embodiment, the VLP or cage structure is a multimeric assembly of capsids, including from three to about 1,000 capsids. In one embodiment, the VLP or cage structure includes at least 30, at least 50, at least 60, at least 90 or at least 120 capsids. In another embodiment, each VLP or cage structure includes at least 150 capsids, at least 160, at least 170, or at least 180 capsids.
- In one embodiment, the VLP is expressed as an icosahedral structure. In another embodiment, the VLP is expressed in the same geometry as the native virus that the capsid sequence is derived of. In a separate embodiment, however, the VLP does not have the identical geometry of the native virus. In certain embodiments, for example, the structure is produced in a particle formed of multiple capsids but not forming a native-type VLP. For example, a cage structure of as few as 3 viral capsids can be formed. In separate embodiments, cage structures of about 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, or 60 capsids can be formed.
- In one embodiment, at least one of the capsids includes at least one peptide of interest. In one embodiment, the peptide is expressed within at least one internal loop, or in at least one external surface loop of the VLP.
- More than one loop of the viral capsid can be modified. In one particular embodiment, the recombinant peptide is expressed on at least two surface loops of the virus-like particle. In another embodiment, at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle. In another embodiment, at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle. The recombinant peptides in the surface loops can have the same amino acid sequence. In separate embodiments, the amino acid sequence of the recombinant peptides in the surface loops differs.
- In certain embodiments, the host cell can be modified to improve assembly of the VLP. The host cell can, for example, be modified to include chaperone proteins that promote the formation of VLPs from expressed viral capsids. In another embodiment, the host cell is modified to include a repressor protein to more efficiently regulate the expression of the capsid to promote regulated formation of the VLPs.
- The nucleic acid sequence encoding the viral capsid or proteins can also be additionally modified to alter the formation of VLPs (see e.g. Brumfield, et al. (2004) J. Gen. Virol. 85: 1049-1053). For example, these modifications are designed to alter the interior, exterior or the interface between adjacent subunits in the assembled protein cage. To accomplish this, mutagenic primers can be used to: (i) alter the interior surface charge of the viral nucleic acid binding region by replacing basic residues (e.g. K, R) in the N terminus with acidic glutamic acids (Douglas et al., 2002b); (ii) delete interior residues from the N terminus (in CCMV, usually residues 4-37); (iii) insert a cDNA encoding an 11 amino acid peptide cell-targeting sequence (Graf et al., 1987) into a surface exposed loop; and (iv) modify interactions between viral subunits by altering the metal binding sites (in CCMV, residues 81/148 mutant).
- Recombinant Peptides Size
- In one embodiment, the peptides operably linked to a viral capsid sequence contain at least two amino acids. In another embodiment, the peptides are at least three, at least four, at least five, or at least six amino acids in length. In a separate embodiment, the peptides are at least seven amino acids long. The peptides can also be at least eight, at least nine, at least ten, at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 45, 50, 60, 65, 75, 85, 95, 96, 99 or more amino acids long. In one embodiment, the peptides encoded are at least 25 kD.
- In one embodiment, the peptide will contain from 2 to about 300 amino acids, or about 5 to about 250 amino acids, or about 5 to about 200 amino acids, or about 5 to about 150 amino acids, or about 5 to about 100 amino acids. In another embodiment, the peptide contains or about 10 to about 140 amino acids, or about 10 to about 120 amino acids, or about 10 to about 100 amino acids.
- In one embodiment, the peptides or proteins operably linked to a viral capsid sequence will contain about 500 amino acids. In one embodiment, the peptide will contain less than 500 amino acids. In another embodiment, the peptide will contain up to about 300 amino acids, or up to about 250, or up to about 200, or up to about 180, or up to about 160, or up to about 150, or up to about 140, or up to about 120, or up to about 110, or up to about 100, or up to about 90, or up to about 80, or up to about 70, or up to about 60, or up to about 50, or up to about 40 or up to about 30 amino acids.
- In one embodiment, the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids.
- In one embodiment of the present invention, the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In certain embodiments, the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid. In another embodiment, the individual monomers in the concatameric peptide are linked by cleavable linker regions. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus-like particle. In one embodiment, at least one monomer is inserted in a surface loop of the virus-like particle.
- Classification
- The peptides of interest that are fused to the viral capsids can be a heterologous protein that is not derived from the virus and, optionally, that is not derived from the same species as the cell.
- The peptides of interest that are fused to the viral capsids can be functional peptides; structural peptides; antigenic peptides, toxic peptides, antimicrobial peptides, fragments thereof; precursors thereof, combinations of any of the foregoing; and/or concatamers of any of the foregoing. In one embodiment of the present invention, the recombinant peptide is a therapeutic peptide useful for human and animal treatments, including antigenic peptides used in a vaccine strategy. In a particular embodiment, the antigenic peptide is glycosylated in vivo.
- Functional peptides include, but are not limited to, e.g.: bio-active peptides (i.e. peptides that exert, elicit, or otherwise result in the initiation, enhancement, prolongation, attenuation, termination, or prevention of a biological function or activity in or of a biological entity, e.g., an organism, cell, culture, tissue, organ, or organelle); catalytic peptides; microstructure- and nanostructure-active peptides (i.e. peptides that form part of engineered micro- or nanostructures in which, or in conjunction with which, they perform an activity, e.g., motion, energy transduction); and stimulant peptides (e.g., peptide flavorings, colorants, odorants, pheromones, attractants, deterrents, and repellants).
- Bio-active peptides include, but are not limited to, e.g.: immunoactive peptides (e.g., antigenic peptides, allergenic peptides, peptide immunoregulators, peptide immunomodulators); signaling and signal transduction peptides (e.g., peptide hormones, cytokines, and neurotransmitters; receptors; agonist and antagonist peptides; peptide targeting and secretion signal peptides); and bio-inhibitory peptides (e.g., toxic, biocidal, or biostatic peptides, such as peptide toxins and antimicrobial peptides).
- Structural peptides include, but are not limited to, e.g.: peptide aptamers; folding peptides (e.g., peptides promoting or inducing formation or retention of a physical conformation in another molecule); adhesion-promoting peptides (e.g., adhesive peptides, cell-adhesion-promoting peptides); interfacial peptides (e.g., peptide surfactants and emulsifiers); microstructure and nanostructure-architectural peptides (i.e. structural peptides that form part of engineered micro- or nano-structures); and pre-activation peptides (e.g., leader peptides of pre-, pro-, and pre-pro-proteins and -peptides; inteins).
- Catalytic Peptides include, e.g., apo B RNA-editing cytidine deaminase peptides; catalytic peptides of glutaminyl-tRNA synthetases; catalytic peptides of aspartate transcarbamoylases;
plant Type 1 ribosome-inactivating peptides; viral catalytic peptides such as, e.g., the foot-and-mouth disease virus [FMDV-2A] catalytic peptide; matrix metalloproteinase peptides; and catalytic metallo-oligopeptides. - The peptide can also be a peptide epitope, hapten, or a related peptide (e.g., antigenic viral peptide; virus related peptide, e.g., HIV-related peptide, hepatitis-related peptide; antibody idiotypic domain; cell surface peptide; antigenic human, animal, protist, plant, fungal, bacterial, and/or archaeal peptide; allergenic peptide and allergen desensitizing peptide).
- The peptide can also be a peptide immunoregulators or immunomodulators (e.g., interferons, interleukins, peptide immunodepressants and immunopotentiators); an antibody peptides (e.g., single chain antibodies; single chain antibody fragments and constructs, e.g., single chain Fv molecules; antibody light chain molecules, antibody heavy chain molecules, domain-deleted antibody light or heavy chain molecules; single chain antibody domains and molecules, e.g., a CH1, CH1-3, CH3, CH1-4, CH4, VHCH1, CL, CDR1, or FR1-CDR1-FR2 domain; paratopic peptides; microantibodies); another binding peptide (e.g., peptide aptamers, intracellular and cell surface receptor proteins, receptor fragments; anti-tumor necrosis factor peptides).
- The peptide can also be an enzyme substrate peptide or an enzyme inhibitor peptide (e.g., caspase substrates and inhibitors, protein kinase substrates and inhibitors, fluorescence-resonance-energy transfer-peptide enzyme substrates).
- The peptide can also be a cell surface receptor peptide ligand, agonist, and antagonist (e.g., caeruleins, dynorphins, orexins, pituitary adenylate cyclase activating peptides, tumor necrosis factor peptides; synthetic peptide ligands, agonists, and antagonists); a peptide hormone (e.g., endocrine, paracrine, and autocrine hormones, including, e.g.: amylins, angiotensins, bradykinins, calcitonins, cardioexcitatory neuropeptides, casomorphins, cholecystokinins, corticotropins and corticotropin-related peptides, differentiation factors, endorphins, endothelins, enkephalins, erythropoietins, exendins, follicle-stimulating hormones, galanins, gastrins, glucagons and glucagon-like peptides, gonadotropins, growth hormones and growth factors, insulins, kallidins, kinins, leptins, lipotropic hormones, luteinizing hormones, melanocyte stimulating hormones, melatonins, natriuretic peptides, neurokinins, neuromedins, nociceptins, osteocalcins, oxytocins (i.e. ocytocins), parathyroid hormones, pleiotrophins, prolactins, relaxins, secretins, serotonins, sleep-inducing peptides, somatomedins, thymopoietins, thyroid stimulating hormones, thyrotropins, urotensins, vasoactive intestinal peptides, vasopressins); a peptide cytokine, chemokine, virokine, and viroceptor hormone releasing and release-inhibiting peptide (e.g., corticotropin-releasing hormones, cortistatins, follicle-stimulating-hormone-releasing factors, gastric inhibitory peptides, gastrin releasing peptides, gonadotropin-releasing hormones, growth hormone releasing hormones, luteinizing hormone-releasing hormones, melanotropin-releasing hormones, melanotropin-release inhibiting factors; nocistatins, pancreastatins, prolactin releasing peptides, prolactin release-inhibiting factors; somatostatins; thyrotropin releasing hormones); a peptide neurotransmitter or channel blocker (e.g., bombesins, neuropeptide Y, neurotensins, substance P) a peptide toxin, toxin precursor peptide, or toxin peptide portion. In certain embodiments, a peptide toxin contains no D-amino acids. Toxin precursor peptides can be those that contain no D-amino acids and/or that have not been converted by posttranslational modification into a native toxin structure, such as, e.g., by action of a D configuration inducing agent (e.g., a peptide isomerase(s) or epimeras(e) or racemase(s) or transaminase(s)) that is capable of introducing a D-configuration in an amino acid(s), and/or by-action of a cyclizing agent (e.g., a peptide thioesterase, or a peptide ligase such as a trans-splicing protein or intein) that is capable of form a cyclic peptide structure.
- Toxin peptide portions can be the linear or pre-cyclized oligo- and poly-peptide portions of peptide-containing toxins. Examples of peptide toxins include, e.g., agatoxins, amatoxins, charybdotoxins, chlorotoxins, conotoxins, dendrotoxins, insectotoxins, margatoxins, mast cell degranulating peptides, saporins, sarafotoxins; and bacterial exotoxins such as, e.g., anthrax toxins, botulism toxins, diphtheria toxins, and tetanus toxins.
- The peptide can also be a metabolism- and digestion-related peptide (e.g., cholecystokinin-pancreozymin peptides, peptide yy, pancreatic peptides, motilins); a cell adhesion modulating or mediating peptide, extracellular matrix peptide (e.g., adhesins, selectins, laminins); a neuroprotectant or myelination-promoting peptide; an aggregation inhibitory peptide (e.g., cell or platelet aggregation inhibitor peptides, amyloid formation or deposition inhibitor peptides); a joining peptide (e.g., cardiovascular joining neuropeptides, iga joining peptides); or a miscellaneous peptide (e.g., agouti-related peptides, amyloid peptides, bone-related peptides, cell-permeable peptides, conantokins, contryphans, contulakins, myelin basic protein, and others).
- The peptide can also be post-translationally modified in vivo. In particular embodiments, the peptide may be, singularly or in combination, glycosylated, acetylated, acylated, phosphorylated, or gamma-carboxylated.
- In certain embodiments, the peptide of interest is exogenous to the selected viral capsid. Peptides may be either native or synthetic in sequence (and their coding sequences may be either native or synthetic nucleotide sequences). Thus, e.g., native, modified native, and entirely artificial sequences of amino acids are encompassed. The sequences of the nucleic acid molecules encoding these amino acid sequences likewise may be native, modified native, or entirely artificial nucleic acid sequences, and may be the result of, e.g., one or more rational or random mutation and/or recombination and/or synthesis and/or selection process employed (i.e. applied by human agency) to obtain the nucleic acid molecules.
- The coding sequence can be a native coding sequence for the target peptide, if available, but will more typically be a coding sequence that has been selected, improved, or optimized for use in the selected expression host cell: for example, by synthesizing the gene to reflect the codon use preference of a host species. In one embodiment of the invention, the host species is Nicotiana tabacum, and the codon preference of Nicotiana tabacum is taken into account when designing both the signal sequence and the peptide sequence. In an alternative embodiment of the invention, the host species is Oryza sativa, and the codon preference of Oryza sativa is taken into account when designing both the signal sequence and the peptide sequence
- Antigenic Peptides (Peptide Epitopes)
- In one embodiment, an antigenic peptide is produced through expression with a viral capsid. The antigenic peptide can be selected from those that are antigenic peptides of human or animal pathogenic agents, including infectious agents, parasites, cancer cells, and other pathogenic agents. Such pathogenic agents also include the virulence factors and pathogenesis factors, e.g., exotoxins, endotoxins, et al., of those agents. The pathogenic agents may exhibit any level of virulence, i.e. they may be, e.g., virulent, avirulent, pseudo-virulent, semi-virulent, and so forth. In one embodiment, the antigenic peptide will contain an epitopic amino acid sequence from the pathogenic agent(s). In one embodiment, the epitopic amino acid sequence will include that of at least a portion of a surface peptide of at least one such agent. In one embodiment, the capsid-recombinant peptide virus like particles can be used as a vaccine in a human or animal application.
- More than one antigenic peptide may be selected, in which case the resulting virus-like particles can present multiple different antigenic peptides. In a particularly embodiment of a multiple antigenic peptide format, the various antigenic peptides will all be selected from a plurality of epitopes from the same pathogenic agent. In a particular embodiment of a multi-antigenic-peptide format, the various antigenic peptides selected will all be selected from a plurality of closely related pathogenic agents, for example, different strains, subspecies, biovars, pathovars, serovars, or genovars of the same species or different species of the same genus.
- In one embodiment, the pathogenic agent(s) will belong to at least one of the following groups: Bacteria and Mycoplasma agents including, but not limited to, pathogenic: Bacillus spp., e.g., Bacillus anthracis; Bartonella spp., e.g., B. quintana; Brucella spp.; Burkholderia spp., e.g., B. pseudomallei; Campylobacter spp.; Clostridium spp., e.g., C. tetani, C. botulinum; Coxiella spp., e.g., C. burnetii; Edwardsiella spp., e.g., E. tarda; Enterobacter spp., e.g., E. cloacae; Enterococcus spp., e.g., E. faecalis, E. faecium; Escherichia spp., e.g., E. coli; Francisella spp., e.g., F. tularensis; Haemophilus spp., e.g., H. influenzae; Klebsiella spp., e.g., K. pneumoniae; Legionella spp.; Listeria spp., e.g., L. monocytogenes; Meningococci and Gonococci, e.g., Neisseria spp.; Moraxella spp.; Mycobacterium spp., e.g., M. leprae, M. tuberculosis; Pneumococci, e.g., Diplococcus pneumoniae; Pseudomonas spp., e.g., P. aeruginosa; Rickettsia spp., e.g., R. prowazekii, R. rickettsii, R. typhi; Salmonella spp., e.g., S. typhi; Staphylococcus spp., e.g., S. aureus; Streptococcus spp., including Group A Streptococci and hemolytic Streptococci, e.g., S. pneumoniae, S. pyogenes; Streptomyces spp.; Shigella spp.; Vibrio spp., e.g., V. cholerae; and Yersinia spp., e.g., Y. pestis, Y. enterocolitica. Fungus and Yeast agents including, but not limited to, pathogenic: Alternaria spp.; Aspergillus spp.; Blastomyces spp., e.g., B. dermatiditis; Candida spp., e.g., C. albicans; Cladosporium spp.; Coccidiodes spp., e.g., C. immitis; Cryptococcus spp., e.g., C. neoformans; Histoplasma spp., e.g., H. capsulatum; and Sporothrix spp., e.g., S. schenckii.
- In one embodiment, the pathogenic agent(s) will be from a protist agent including, but not limited to, pathogenic: Amoebae, including Acanthamoeba spp., Amoeba spp., Naegleria spp., Entamoeba spp., e.g., E. histolytica; Cryptosporidium spp., e.g., C. parvum; Cyclospora spp.; Encephalitozoon spp., e.g., E. intestinalis; Enterocytozoon spp.; Giardia spp., e.g., G. lamblia; Isospora spp.; Microsporidium spp.; Plasmodium spp., e.g., P. falciparum, P. malariae, P. ovate, P. vivax; Toxoplasma spp., e.g., T. gondii; and Trypanosoma spp., e.g., T. brucei.
- In one embodiment, the pathogenic agent(s) will be from a parasitic agent (e.g., helminthic parasites) including, but not limited to, pathogenic: Ascaris spp., e.g. A. lumbricoides; Dracunculus spp., e.g., D. medinensis; Onchocerca spp., e.g., O. volvulus; Schistosoma spp.; Trichinella spp., e.g., T. spiralis; and Trichuris spp., e.g., T. trichiura.
- In another embodiment, the pathogenic agent(s) will be from a viral agent including, but not limited to, pathogenic: Adenoviruses; Arenaviruses, e.g., Lassa Fever viruses; Astroviruses; Bunyaviruses, e.g., Hantaviruses, Rift Valley Fever viruses; Coronaviruses, Deltaviruses; Cytomegaloviruses, Epstein-Barr viruses, Herpes viruses, Varicella viruses; Filoviruses, e.g., Ebola viruses, Marburg viruses; Flaviruses, e.g., Dengue viruses, West Nile Fever viruses, Yellow Fever viruses; Hepatitis viruses; Influenzaviruses; Lentiviruses, T-Cell Lymphotropic viruses, other leukemia viruses; Norwalk viruses; Papillomaviruses, other tumor viruses; Paramyxoviruses, e.g., Measles viruses, Mumps viruses, Parainfluenzaviruses, Pneumoviruses, Sendai viruses; Parvoviruses; Picornaviruses, e.g., Cardioviruses, Coxsackie viruses, Echoviruses, Poliomyelitis viruses, Rhinoviruses, Other Enteroviruses; Poxviruses, e.g., Variola viruses, Vaccinia viruses, Parapoxviruses; Reoviruses, e.g., Coltiviruses, Orbiviruses, Rotaviruses; Rhabdoviruses, e.g., Lyssaviruses, Vesicular Stomatitis viruses; and Togaviruses, e.g., Rubella viruses, Sindbis viruses, Western Encephalitis viruses.
- In one particular embodiment, the antigenic peptide is selected from the group consisting of a Canine parvovirus peptide, Bacillus anthracis protective antigen (PA) antigenic peptide, and an Eastern Equine Encephalitis virus antigenic peptide. In a particular embodiment, the antigenic peptide is the Bacillus antracis-derived peptide with the amino acid sequence selected from PA1 (SEQ. ID. NO. 1), PA2 (SEQ. ID. NO. 2), PA3 (SEQ. ID. NO. 3), or PA4 (SEQ. ID. NO. 4).
- Host-Cell Toxic Peptide
- In another particular embodiment, the recombinant peptide is a peptide that is toxic to the host cell when in free monomeric form. In certain embodiments, the peptide of interest expressed in conjunction with a viral capsid will be a host cell toxic peptide. A host cell toxic peptide indicates a bio-inhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed, or to other cells in the cell culture or organism of which the host cell is a member, or to cells of the organism or species providing the host cells. In one embodiment, the host-cell-toxic peptide will be a bioinhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed. Some examples of host-cell-toxic peptides include, but are not limited to: peptide toxins, anti-microbial peptides, and other antibiotic peptides.
- Antimicrobial Peptides
- In another particular embodiment, the recombinant peptide is a peptide that is an antimicrobial peptide. Anti-Microbial Peptides include, e.g., anti-bacterial peptides such as, e.g., magainins, betadefensins, some alpha-defensins; cathelicidins; histatins; anti-fungal peptides; antiprotozoal peptides; synthetic AMPs; peptide antibiotics or the linear or pre-cyclized oligo- or poly-peptide portions thereof; other antibiotic peptides (e.g., anthelmintic peptides, hemolytic peptides, tumoricidal peptides); and anti-viral peptides (e.g., some alpha-defensins; virucidal peptides; peptides that inhibit viral infection). In one embodiment, the antimicrobial peptide is selected from the group consisting of D2A21 antimicrobial peptides.
- Cells for Use in Expressing the VLP
- The cell used as a host for the expression of the viral capsid or viral capsid fusion peptide (also referred to as “host cell”) of the invention will be one in which the expression of viral capsid does not allow replication or infection of the cell. In one embodiment, the viral capsid will be derived from a virus that does not infect the specific species of cell that the host cell is derived from. For example, in one embodiment, the viral capsid is derived from an icosahedral plant virus and is expressed in a host cell of a plant species that is not the native trophic host of the virus. In another embodiment, the viral species infects mammals and the expression system includes a plant host cell. In an alternative embodiment, the virus is a trophic virus of the particular plant species utilized as a host cell for expressing the capsid-recombinant peptide fusion.
- The plant host cell may be any plant cell from the Tracheophyta, Euphyllophyta, Spermatophyta, or Angiospermophyta. In a particular embodiment, the plant cell is a Monocot, including, but not limited to, members of, e.g.: Arecaceae, e.g., Cocos spp., Elaeis spp.; Dioscoreaceae, e.g., Dioscorea spp.; Gramineae (Poaceae), e.g., Avena spp., Hordeum spp., Oryza spp., Panicum spp., Triticum spp., Zea spp.; and Musaceae, e.g., Musa spp.
- In an alternative embodiment, the plant cell is a member of the Dicots, including, but not limited to, e.g.: Amaranthaceae, e.g., Amaranthus spp., Beta spp., Chenopodium spp.; Apiaceae (Umbelliferae), e.g., Daucus spp., Pastinaca spp.; Brassicaceae (Cruciferae), e.g., Arabidopsis spp., Brassica spp.; Compositae, e.g., Helianthus spp.; Convolvulaceae, e.g., Ipomoea spp.; Cucurbitaceae, e.g., Citrullus spp., Cucumis spp., Cucurbita spp.; Euphorbiaceae; Leguminosae (Fabaceae), e.g, Glycine spp., Lens spp., Medicago spp., Phaseolus spp., Pisum spp., Trifolium spp., Vicia spp., Vigna spp.; Linaceae, e.g., Linum spp.; and Solanaceae, e.g, Capsicum spp., Lycopersicon spp., Nicotiana spp., Solanum spp.
- In a particular embodiment, the host cell is selected from the group consisting of Aradiposis thialiana, Taxus cuspidate, Catharanthus roseus, Nicotiana tabacum, Oryza sativa, Lycopersicum esculentum, and Glycine max.
- The present invention further provides non-infectious nucleic acid constructs capable of stably integrating into the host cell's genome and encoding a fusion peptide of a capsid and a recombinant peptide. The fusion peptide can be operably linked to a promoter sequence and a termination sequence. In one embodiment, a nucleic acid construct for use in transforming plant host cells including a) a nucleic acid sequence encoding a recombinant peptide, and b) a nucleic acid sequence encoding a viral capsid is provided, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein is stably inserted into the genome of the plant host cell, wherein it is expressed in the plant cell.
- In certain embodiments, the vector can include sequence for multiple capsids, or for multiple peptides of interest. In one embodiment, the vector can include at least two different capsid-peptide coding sequences. In one embodiment, the coding sequences are linked to the same promoter. In certain embodiments, the coding sequences are separated by an internal ribosomal binding site. In other embodiments, the coding sequences are linked by a linker sequence that allows the formation of virus like particles in the cell. In another embodiment, the coding sequences are linked to different promoters. These promoters may be constitutive or driven by the same or different induction conditions. In another embodiment, multiple vectors capable of insertion into the genome and encoding different capsid-peptide combinations are provided. The multiple vectors can include promoters that are constitutive or driven by the same induction conditions, or by different induction conditions. In one embodiment, the viral capsid is derived from an icosahedral viral capsid.
- The coding sequence for a peptide of interest can be inserted into the coding sequence for a viral capsid or capsid in a predetermined site. The peptide can also be inserted at a non-predetermined site and cells screened for production of VLPs. In one embodiment, the peptide is inserted into the capsid coding sequence so as to be expressed as a loop during formation of a VLP. In one embodiment, one peptide coding sequence is included in the vector, however in other embodiments, multiple sequences are included. The multiple sequences can be in the form of concatamers, for example concatamers linked by cleavable linker sequences.
- Peptides may be inserted at more than one insertion site in a capsid. Thus, peptides may be inserted in more than one surface loop motif of a capsid; peptides may also be inserted at multiple sites within a given loop motif. The individual functional and/or structural peptide(s) of the insert(s), and/or the entire peptide insert(s), may be separated by cleavage sites, i.e. sites at which an agent that cleaves or hydrolyzes protein can act to separate the peptide(s) from the remainder of the capsid structure or assemblage.
- Peptides may be inserted within external-facing loop(s) and/or within internal-facing loop(s), i.e. within loops of the capsid that face respectively away from or toward the center of the capsid. Any amino acid or peptide bond in a surface loop of a capsid can serve as an insertion for the peptide. Typically, the insertion site will be selected at about the center of the loop, i.e. at about the position located most distal from the center of the tertiary structure of the folded capsid peptide. The peptide coding sequence may be operably inserted within the position of the capsid coding sequence corresponding to this approximate center of the selected loop(s). This includes the retention of the reading frame for that portion of the peptide sequence of the capsid that is synthesized downstream from the peptide insertion site.
- In another embodiment, the peptide can be inserted at the amino terminus of the capsid. The peptide can be linked to the capsid through one or more linker sequences, including the cleavable linkers described above. In yet another embodiment, the peptide can be inserted at the carboxy terminus of the capsid. The peptide can also be linked to the carboxy terminus through one or more linkers, which can be cleavable by chemical or enzymatic hydrolysis. In one embodiment, peptide sequences are linked at both the amino and carboxy termini, or at one terminus and at at least one internal location, such as a location that is expressed on the surface of the capsid in its three dimensional conformation.
- In one embodiment, the peptide can be inserted into the capsid from a Cowpea Chlorotic Mosaic Virus. In one particular embodiment, the peptide can be inserted at amino acid 129 of the CCMV coat protein. In one embodiment, the peptide sequence can be inserted at amino acid 63, 102, 114, 129, or 160 of the CCMV coat protein. In another embodiment, the peptide sequence can be inserted at amino acids 60, 61, 62 or 63 of the CCMV coat protein. In still another embodiment, the peptide can be inserted at both amino acids 129 and amino acids 60-63 of the CCMV protein.
- In a particular embodiment, the present invention provides a nucleic acid construct including a) a nucleic acid encoding an antigenic peptide, and b) a nucleic acid encoding a viral capsid, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein when expressed in a cell. Other capsids and recombinant peptides useful in constructing the nucleic acid construct are disclosed above.
- Promoters
- In one embodiment, the nucleic acid construct includes a promoter sequence operably attached to the nucleic acid sequence encoding the capsid-recombinant peptide fusion peptide. An operable attachment or linkage refers to any configuration in which the transcriptional and any translational regulatory elements are covalently attached to the described sequence so that by action of the host cell, the regulatory elements can direct the expression of the sequence of interest. In alternative embodiment, the nucleic acid construct encoding the capsid fusion product can be inserted in frame with a host cell native promoter utilizing a gene trapping strategy.
- In a fermentation process, once fermentation begins, it is ideal to have a high level of production in order to maximize efficiency of the expression system. The promoter initiates transcription and is generally positioned 1-100 nucleotides upstream of the transcription start site. Ideally, a promoter will be strong enough to allow for a large amount of recombinant peptide accumulation.
- The promoters used in accordance with the present invention may be constitutive promoters or regulated promoters. Common examples of useful regulated promoters used in the art include: ethanol-inducible promoters; iron deficiency-inducible promoters; wound-inducible promoters; and hormone-inducible, e.g., auxin-inducible, promoters. Common examples of useful constitutive promoters include the ubiquitin promoter, the actin promoter, the tubulin promoter, and the Cassava Vein Mosaic Virus promoter. Other types of promoters useful in the present invention include tissue-specific promoters such as corn sucrose synthetase 1 (Yang et al., 1990), corn alcohol dehydrogenase 1 (Vogel et al., 1989), corn light harvesting complex (Simpson, 1986), corn heat shock protein (Odell et al., 1985), pea small subunit RuBP carboxylase (Poulsen et al., 1986; Cashmore et al., 1983), Ti plasmid mannopine synthase (Langridge et al., 1989), Ti plasmid nopaline synthase (Langridge et al., 1989), petunia chalcone isomerase (Van Tunen et al., 1988), bean glycine rich protein 1 (Keller et al., 1989), CaMV 35s transcript (Odell et al., 1985) and Potato patatin (Wenzler et al., 1989). Preferred promoters are the cauliflower mosaic virus (CaMV 35S) promoter, the rice alpha-amylase RAmy3D promoter, and the S-E9 small subunit RuBP carboxylase promoter. In addition, a variety of plant gene promoters that are regulated in response to environmental, hormonal, chemical, and/or developmental signals can be used for expression of an operably linked gene in plant cells, including promoters regulated by (1) heat (Callis et al., Plant Physiol. 88:965, 1988), (2) light (e.g., pea rbcS-3A promoter, Kuhlemeier et al., Plant Cell 1:471, 1989; maize rbcS promoter, Schaffner and Sheen, Plant Cell 3:997, 1991; or chlorophyll a/b-binding protein promoter, Simpson et al., EMBO J. 4:2723, 1985), (3) hormones, such as abscisic acid (Marcotte et al., Plant Cell 1:969, 1989), (4) wounding (e.g., wunI, Siebertz et al., Plant Cell 1:961, 1989); or (5) chemicals such as methyl jasmonate, salicylic acid, or Safener. It may also be advantageous to employ (6) organ-specific promoters (e.g., Roshal et al., EMBO J. 6:1155, 1987; Schernthaner et al., EMBO J. 7:1249, 1988; Bustos et al., Plant Cell 1:839, 1989). Additional promoters useful in the present invention include those described in WO 97/48819; the phaseolin promoters described in U.S. Pat. No. 5,591,605; rice actin promoters described in U.S. Pat. No. 5,641,876; the per 5 promoter described in WO 98/56921; the gamma zein promoters described in WO 00/12681; and other promoters as described in U.S. Pat. No. 6,825,006, U.S. Pat. No. 6,660,911, and plant promoters described the plant promoter sequence database PlantProm, described in Shahmuradov et al. (2003), “PlantProm: a database of plant promoter sequences,” Nucleic Acid Res. 31(1): 114-117, and available at http://mendel.cs.rhul.ac.uk/mendel.php?topic=plantprom. Additional promoters may also include cauliflower mosaic virus (CaMV) 35S promoter or its enhanced version, the hybrid (ocs)3mas promoter, and ubiquitin promoters from maize or A. thaliana.
- A promoter having the nucleotide sequence of a promoter native to the selected plant host cell can also be used to control expression of the transgene encoding the target peptide. Tandem promoters may also be used in which more than one promoter is covalently attached to another, whether the same or different in sequence.
- A promoter having the nucleotide sequence derived from a virus can also be used to direct expression of the transgene encoding the target peptide.
- Regulated promoters can utilize promoter regulatory proteins in order to control transcription of the gene of which the promoter is a part. Where a regulated promoter is used herein, a corresponding promoter regulatory protein will also be part of an expression system according to the present invention. Many regulated-promoter/promoter-regulatory-protein pairs are known in the art.
- Other Elements
- Other regulatory elements can be included in a nucleic acid construct. Such elements include, but are not limited to, for example, transcriptional enhancer sequences, translational enhancer sequences, other promoters, activators, translational start and stop signals, transcription terminators, cistronic regulators, polycistronic regulators, tag sequences, such as nucleotide sequence “tags” and “tag” peptide coding sequences, which facilitates identification, separation, purification, or isolation of an expressed peptide, including His-tag, Flag-tag, T7-tag, S-tag, HSV-tag, B-tag, Strep-tag, polyarginine, polycysteine, polyphenylalanine, polyaspartic acid, (Ala-Trp-Trp-Pro)n, thioredoxin, beta-galactosidase, chloramphenicol acetyltransferase, cyclomaltodextrin gluconotransferase, CTP:CMP-3-deoxy-D-manno-octulosonate cytidyltransferase, trpE or trpLE, avidin, streptavidin,
T7 gene 10, T4 gp55, Staphylococcal protein A, streptococcal protein G, GST, DHFR, CBP, MBP, galactose binding domain, Calmodulin binding domain, GFP, KSI, c-myc, ompT, ompA, pelB, NusA, ubiquitin, and hemosylin A. - In one embodiment, the nucleic acid construct further comprises a tag sequence adjacent to the coding sequence for the recombinant peptide of interest, or linked to a coding sequence for a viral capsid. In one embodiment, this tag sequence allows for purification of the protein. The tag sequence can be an affinity tag, such as a hexa-histidine affinity tag. In another embodiment, the affinity tag can be a glutathione-S-transferase molecule. The tag can also be a fluorescent molecule, such as YFP or GFP, or analogs of such fluorescent proteins. The tag can also be a portion of an antibody molecule, or a known antigen or ligand for a known binding partner useful for purification.
- The present invention can include, in addition to the capsid-recombinant peptide coding sequence, the following regulatory elements operably linked thereto: a promoter, a transcription terminator, translational start and stop signals.
- Further examples of translation and transcription elements, and other elements useful in the present invention are described in: J D Watson et al. (eds.), Recombinant DNA, pp. 273-92 (1992) (Scientific American Books, W. H. Freeman and Co., New York, N.Y., USA); and I Mitsuhara et al., “Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants,” Plant Cell Physiol. 37(1):49-59 (1996).
- In one particular embodiment, the nucleic acid construct includes additional nucleic acid sequences derived from the 3′ untranslated region (3′ UTR) of the viral genomic nucleic acid sequence utilized to derive the viral capsid protein. In one particular embodiment, the 3′UTR contains sequences that play a role in regulation of translation or capsid formation in the wild type virus. In one embodiment, the 3′UTR sequences are upstream pseudoknot domains (UPD). See, for example, Leathers et al. (1993) “A phylogenetically conserved sequence within viral 3′ untranslated RNA pseudoknots regulates translation,” Mol. Cell Biol. 13(9): 5331-5347. In a particular embodiment, the 3′UTR are derived from the 3′UTR of the viral capsid encoding region of the viral genome. In a more particular embodiment, the 3′UTR is derived from the cowpea chlorotic
mosaic virus RNA3 3′ untranslated region. In one embodiment, the 3′UTR sequence includes an encapsidation signal. - In an alternative embodiment, the nucleic acid construct includes at least one encapsidation signal derived from a viral nucleic acid sequence. The encapsidation signal can be derived from 5′UTR, 3′UTR, or internal sequence of the viral genomic sequence. In one embodiment, the nucleic acid construct is encapsidated in the VLP.
- In one embodiment, the non-infectious nucleic acid construct also includes other sequences derived from the viral or non-viral nucleic acid sequence other than the viral capsid protein sequence.
- Vectors
- Useful expression vectors for use in plant cells in stably integrating into the host cell genome and expressing capsid-recombinant peptide fusion peptides are constructed by inserting a structural DNA sequence encoding a desired target peptide fused with a capsid peptide together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector may also comprise one or more phenotypic selectable or screenable markers to allow for selection of host cells. Alternatively, the selectable or screenable markers can be provided on a separate plasmid.
- A wide variety of vectors and/or carriers are known in the art as useful for transforming a target plant host cell with recombinant capsid-encoding nucleic acid for expression, and any of these may be used for expressing the genes according to the present invention. See, e.g., U Goderis I J et al., “A set of modular plant transformation vectors allowing flexible insertion of up to six expression units,” Plant Mol. Biol. 50(1):17-27 (2002); A H Christensen & P H Quail, “Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants,” Transgenic Res. 5(3):213-18 (1996); JD Jones et al., “Effective vectors for transformation, expression of heterologous genes, and assaying transposon excision in transgenic plants,” Transgenic Res. 1(6):285-97 (1992); A P Gleave AP, “A versatile binary vector system with a T-DNA organisational structure conducive to efficient integration of cloned DNA into the plant genome,” Plant Mol. Biol. 20(6):1203-07 (1992).
- Thus, plasmids, transposons, genomic DNA, genomic RNA, plant artificial chromosomes, and other nucleic acid vectors may be used. Examples of some vectors that may be used include, but are not limited to, pRT101, pRT101-MCS, pRT104, pRT104.24LS, pRT104.N-myc, pRT104.C-myc, pRT104.N-3HA, pRT104-N3HAdAsp, pRT104.N-6HA, pRT104-N6HAdAsp, pRT104.C-3HA, pRT104-GST, pRT104 NES(A2), pRT103-3HA, pRTd35S-Luci(−), pRTd35S-Luci-NES, pRTd35S-GFP, pRTd35S-GFP.SacI, pRTdS GFP.BglII, pRTd35S-Ds-Red, pRTd35S-profillin, pBIGal4 DBD, pRT-3HAxHsfA2 DBD, pRT-3HAxGal4 DBD, pUC, pIL-TAB, pET, pME, pBBR, and pROKII. When particle bombardment is used to introduce the vector into the cell, any DNA plasmid or DNA molecule may be utilized in the present invention.
- In a particular embodiment, the vector is pIL-Tab. In a more particular embodiment, the vector is pIL-Tab encoding for the coat protein from Cowpea Chlorotic Mosaic Virus (CCMV). In a particular embodiment, the vector is pIL-Tab, and the heterologous peptide is selected from the group consisting of PA1, PA2, PA3 or PA4. In a still further embodiment, the vector is selected from the group consisting of pDOW2160 (Seq. ID. No. 5), pDOW 2161 (Seq. ID. No. 6), pDOW2162 (Seq. ID. No. 7), pDOW2163 (Seq. ID. No. 8), pDOW 2169 (Seq. ID. No. 9), pDOW2170 (Seq. ID. No. 10), pDOW2171 (Seq. ID. No. 11), and pDOW2172 (Seq. ID. No. 12).
- Alternatively, or in addition, carriers may be used, such as liposomes, dendrimers, cationic polymers, and cationic polymer-lipid complexes, all of which have been employed in widely published methods for delivery of nucleic acids to cells or protoplasts. Alternatively, naked DNA or naked RNA may be delivered to the plant host.
- The vector, carrier, or naked nucleic acid may be directly transformed into a plant cell or protoplast by any method known effective therefore in the art. For example, any of the following methods may be used to transform the plant target host with the recombinant capsid-encoding nucleic acid: Agrobacterium spp.; microparticle bombardment as described by V. Vasil et al., Bio/Technology 9, 743 (1991); electroporation of protoplasts as described, for example, for lettuce by M C Chupeau et al., Bio/Technology 7, 503 (1989); surface abrasion using, e.g., silicon carbide whiskers, glass, or carborundum; liposome fusion with protoplasts as described, for example, by A. Deshayes et al., EMBO J. 4, p. 2731-2737 (1985); cell-cell (protoplast-protoplast) fusion; and endogenous plant virus infection, i.e. transformation of the plant target host with an engineered virus vector, the engineered virus vector being of a type of virus for which the selected plant target host is its native host and wherein the virus has been engineered to contain a recombinant capsid-protein-encoding nucleic acid (wherein the capsid-protein-nucleic acid from which the recombinant is made is selected from a virus for which the plant target host is not its native host); polyethylene glycol mediated transformations as described by, for example, I. Potrykus et al., Mol. Gen. Genetics, 197, 183-188; and microinjection as described by, for example, R. Griesbach, Biotechnology 3, p. 348-350 and C K Shewmaker Mol. Gen. Genetics, 202 p. 179-185 (1986).
- The present invention also provides a process for producing a recombinant peptide. The process includes:
-
- a) providing a plant cell;
- b) providing a non-infectious nucleic acid containing an expression cassette encoding a fusion peptide; wherein the fusion is of a recombinant peptide and an icosahedral capsid;
- c) expressing the nucleic acid in the plant cell, wherein the expression in the cell provides for in vivo assembly of the fusion peptide into virus like particles; and
- d) isolating the virus like particles.
- The fusion peptide is operably linked to a promoter sequence and a terminator sequence. In one embodiment, the process further comprises: e) cleaving the recombinant peptide from the viral capsid protein. In still another embodiment, the process further comprises: f) isolating the recombinant peptide from step e. See, for example,
FIG. 1 . - Peptides may be expressed as single-copy peptide inserts within a capsid peptide (i.e. expressed as individual inserts from recombinant capsid peptide coding sequences that are mono-cistronic for the peptide) or may be expressed as di-, tri-, or multi-copy peptide inserts (i.e. expressed as concatemeric inserts from recombinant capsid peptide coding sequences that are poly-cistronic for the peptide; the concatemeric insert(s) may contain multiple copies of the same exogenous peptide of interest or may contain copies of different exogenous peptides of interest). Concatemers may be homo- or hetero-concatemers.
- In one embodiment, the isolated virus like particle can be administered to a human or animal in a vaccine strategy.
- In another embodiment, the nucleic acid construct can be co-expressed with another nucleic acid encoding a wild type capsid. In a particular embodiment, the co-expressed capsid/capsid-recombinant peptide fusion particles assemble in vivo to form a chimeric virus like particle. The chimeric VLP is a virus like particle including capsids or capsid-peptide fusions encoded by at least two different nucleic acid constructs.
- In still another embodiment, the nucleic acid construct can be co-expressed with another nucleic acid encoding a different capsid-recombinant peptide fusion particle. In a particular embodiment, the co-expressed capsid fusion particles will assemble in vivo to form a chimeric virus like particle.
- In still another embodiment, a second nucleic acid, which is designed to express a different peptide, such as a chaperone protein, can be expressed concomitantly with the nucleic acid encoding the fusion peptide.
- The plant cells, capsids, and recombinant peptides useful for the present invention are discussed above.
- In one embodiment, the expressed viral capsid-heterologous peptide fusion product is expressed in soluble form in the cell.
- In one embodiment, the expressed viral capsid-recombinant heterologous fusion product is assembled into VLPs in the cell.
- In a separate embodiment, a portion of the expressed viral capsid-heterologous peptide fusion product of interest is formed in an insoluble aggregate in the cell. In one embodiment, the peptide of interest can be renatured from the insoluble aggregate.
- Cleavage of Peptide of Interest
- In one embodiment, the process further provides: e) cleaving the fusion product to separate the recombinant peptide from the capsid.
- A cleavable linkage sequence can be included between the viral protein and the recombinant peptide. Examples of agents that can cleave such sequences include, but are not limited to chemical reagents such as acids (HCl, formic acid), CNBr, hydroxylamine (for asparagine-glycine), 2-Nitro-5-thiocyanobenzoate, O-Iodosobenzoate, and enzymatic agents, such as endopeptidases, endoproteases, trypsin, clostripain, and Staphylococcal protease.
- Cleavable linkage sequences are well known in the art. In the present invention, any cleavable linkage sequence recognized by cleavage agents, including dipeptide cleavage sequences such as Asp-Pro, can be utilized.
- Expression
- The process of the invention optimally leads to the increased production of desired capsid-fusion products in a plant host cell in the desired sequence and conformation. The increased production alternatively can be an increased level of desired peptide per gram of protein produced, per gram of host protein, or as a percentage of total recombinant peptide produced. The increased production can also be an increased level of recoverable peptide, such as soluble protein, produced per gram of recombinant or per gram of host cell protein. The increased production can also be any combination of increased total level and increased active or soluble level of protein.
- The improved expression of recombinant protein can be through expression of the protein as a capsid fusion protein and subsequently inserted in VLPs. In certain embodiments, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, or at least 180 copies of a peptide of interest are expressed in each VLP. The VLPs can be produced and recovered from the cytoplasm, periplasm or extracellular medium of the host cell.
- In another embodiment, the peptide can be insoluble in the cell. In certain embodiments, the soluble or insoluble peptide is produced in a particle formed of multiple capsids but not forming a native-type VLP. For example, a cage structure of as few as 3 viral capsids can be formed. In certain embodiments, the capsid structure includes more than one copy of a peptide of interest and in certain embodiments, includes at least ten, at least 20, or at least 30 copies. In certain embodiments, the peptide is formed in the vacuole of the plant cell.
- The peptide or viral capsid sequence can also include one or more targeting sequences or sequences to assist purification. These can be an affinity tag. These can also be targeting sequences directing the assembly of capsids into a VLP.
- Cell Growth
- Transformation of the plant host cells with the vector(s) may be performed using any transformation methodology known in the art, and the plant host cells may be transformed as intact cells or as protoplasts. Exemplary transformation methodologies have been described above.
- As used herein, the term “fermentation” includes both embodiments in which literal fermentation is employed and embodiments in which other, non-fermentative culture modes are employed. Fermentation may be performed at any scale. Any method generally known in the art may be utilized in fermentation. See, for example, Hellwig et al. (2004) “Plant cell cultures for the production of recombinant proteins,” Nature Biotech 22(11): 1415-1422; Sajc et al. (2000) “Bioreactors for plant engineering: an outlook for further research,” Biochem Engin. J. 4:89-99. In one embodiment, the fermentation medium may be selected from among any viable plant cell culture media. Optionally, additives to the medium can include, for example, PVP, BSA, NaCl, BrefeldinA, reducing manganese, pluronic antifoam, polyethylene glycol, gelatin, protease inhibitors, redox co-factors, and dimethylsulfoxide.
- The expression system according to the present invention can be cultured in any fermentation format. For example, batch, fed-batch, semi-continuous, and continuous fermentation modes may be employed herein.
- The expression systems according to the present invention are useful for transgene expression at any scale (i.e. volume) of fermentation. Thus, e.g., microliter-scale, centiliter scale, and deciliter scale fermentation volumes may be used; and 1 Liter scale and larger fermentation volumes can be used. In one embodiment, the fermentation volume will be at or above 1 Liter. In another embodiment, the fermentation volume will be at or above 5 Liters, 10 Liters, 15 Liters, 20 Liters, 25 Liters, 50 Liters, 75 Liters, 100 Liters, 200 Liters, 500 Liters, 1,000 Liters, 2,000 Liters, 5,000 Liters, 10,000 Liters or 50,000 Liters.
- In the present invention, growth, culturing, and/or fermentation of the transformed host cells is performed within a temperature range permitting survival of the host cells, preferably a temperature within the range of about 4° C. to about 55° C., inclusive.
- Cell Density (Packed Wet Cells)
- Plant cell expressions systems according to the present invention can provide a cell density or comparable packed wet cell density of about from about 20 g/L (2% packed cell volume) to more than 550 g/L (55% packed cell volume). In one embodiment, the packed cell volume is between 2% to about 60%. In another embodiment, the packed cell volume is 2%, 5%, 10%, 15%, 20%, 25%, 35%, 40%, 50%, 55%, 60%, 70%, or 85%.
- Isolation of VLP or Peptide of Interest
- In certain embodiments, the invention provides a process for improving the recovery of peptides of interest by protection of the peptide during expression through linkage and co-expression with a viral capsid. In certain embodiments, the viral capsid fusion forms a VLP, which can be readily separated from the cell lysate.
- The proteins of this invention may be isolated and purified to substantial purity by standard techniques well known in the art, including, but not limited to, PEG precipitation, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, detergent solubilization, selective precipitation with such substances as column chromatography, immunopurification methods, and others. For example, proteins having established molecular adhesion properties can be reversibly fused to a ligand. With the appropriate ligand, the protein can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein can then be removed by enzymatic or other activity. In addition, protein can be purified using immunoaffinity columns or Ni-NTA columns. General techniques are further described in, for example, R. Scopes, Protein Purification: Principles and Practice, Springer-Verlag: N.Y. (1982); Deutscher, Guide to Protein Purification, Academic Press (1990); U.S. Pat. No. 4,511,503; S. Roe, Protein Purification Techniques: A Practical Approach (Practical Approach Series), Oxford Press (2001); D. Bollag, et al., Protein Methods, Wiley-Lisa, Inc. (1996); A K Patra et al., Protein Expr Purif, 18(2): p/182-92 (2000); and R. Mukhija, et al., Gene 165(2): p. 303-6 (1995). See also, for example, Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) “Guide to Protein Purification,” Methods in Enzymology vol. 182, and other volumes in this series; Coligan, et al. (1996 and periodic Supplements) Current Protocols in Protein Science Wiley/Greene, NY; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, Calif. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See also, for example, Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) “Purification of Recombinant Proteins with Metal Chelate Absorbent” in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, NY; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, Calif.
- Similarly, the virus-like particles or cage-like structures can be isolated and purified to substantial purity by standard techniques well known in the art. Techniques for isolation of VLPs include, in addition to those described above, precipitation techniques such as polyethylene glycol or salt precipitation. Separation techniques include anion or cation exchange chromatography, size exclusion chromatograph, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, immunopurification methods, centrifugation, ultracentrifugation, density gradient centrifugation (for example, on a sucrose or on a cesium chloride (CsCl) gradient), ultrafiltration through a size exclusion filter, and any other protein isolation methods known in the art.
- The invention can also improve recovery of active recombinant peptides. Levels of active protein can be measured, for example, by measuring the interaction between an identified and a parent peptide, peptide variant, segment-substituted peptide and/or residue-substituted peptide by any convenient in vitro or in vivo assay. Thus, in vitro assays can be used to determine any detectable interaction between an identified protein and a peptide of interest, e.g. between enzyme and substrate, between hormone and hormone receptor, between antibody and antigen, etc. Such detection can include the measurement of calorimetric changes, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion processes, etc. In vivo assays include, but are not limited to, assays to detect physiological effects, e.g. weight gain, change in electrolyte balance, change in blood clotting time, changes in clot dissolution and the induction of antigenic response. Generally, any in vivo assay can be used so long as a variable parameter exists so as to detect a change in the interaction between the identified and the peptide of interest. See, for example, U.S. Pat. No. 5,834,250.
- Detection of the expressed protein is achieved by methods known in the art and includes, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.
- An initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. One such example can be ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.
- The molecular weight of a recombinant protein can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture can be ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration can then be ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed.
- Recombinant proteins can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).
- Renaturation and Refolding
- Insoluble protein can be renatured or refolded to generate secondary and tertiary protein structure conformation. Protein refolding steps can be used, as necessary, in completing configuration of the recombinant product. Refolding and renaturation can be accomplished using an agent that is known in the art to promote dissociation/association of proteins. For example, the protein can be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea.
- Recombinant protein can also be renatured, for example, by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate,
pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be refolded while immobilized on a column, such as the Ni NTA column by using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, and 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation can be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM immidazole. Immidazole can be removed by a final dialyzing step against PBS or 50 mMsodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein can be stored at room temperature, 4° C. or frozen at −20° C. to −80° C. - Other methods include, for example, those that may be described in M H Lee et al., Protein Expr. Purif., 25(1): p. 166-73 (2002), W. K. Cho et al., J. Biotechnology, 77(2-3): p. 169-78 (2000), Ausubel, et al. (1987 and periodic supplements), Deutscher (1990) “Guide to Protein Purification,” Methods in Enzymology vol. 182, and other volumes in this series, Coligan, et al. (1996 and periodic Supplements) Current Protocols in Protein Science Wiley/Greene, NY, S. Roe, Protein Purification Techniques: A Practical Approach (Practical Approach Series), Oxford Press (2001); D. Bollag, et al., Protein Methods, Wiley-Lisa, Inc. (1996)
- Active Peptide Analysis
- Active proteins can have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native peptide that the sequence is derived from. Further, the substrate specificity (kcat/Km) is optionally substantially similar to the native peptide. Typically, kcat/Km will be at least 30%, 40%, or 50%, that of the native peptide; and more preferably at least 60%, 70%, 80%, or 90%. Methods of assaying and quantifying measures of protein and peptide activity and substrate specificity (kcat/Km), are well known to those of skill in the art.
- The activity of a recombinant peptide produced in accordance with the present invention by can be measured by any protein specific conventional or standard in vitro or in vivo assay known in the art. The activity of the plant cell host produced recombinant peptide can be compared with the activity of the corresponding native protein to determine whether the recombinant protein exhibits substantially similar or equivalent activity to the activity generally observed in the native peptide under the same or similar physiological conditions.
- The activity of the recombinant protein can be compared with a previously established native peptide standard activity. Alternatively, the activity of the recombinant peptide can be determined in a simultaneous, or substantially simultaneous, comparative assay with the native peptide. For example, an in vitro assays can be used to determine any detectable interaction between a recombinant peptide and a target, e.g. between an expressed enzyme and substrate, between expressed hormone and hormone receptor, between expressed antibody and antigen, etc. Such detection can include the measurement of colorimetric changes, proliferation changes, cell death, cell repelling, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion methods, phosphorylation abilities, antibody specificity assays such as ELISA assays, etc. In addition, in vivo assays include, but are not limited to, assays to detect physiological effects of the plant host cell produced peptide in comparison to physiological effects of the native peptide, e.g. antigenic response. Generally, any in vitro or in vivo assay can be used to determine the active nature of the recombinant peptide that allows for a comparative analysis to the native peptide so long as such activity is assayable. Alternatively, the peptides produced in the present invention can be assayed for the ability to stimulate or inhibit interaction between the peptide and a molecule that normally interacts with the peptide, e.g. a substrate or a component of the signal pathway that the native protein normally interacts. Such assays can typically include the steps of combining the protein with a substrate molecule under conditions that allow the peptide to interact with the target molecule, and detect the biochemical consequence of the interaction with the protein and the target molecule.
- Assays that can be utilized to determine peptide activity are described, for example, in Ralph, P. J., et al. (1984) J. Immunol. 132:1858 or Saiki et al. (1981) J. Immunol. 127:1044, Steward, W. E. II (1980) The Interferon Systems. Springer-Verlag, Vienna and New York, Broxmeyer, H. E., et al. (1982) Blood 60:595, “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987, AK Patra et al., Protein Expr Purif, 18(2): p/182-92 (2000), Kodama et al., J. Biochem. 99: 1465-1472 (1986); Stewart et al., Proc. Nat'l Acad. Sci. USA 90: 5209-5213 (1993); (Lombillo et al., J. Cell Biol. 128:107-115 (1995); (Vale et al., Cell 42:39-50 (1985).
- Viral Source of Coat Protein-Encoding Nucleic Acid
- In the following examples, the cowpea chlorotic mottle virus (CCMV) has been used as the source of the coat protein for expression of the desired recombinant peptides. CCMV is a member of the bromovirus group of the Bromoviridae. Bromoviruses are 25-28 nm diameter icosahedral viruses with a four-component, positive sense, single-stranded RNA genome. RNA1 and RNA2 code for replicase enzymes. RNA3 codes for a protein involved in viral movement within plant hosts. RNA4 (a subgenomic RNA derived from RNA 3), i.e. sgRNA4, codes for the 20 kDa coat protein (CP) (SEQ ID NO:13) (Table 1). Each CCMV particle contains 180 copies of the CCMV CP. An exemplary DNA sequence encoding the CCMV CP is shown in SEQ ID NO:14 (Table 2).
TABLE 1 Wild type CCMV coat protein encoded by sgRNA4 (Seq. ID No. 13) Met Ser Thr Val Gly Thr Gly Lys Leu Thr Arg Ala Gln Arg Arg Ala Ala Ala Arg Lys Asn Lys Arg Asn Thr Arg Val Val Gln Pro Val Ile Val Glu Pro Ile Ala Ser Gly Gln Gly Lys Ala Ile Lys Ala Trp Thr Gly Tyr Ser Val Ser Lys Trp Thr Ala Ser Cys Ala Ala Ala Glu Ala Lys Val Thr Ser Ala Ile Thr Ile Ser Leu Pro Asn Glu Leu Ser Ser Glu Arg Asn Lys Gln Leu Lys Val Gly Arg Val Leu Leu Trp Leu Gly Leu Leu Pro Ser Val Ser Gly Thr Val Lys Ser Cys Val Thr Glu Thr Gln Thr Thr Ala Ala Ala Ser Phe Gln Val Ala Leu Ala Val Ala Asp Asn Ser Lys Asp Val Val Ala Ala Met Tyr Pro Glu Ala Phe Lys Gly Ile Thr Leu Glu Gln Leu Thr Ala Asp Leu Thr Ile Tyr Leu Tyr Ser Ser Ala Ala Leu Thr Glu Gly Asp Val Ile Val His Leu Glu Val Glu His Val Arg Pro Thr Phe Asp Asp Ser Phe Thr Pro Val Tyr -
TABLE 2 Exemplary DNA Sequence Encoding the CCMV CP (Seq. ID. No. 14) atg tct aca gtc gga aca ggg aag tta act cgt gca caa cga agg gct gcg gcc cgt aag aac aag cgg aac act cgt gtg gtc caa cct gtt att gta gaa ccc atc gct tca ggc caa ggc aag gct att aaa gca tgg acc ggt tac agc gta tcg aag tgg acc gcc tct tgc gcg gcc gcc gaa gct aaa gta acc tcg gct ata act atc tct ctc cct aat gag cta tcg tcc gaa agg aac aag cag ctc aag gta ggt aga gtt tta tta tgg ctt ggg ttg ctt ccc agt gtt agt ggc aca gtg aaa tcc tgt gtt aca gag acg cag act act gct gct gcc tcc ttt cag gtg gca tta gct gtg gcc gac aac tcg aaa gat gtt gtc gct gct atg tac ccc gag gcg ttt aag ggt ata acc ctt gaa caa ctc acc gcg gat tta acg atc tac ttg tac agc agt gcg gct ctc act gag ggc gac gtc atc gtg cat ttg gag gtt gag cat gtc aga cct acg ttt gac gac tct ttc act ccg gtg tat tag - The crystal structure of CCMV has been solved. This structure provides a clearer picture of the coat protein interactions that appear to be critical to particle stability and dynamics and has been helpful in guiding rational design of insertion sites. Previous studies have demonstrated that CCMV coat proteins can be genetically modified to carry heterologous peptides without interfering with their ability to form particles. A number of suitable insertion sites have been identified. A total of up to 180 copies of a heterologous peptide unit (whether as individual peptide units or in concatameric units) can be inserted into the CCMV particle at a single insertion site in the CCMV CP. Insertion sites identified within CCMV CP to date can accommodate peptides of various lengths.
- Materials and Methods
- Unless otherwise noted, standard techniques, vectors, control sequence elements, and other expression system elements known in the field of molecular biology are used for nucleic acid manipulation, transformation, and expression. Such standard techniques, vectors, and elements can be found, for example, in: Ausubel et al. (eds.), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch, & Maniatis (eds.), Molecular Cloning (1989) (Cold Spring Harbor Laboratory Press, NY); Berger & Kimmel, Methods in Enzymology 152: Guide to Molecular Cloning Techniques (1987) (Academic Press); and Bukhari et al. (eds.), DNA Insertion Elements, Plasmids and Episomes (1977) (Cold Spring Harbor Laboratory Press, NY).
- Unless noted otherwise, PCR reactions were performed using a PTC225 thermocycler (MJ Research, South San Francisco, Calif., USA) according to the following protocol:
TABLE 3 PCR protocol Reaction Mix (100 μL total volume) Thermocycling Steps 10 μL 10× PT HIFI buffer * Step 11 Cycle 2 min. 94° C. 4 μL 50 mM MgSO4 * Step 235 Cycles 30 sec. 94° C. 2 μL 10 mM dNTPs * 30 sec. 55° C. 0.25 ng Each Primer 1 min. 68° C. 1-5 ng Template DNA Step 3 1 Cycle 10 min. 70° C. 1 μL PT HIFI Taq DNA Polymerase * Step 41 Cycle Maintain 4° C. Remainder Distilled De-ionized H2O (ddH2O)
* (from Invitrogen Corp, Carlsbad, CA, USA, hereinafter “Invitrogen”)
- Expression of Bacillus anthracis antigenic peptides was performed in whole plants, using cowpea chlorotic mottle virus (CCMV) with capsid proteins (CP) engineered to contain one of four different antigenic peptides.
- DNA having the nucleotide sequence of
CCMV RNA 1 and DNA having the nucleotide sequence ofCCMV RNA 2 were each separately subcloned in the cloning vector pUC19 downstream from, and under the control of, a T7 promoter and upstream from a unique Xba I site. This produced plasmids pDOW2122 (CCMV RNA1) and pDOW2123 (CCMV RNA2). - DNA having the nucleotide sequence of
CCMV RNA 3, engineered to contain five BamH I restriction enzyme cleavage sites, was further engineered for production of the recombinant capsid protein-encoding nucleic acid. Four DNA molecules, each encoding a different one of four exogenous peptides (four different antigenic peptides from Bacillus anthracis Protective Antigen PA) were each synthesized by SOE (splicing-by-overlap-extension) of synthetic oligonucleotides. The resulting nucleic acids contained BamHI recognition site termini. Each PA DNA fragment was restricted with BamHI restriction enzyme and independently inserted into the coat protein at one of the five different engineered restriction enzyme cleavage sites in the CCMV coat protein coding sequence: BamHI at codon 63, BamHI at codon 102, BamHI at codon 114, BamHI at codon 129, and BamHI at codon 160. - The four different peptides were PA1 (SEQ ID NO: 1 encoded by SEQ ID NO: 15), PA2 (SEQ ID NO: 2, encoded by SEQ ID NO: 16), PA3 (SEQ ID NO: 3, encoded by SEQ ID NO:17), and PA4 (SEQ ID NO:4, encoded by SEQ ID NO: 18).
TABLE 4 Bacillus anthracis antigenic nucleic acid and amino acid sequences. PA1 Nucleic Acid Sequence 5′-agt aat tct cgt aag aaa cgt tct acc tct gct ggc cct acc (SEQ ID NO: 15) gtg cct gat cgt gat aat gat ggc aft cct gat-3′ Amino Acid Sequence Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro (SEQ ID NO: 1) Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro Asp PA2 Nucleic Acid Sequence 5′-agt cct gaa gct cgt cat cct ctc gtg gct gcg tat cct att (SEQ ID NO: 16) gtg cat gtt gat atg gaa aat aft atc ctc tct-3′ Amino Acid Sequence Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro (SEQ ID NO: 2) Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser PA3 Nucleic Acid Sequence 5′-cgt att aft ftc aat ggc aaa gat ctc aat ctc gtg gaa cgt (SEQ ID NO: 17) cgt att gct gct gtg aat cct tct gat cct ctc -3′ Amino Acid Sequence Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu (SEQ ID NO: 3) Arg Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu PA4 Nucleic Acid Sequence 5′-cgt caa gat ggc aaa acc ftc aft gat ftc aaa aag tat aat (SEQ ID NO: 18) gat aaa ctc cct ctc tat aft tct aat cct aat-3′ Amino Acid Sequence Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys (SEQ ID NO: 4) Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn - Each of these was inserted into each of the five plasmids: pDOW2125 (pUC-CCMV RNA3-CP63BamHI), pDOW2126 (pUC-CCMV-RNA3-102BamHI), pDOW2127 (pUC-CCMV-RNA3-CP114BamHI), pDOW2128 (pUC-CCMV-RNA3-CP129BamHI), and pDOW2129 (pUC-CCMV-RNA3-CP160BamHI) which had been digested with BamHI restriction enzyme and then dephoshorylated.
- This produced a total of 20 different versions of DNA for “
chimeric RNA 3.” Plasmids pDOW2135 (pUC-CCMV-RNA3-CP63BamHI-PA1), pDOW2139 (pUC-CCMV-RNA3-CP102BamHI-PA1), pDOW2143 (pUC-CCMV-RNA3-CP114BamHI-PA1), pDOW2147 (pUC-CCMV-RNA3-CP129BamHI-PA1), and pDOW2151 (pUC-CCMV-RNA3-CP160BamHI-PA1) are examples of chimeric RNA3 having a PA1 insert at position 63, 102, 114, 129, and 160. Wild-type CCMV coat protein-encoding RNA 3 and engineered CCMV coat protein-encoding RNA 3 containing BamHI restriction site but no inserts were used as controls. Each modified RNA3 construct was separately sub-cloned in the cloning vector pUC19 downstream from and under the control of a T7 promoter, and upstream from a unique Xba I site. - Each of the three classes of plasmids was cloned in E. coli. Plasmids were isolated, linearized by Xba I restriction enzyme digestion, and then one microgram of each was transcribed into RNA in vitro using a mMESSAGE mMACHINE T7 Kit (RNA transcription kit, from Ambion, Inc., Austin, Tex., USA). This produced 24 different RNA varieties: one for RNA1, one for RNA2, 20 for chimeric RNA3, and two for RNA3 controls.
- Cocktail mixes of RNA1, RNA2, RNA3 or chimeric RNA3s containing a PA insert were used to infect cowpea plants. Cowpea plants were sprouted from Cowpea
California Blackeye # 5 seeds (Ferry-Morse Seed Co. KY). Sprouts were transplanted singly into 6 inch pots with Miracle-Gro potting mix (Miracle-Gro Lawn Products OH). Cowpea plants were infected at 2-leaf stage (approximately 7 days post germination). A dusting of Carborundum powder 400grit (Fisher Scientific cat.409-21-2) was applied onto one leaf of each plant. RNA cocktail mixes were applied onto the carborundum layer. Leaves were abraded by gentle rubbing with a gloved finger. Infections were established 7-14 days post inoculation. - Unexpectedly, in this whole plant system, even though the native host plant was used, the chimeric coat proteins reverted to the wild type or in some cases, the desired exogenous antigen peptide was partially deleted. This was verified by sequencing the virus progeny. The RNA was extracted and reverse-transcribed into DNA using ThermoScript RT-PCR system (Invitrogen cat.11146-024) and CCMVRNA4.R gene specific primer (SEQ ID NO:19) (5′-CTC GAG CTA ATA CAC CGG AGT GAA AG-3′). cDNAs were further amplified by PCR using primers CCMVRNA4.F (SEQ ID NO:20) (5′-CTG CAG ATG TCT ACA GTC GGA ACA GG-3′) and CCMVRNA4.R. The reactions were purified and sequenced with CCMV-CP-F1 primer, (SEQ ID NO: 21) (5′-AAC CCA TCG CTT CAG GCC AA-3′). Sequences were analyzed with Sequencher software version 4.0.5 (Gene Codes Corporation). For example, upon sequencing of RNA3 progeny derived from pDOW2128 containing the PA1 insert, the coat protein contained a small, unrecognized nucleotide insert (5′-CGTATTTCTGATCCTCTC-3′) that was translated as RISDPL instead of the PA1 insert amino acid sequence. The inserted nucleotide sequence kept the rest of the coat protein in frame. It has been determined that the engineered CCMV RNA3 is unstable upon expression in the whole plant, easily undergoes recombinations, and that the whole plant system is not useful for production of epitopes on chimeric CCMV virus particles.
- Expression of the same CCMV-peptide-encoding constructs was performed in plant cell suspension culture. Nicotiana tabacum NT1 cells were transfected by electroporation with RNA transcripts of
CCMV RNA 3 coding for the chimeric CCMV coat proteins andCCMV RNA encoding RNA 3 and engineered CCMV coat protein-encoding RNA 3 containing the appropriate BamHI restriction site but no inserts were used as controls. - 24 different RNA varieties were obtained by in vitro RNA transcription as described in the Example 1: one for RNA1, one for RNA2, 20 for chimeric RNA3, and two for RNA3 controls. In 22 different groups, two micrograms of each of three resulting RNAs (RNA1, RNA2, and one of the RNA3s) were transformed into tobacco cells by electroporation.
- The Following Protocol was Used for Plant Cell Transfection:
- 1) Media Preparation:
- NTI Media (1 Liter):
- 4.33 g Murashige & Skoog basal salt (Phyto Technology Laboratories KS cat.M524), 100 mg Myo-Inositol (Sigma cat.I-3011), 1 ml of 1 mg/ml solution of Thiamine HCl (Sigma cat. T-3902), 180 mg Potassium Phosphate Monobasic KH2PO4 (Sigma cat. P-8416), 30 g Sucrose (Sigma cat.S-5390), and 200
μl 2,4-D solution of 10 mg/ml (Sigma cat. D-7299) were mixed in a small amount of water. Purified water was added to the solution to bring volume up to 1 liter. The pH was adjusted to 5.8, and the solution was autoclaved. - Mannitol Wash Solution 0.4M:
- 36.43 Mannitol (Sigma cat. M-1902) was added to small amount of purified water. Purified water was added to bring volume up to 500 ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize.
- Enzyme Solution:
- 0.4M mannitol, and 0.02M MES were mixed in a small amount of water. Purified water was added to bring volume up to 500 ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize, and the solution was stored at 4° C. Prior to use, 1% cellulysin (Calbiochem cat.219466) and 0.3% Macerase Pectinase (Calbiochem cat.441201) was added to solution, and the solution was shaken until cellylysin and Macerase Pectinase were dissolved.
- Electroporation Buffer:
- 0.8% NaCl, 0.02% KCl, 0.02% KH2PO4, and 0.11% Na2HPO4 were added to a small amount of purified water. Purified water was added to bring the solution up to 100 mls, and the pH was adjusted to 6.5. The buffer was autoclaved and stored at 4° C.
- 2) Tobacco Cell Partial Digestion Protocol:
- Tobacco
cell line NT 1 was partially digested prior to electroporation as following. A robust cell line was maintained by sub-culturing weekly, cells were grown in NTI media at 24° C. or 28° C. with gentle shaking, and three days before digestion, 5 ml of cell suspension was sub-cultured into 50 ml of NTI media and incubated at 28° C. Cells were spun down in Soml tubes for 5 minutes at 800 rpm. The enzyme solution was prepared, and cells were washed in the mannitol wash solution (approx. 40 ml). Cells were spun for 5 minutes at 800 rpm, and 3 volumes of enzyme solution were added to the cells. Cells were resuspended by inversion; transferred into 10 cm petri dishes by pouring, and the dish was shaken very slowly at room temperature while wrapped in aluminum foil for 60-120 minutes. The cells were then transferred back into 50 ml plastic tubes; and spun for 5 minutes at 800 rpm. Cells were washed with 40 ml mannitol wash solution and spun again, washed with electroporation buffer, and spun. Three volumes of electroporation buffer (total volume is usually 20 ml) were added to the cells; and the cells were stored at 4° C. wrapped in aluminum foil. - 3) Electroporation of Partially Digested Cells Protocol:
- 1 ml of digested cells were aliquoted into electroporation cuvettes (4 mm gap). 2 μg each RNA transcript—CCMV RNA1, RNA2, and Chimeric RNA3—were added to the cuvettes and placed on ice for 5 minutes. 10 ml of NTI plating media were added (NTI+0.4M mannitol) to each Petri dish. The cells were electroporated at 500 μF, 250V, and the cuvettes were placed back on ice. The cells were then transferred into Petri dishes, and incubate at room temperature in darkness with no shaking. The cells were then collected for analysis at 48 hours post transfection.
- Results
- Expression of chimeric coat protein was analyzed by Western blot using anti-CCMV coat protein polyclonal antibody. Also, RNA was extracted from each of the cultures and the chimeric CCMV RNA4 was reverse transcribed into cDNA, which was then amplified by PCR. The PCR products were sequenced as described in Example 1. All samples were positive on the western blot except for the negative control that was transfected with only RNA1 and 2.
- Compared to control CCMV capsid proteins, the chimeric coat proteins had greater size and slower mobility on the gel indicating that the chimeric coat proteins contained PA inserts. This was verified by sequencing of the viral RNA progeny. Results demonstrated that 19 out of 20 chimeric constructs expressed the chimeric CCMV coat protein properly without mutation in the desired antigen peptide. The results indicate that chimeric CCMV RNA3s expressed in suspension cells are stable.
-
FIG. 2 shows the expression of CCMV CP in cells transfected with CCMV RNA1, RNA2, and RNA3 transcribed from pDOW2125 (CCMV63BamHI), pDOW2126 (CCMV102BamHI), pDOW2127 (CCMV114BamHI), pDOW2128 (CCMV129BamHI) and pDOW2129 (CCMV160BamHI). The results demonstrate that CCMV CP is expressed from all RNA3s with engineered BamHI site in different positions in the CP. - All 4 PA peptides (PA1, PA2, PA3, and PA4) fused to CCMV coat protein at the 63, 102, 114, 129, and 160 BamHI site were successfully produced in tobacco cells.
FIG. 3 andFIG. 4 show the expression of chimeric CCMV CP in cells transfected with CCMV RNA1, RNA2, and chimeric RNA3 containing CP with the four PA peptide inserts in the position 63, 102, 114, 129, and 160.FIG. 3 demonstrates that the fusion protein of CCMV CP with PA1, PA2, PA3, or PA4 peptide that has been inserted at the position 63, 102, or 114, is expressed in the tobacco plant cells with the exception of PA2 peptide that has been inserted into the CCMP CP at the position 63.FIG. 4 demonstrates that the fusion protein of CCMV CP with PA1, PA2, PA3, or PA4 peptide that has been inserted at the position 129 or 160, is expressed in the tobacco plant cells. - 1) Vector Construction:
- Plasmid pIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were XbaI and EcoRI. This plasmid contains the Cassava Vein Mosaic Virus promoter upstream of the XbaI site and a Nos terminator downstream of the EcoRI site. The vector was prepared by digestion with XbaI and EcoRI and dephosphorylated before litigation with the inserts.
- 2) Insert Construction:
- CCMV CP-PA fusions were amplified by PCR out of pDOW2147 (PUC-CCMV-RNA3-CP129BamHI-PA1), pDOW2148 (pUC-CCMV-RNA3-CP129BamHI-PA2), pDOW2149 (pUC-CCMV-RNA3-CP 129BamHI-PA3), pDOW2150 (pUC-CCMV-RNA3-CP 129BamHI-PA4) using primers CCMV-CP-XbaI (SEQ ID NO:22) and CCMV-CP-EcoRI (SEQ ID NO: 23) to create pDOW2160 (pIL-Tab-CCMV129BamHI-PA1) (SEQ ID NO: 5), pDOW2161 (pIL-Tab-CCMV129BamHI-PA2) (SEQ ID NO:6), pDOW2162 (pIL-Tab-CCMV129BamHI-PA3) (SEQ ID NO:7), and pDOW2163 (pIL-Tab-CCMV129BamHI-PA4) (SEQ ID NO:8). Plasmid maps for pDOW2160, pDOW 2161, pDOW2162, and pDOW 2163 are shown in
FIGS. 5, 6 , 7, and 8. - 3) Plant Cell Transfection:
- Plant cells were transfected with 10%g of plasmid pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Plant cell transfection was performed as in Example 2.
- Results
- All four PA peptides-CCMV CP fusions at 129BamHI site were successfully expressed in tobacco cells.
FIG. 9 shows the expression of chimeric CCMV CP in cells transfected with pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Compared to the control (CCMV coat protein with no insert), all four chimeric coat proteins showed slower mobility indicative of having PA inserts. - 1) Vector Construction.
- Plasmid pIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were XbaI and EcoRI. This plasmid contains the Cassava Vein Mosaic Virus promoter upstream of the XbaI site and a Nos terminator downstream of the EcoRI site. The vector was prepared by digestion with XbaI and EcoRI and depshophorylated before litigation with the inserts.
- 2) Insert Construction:
- CCMV CP-PA fusions containing the 3′UTR of RNA3 were amplified by PCR out of pDOW2147, pDOW2148, pDOW2149, and pDOW2150 using primers CCMV-CP-XbaI and CCMV-CP-EcoRI-3′UTR (SEQ ID NO: 24) to create pDOW2169 (pIL-Tab-CP129BamHI-PA1-3′UTR) (SEQ ID NO: 9), pDOW2170 (pIL-Tab-CP129BamHI-PA2-3′UTR) (SEQ ID NO:
-
- 10), pDOW2171 (pIL-Tab-CP129BamHI-PA3-3′UTR) (SEQ ID NO: 11), and pDOW2172 (pIL-Tab-CP 129BamHI-PA4-3′UTR) (SEQ ID NO: 12).
- 3) Plant Cell Transfection:
- Plant cells were transfected with 10%g of plasmid pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Plant cell transfection was performed as in Example 2.
- Results
- All four PA peptides-CCMV CP fusions at 129BamHI site containing the 3′UTR were successfully expressed in tobacco cells.
FIG. 10 shows the expression of chimeric CCMV CP in cells transfected with pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Compared to the control (CCMV coat protein with no insert), all four chimeric coat proteins showed slower mobility indicative of having PA inserts. - Tobacco cell line NT1 was maintained by subculturing weekly. Cells were grown in NTI media at 24° C. or 28° C. with gentle shaking. Three days before transformation, 5 ml of cell suspension was subcultured into 50 ml of NTI media and incubated at 28° C.
- 1) Plant Cell Transformation by Particle Bombardment:
- Plasmids pDOW2160, pDOW2161, pDOW2162, pDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter (pBBV) were used for NT1 tobacco cells transformation by micro-particle bombardment. The plasmid ratio used was 1:6 pBBV:pDOW2160, pBBV:pDOW2161, pBBV:pDOW2162, or pBBV:pDOW2163. Total of 5 ug of plasmid DNAs were sufficient for 6 bombardments. Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
- 2) Plating
- Bombarded cells were transferred on non-selective NT1 media agar plates for 4 hours before transferring to NT1 media agar plate with 25 ug/ml of Glufosinate-ammonium (Sigma cat#45520).
- 3) Selecting Transgenic Calli.
- After 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting to test for the expression of CP fusions and PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome. Transgenic calli expressing chimeric CCMV CPs were transferred to liquid NT1 media. Cells were grown in NTI media at 24° C. or 28° C. with gentle shaking and subcultured weekly.
- Results
-
FIG. 11 shows the expression of chimeric CCMV CP in cells stably transformed with pDOW2160, pDOW2161, pDOW2162, and pDOW2163. The CP fusion was detected by polyclonal antibodies for CCMV. Expression of all four chimeric coat protein transgenes was detected. - Rice cell lines were maintained by sub-culturing weekly. Cells were grown in NB media (Li, L et al. Plant Cell Reports. (1993) 12: 250-255) at 28° C. with gentle shaking. Three days before transformation, 5 ml of cell suspension was sub-cultured into 50 ml of NB media and incubated at 28° C.
- 1) Plant Cell Transformation by Particle Bombardment.
- Plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter were used for rice cells transformation by microparticle bombardment. The plasmid ratio used was 1:6 pBBV:pDOW2160, pBBV:pDOW2161, pBBV:pDOW2162, or pBBV:pDOW2163. Total of 5 ug of plasmid DNAs were sufficient for 6 bombardments. Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
- 2) Plating.
- Bombarded cells were transferred to NB media agar plates with 25 ug/ml of Glufosinate-ammonium (Sigma cat#45520) for selection.
- 3) Selecting Transgenic Calli.
- After 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting to test for the expression of CP fusions and PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome.
- Results
-
FIG. 12 shows the expression of chimeric CCMV CP in cells stably transformed with pDOW2160, pDOW2161, pDOW2162, and pDOW2163 as detected by polyclonal antibodies to CCMV. Expression of all four chimeric coat protein transgenes was detected. - The following protocol has been used to extract genomic DNA and test for integration of promoter-CP fusion gene-terminator cassette into the plant genome by PCR. Qiagen DNeasy Plant Mini was used to extract genomic DNA following the manufacturer directions.
- Approximately 50-100 mg of fresh rice callus was placed into a 1.5 ml tube. The tissue was frozen in liquid N2 for immediate DNA extraction or placed in −80° C. freezer for storage. Prior to DNA extraction the tissue was manually disrupted by grinding with a micropestle. The sample was placed on ice and the genomic DNA was extracted as described in Qiagen DNeasy Plant Mini Kit manual. The Access
Quick Master Mix 2× (Promega cat#A1720) was used to set up the PCR reaction as follows:Master mix 25 ul CCMV-F (10 mM) primer, SEQ ID NO: 25 1 ul Nos-term-R (10 mM) primer, SEQ ID NO: 26 1 ul Genomic DNA 1 ul water 22 ul Total 50 ul - The following PCR cycle has been used to amplify the promoter-CP fusion gene-terminator cassette from the genomic DNA:
1 cycle 95° C. 2 min 35 cycles of 95° C. 30 sec 55° C. 30 sec 70° C. 2 min 1 cycle 70° C. 5 min 4° C. hold - 10 ul of PCR reaction was run on 1.2% agarose gel stained with EtBr.
FIG. 13 shows a PCR products amplified from selected individual rice calli. The samples that contained a PCR product of predicted size were scored as positive for stable transformation and integration of the chimeric CP transgene into the plant genome. - Transgenic calli expressing chimeric CCMV CPs were transferred to liquid NB media to create a cell suspension culture suitable for scale up fermentation. Cells were grown in NB media at 28° C. with gentle shaking and subcultured weekly.
- VLP Extraction:
- Chimeric VLPs were precipitated by lysis of shake-flask culture samples, followed by PEG (polyethylene glycol)-treatment of the resulting cell lysates and ultrafiltration, according to the following protocol:
- 50 mL aliquots of each shake-flask culture were centrifuged to pellet the cells. Pelleted cells were resuspended in virus buffer (0.2M Sodium Acetate pH 5.2; 10 mM EDTA.0) at a 2 volume buffer to 1 volume pellet ratio. Cells were then disrupted by blending for 60 sec multiple times, with 2 minutes resting on ice in between. The resulting homogenate was squeezed through 3 layers of cheese cloth and was then centrifuged for 15 min at 15,000×G at 4° C. The resulting supernatants were removed and their volumes measured. To each supernatant, PEG8000 was added to a final concentration of 10% and the solution was incubated on ice for 1 hr or overnight at 4° C. Then, the solution was centrifuged at 15,000×G for 10 min at 4° C. Precipitated pellets were then resuspended in 1/10 initial supernatant volume of virus buffer and stored at 4° C. and analyzed by western blotting with polyclonal anti-CCMV antibodies.
-
FIG. 14 shows that the chimeric CCMV VLPs were recovered from cells stably transformed with pDOW2160. Chimeric CP-PA1 fusion proteins were detected in the resuspended PEC pellets but not the supernatant indicating the chimeric CP assembled into VLPs. - Alternatively, the resuspended samples were centrifuged for 10 min at 15,000×G at 4° C., the supernatant was recovered and subjected to the second round of PEG precipitation. PEG8000 was added to final concentration of 15% and stirred at 4° C. for 2 hours. The solution was then centrifuged at 15,000×G for 10 mins and the pellet was resuspended in small volume of virus buffer. The resuspended VLP solution was loaded on to Centricon Plus-20 with 300K molecular weight cut-off and spun at 4,000×G for 5 mins. The concentrated VLP sample was then analyzed by western blotting with polyclonal anti-CCMV antibodies (see
FIG. 14 ). Chimeric CP-PA1 fusion proteins were detected in the resuspended and size-filtered second PEG pellets, but not in the supernatant, indicating the chimeric CP assembled into VLPs.
Claims (35)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/069,601 US7928290B2 (en) | 2004-02-27 | 2005-02-28 | Viral capsid fusion peptide expressing plant cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54874404P | 2004-02-27 | 2004-02-27 | |
US11/069,601 US7928290B2 (en) | 2004-02-27 | 2005-02-28 | Viral capsid fusion peptide expressing plant cells |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050260758A1 true US20050260758A1 (en) | 2005-11-24 |
US7928290B2 US7928290B2 (en) | 2011-04-19 |
Family
ID=34976075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/069,601 Active 2027-04-05 US7928290B2 (en) | 2004-02-27 | 2005-02-28 | Viral capsid fusion peptide expressing plant cells |
Country Status (7)
Country | Link |
---|---|
US (1) | US7928290B2 (en) |
EP (2) | EP1720990A4 (en) |
JP (1) | JP2007528727A (en) |
CN (1) | CN1926238A (en) |
AU (1) | AU2005220734A1 (en) |
CA (1) | CA2557668A1 (en) |
WO (1) | WO2005086667A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009019693A2 (en) * | 2007-08-07 | 2009-02-12 | Sepal Pharma Sa | Analgesic effect of jasmonate derivatives |
US20090117144A1 (en) * | 2005-07-19 | 2009-05-07 | Lada Rasochova | Recombinant flu vaccines |
US20090215179A1 (en) * | 2001-07-20 | 2009-08-27 | Transalgae | Transgenically preventing establishment and spread of transgenic algae in natural ecosystems |
US20100081177A1 (en) * | 2008-09-05 | 2010-04-01 | TransAlgae Ltd | Decreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide |
WO2010027516A3 (en) * | 2008-09-05 | 2010-05-27 | Jonathan Gressel | Transgenically preventing establishment and spread of transgenic algae in natural ecosystems |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
US20110093982A1 (en) * | 2009-10-16 | 2011-04-21 | Dow Agrosciences Llc | Use of dendrimer nanotechnology for delivery of biomolecules into plant cells |
US20120219579A1 (en) * | 2009-09-18 | 2012-08-30 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
WO2014204667A1 (en) * | 2013-06-19 | 2014-12-24 | Apse, Llc | Compositions and methods using capsids resistant to hydrolases |
US9181531B2 (en) | 2011-12-21 | 2015-11-10 | Apse, Llc | Process for purifying VLPs |
WO2016061149A1 (en) * | 2014-10-14 | 2016-04-21 | Medgenics Medical Israel Ltd. | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006351933A1 (en) * | 2005-12-02 | 2008-07-17 | Dow Global Technologies Inc. | Novel plant virus particles and methods of inactivation thereof |
AT503690A1 (en) * | 2006-06-09 | 2007-12-15 | Biomay Ag | HYPOALLERGENIC MOLECULES |
EP2139993A2 (en) * | 2007-04-27 | 2010-01-06 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
CA2615372A1 (en) * | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
US20120015899A1 (en) * | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
EP2419143B8 (en) | 2009-04-13 | 2018-06-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Hpv particles and uses thereof |
WO2013119877A1 (en) | 2012-02-07 | 2013-08-15 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
US20140287507A1 (en) | 2012-10-24 | 2014-09-25 | Qian Wang | Incorporation of Plant Virus Particles and Polymers as 2D and 3D Scaffolds to Manipulate Cellular Behaviors |
CN105979967A (en) | 2013-09-18 | 2016-09-28 | 奥拉生物科学公司 | Virus-like particle conjugates for diagnosis and treatment of tumors |
WO2017075440A1 (en) | 2015-10-30 | 2017-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Targeted cancer therapy |
KR101830792B1 (en) * | 2016-01-27 | 2018-02-21 | 건국대학교 산학협력단 | Method for producing antimicrobial peptide using insoluble fusion protein containing antimicrobial peptide |
EP3820997A4 (en) * | 2018-07-09 | 2022-09-21 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Viral-vectored vaccine for malaria |
KR102696265B1 (en) * | 2021-02-25 | 2024-08-21 | 주식회사 바이오앱 | Method for manufacturing alfalfa mosaic virus-like particles using plant expression system and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677274A (en) * | 1993-02-12 | 1997-10-14 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Anthrax toxin fusion proteins and related methods |
US5874087A (en) * | 1991-04-19 | 1999-02-23 | Axis Genetics Plc | Modified plant viruses as vectors |
US5958422A (en) * | 1994-07-13 | 1999-09-28 | Axis Genetics Plc | Modified plant viruses as vectors of heterologous peptides |
US6042832A (en) * | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
US6232099B1 (en) * | 1994-10-18 | 2001-05-15 | Scottish Crop Research Institute | Method of producing a chimeric protein |
US20030018557A1 (en) * | 2001-07-18 | 2003-01-23 | Gilbert James A. | Financial processing gateway structure |
US6660500B2 (en) * | 1988-02-26 | 2003-12-09 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
US6730306B1 (en) * | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
US20050214321A1 (en) * | 2003-12-01 | 2005-09-29 | Dow Global Technologies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US206A (en) | 1837-05-30 | Machine fob | ||
US5693A (en) | 1848-08-01 | Window-catch | ||
US507A (en) | 1837-12-07 | John crabtree | ||
US6515A (en) | 1849-06-05 | Boom-derrick | ||
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US5102796A (en) | 1983-04-15 | 1992-04-07 | Lubrizol Genetics, Inc. | Plant structural gene expression |
US5977438A (en) | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
NL8800725A (en) | 1988-03-23 | 1989-10-16 | Mogen International N V En Rij | RECOMBINANT DNA; TRANSFORMED MICROORGANISMS, PLANT CELLS AND PLANTS; METHOD FOR PRODUCING A POLYPEPTIDE OR PROTEIN M.B.V. PLANTS OR PLANT CELLS; METHOD FOR PRODUCING PLANTS WITH VIRUS RESISTANCE. |
US5693507A (en) | 1988-09-26 | 1997-12-02 | Auburn University | Genetic engineering of plant chloroplasts |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5641876A (en) | 1990-01-05 | 1997-06-24 | Cornell Research Foundation, Inc. | Rice actin gene and promoter |
ES2171398T3 (en) | 1991-08-01 | 2002-09-16 | Large Scale Biology Corp | RECOMBINANT VEGETABLE VIRETAL NUCLEIC ACIDS. |
DE69632403T2 (en) | 1995-08-10 | 2005-05-19 | Rutgers University | CELL CORE-CODED TRANSCRIPTION SYSTEM PLASTIC OF HIGHER PLANTS |
NZ333471A (en) | 1996-06-20 | 1999-07-29 | Scripps Research Inst | Cassava vein mosaic virus promoters and uses thereof |
US5942664A (en) | 1996-11-27 | 1999-08-24 | Ecogen, Inc. | Bacillus thuringiensis Cry1C compositions toxic to lepidopteran insects and methods for making Cry1C mutants |
DK0991764T3 (en) | 1997-06-12 | 2006-11-13 | Dow Agrosciences Llc | Regulatory sequences for transgenic plants |
BR9815611B1 (en) | 1997-08-07 | 2013-09-17 | expression and universal integration vector competent to stably transform the chloroplast genome of different plant species and process to stably transform a target upper plant species | |
US6218145B1 (en) | 1998-04-02 | 2001-04-17 | Monsanto Company | Bacterial expression systems based on plastic or mitochondrial promoter combinations |
EP1108009A4 (en) | 1998-08-27 | 2004-07-14 | Univ Rutgers | Compositions and methods for producing high-level seed-specific gene expression in corn |
US6515206B1 (en) | 1998-12-23 | 2003-02-04 | Calgene Llc | Plastid transformation of Brassica |
AU7603600A (en) | 1999-09-22 | 2001-04-24 | Penn State Research Foundation, The | Quantitative transient protein expression in plant tissue culture |
AU4017701A (en) | 1999-09-24 | 2001-04-24 | Calgene Llc | Enhancer elements for increased translation in plant plastids |
PT1240340E (en) | 1999-12-16 | 2012-08-01 | Monsanto Technology Llc | Dna constructs for expression of heterologous polypeptides in plants |
US20020061309A1 (en) | 2000-03-08 | 2002-05-23 | Garger Stephen J. | Production of peptides in plants as N-terminal viral coat protein fusions |
ATE393232T1 (en) | 2000-03-22 | 2008-05-15 | Icon Genetics Inc | METHOD FOR TRANSFORMING PLANT PLASTIDS AND FOR PRODUCING TRANSPLASTOMES OF PLANTS |
IT1317046B1 (en) * | 2000-06-16 | 2003-05-26 | Ist Superiore Sanita | MELTING PROTEIN, VIRAL PARTICLES THAT EXPOSE IT ON SUCH CAPS, PLANTS INFECTED WITH SUCH PARTICLES, THEIR USES AND COMPOSITIONS |
DE10101276A1 (en) | 2001-01-12 | 2002-07-18 | Icon Genetics Ag | Methods and vectors for transforming plastids |
DE10102389A1 (en) | 2001-01-19 | 2002-08-01 | Icon Genetics Ag | Methods and vectors for plastid transformation of higher plants |
EP1456390B1 (en) * | 2001-12-26 | 2011-03-02 | University Of Central Florida | Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines |
WO2003068948A1 (en) | 2002-02-13 | 2003-08-21 | Dow Global Technologies Inc. | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
WO2003089455A2 (en) | 2002-04-22 | 2003-10-30 | Dow Global Technologies Inc. | Low-cost production of peptides |
DE60325611D1 (en) | 2002-07-03 | 2009-02-12 | Dow Global Technologies Inc | BENZOATE AND AN ANTILANEABLE PROMOTERS |
EP1549140A4 (en) | 2002-09-03 | 2009-04-29 | Kentucky Bioproc Llc | Production of peptides in plants as viral coat protein fusions |
CN1894277A (en) | 2003-02-24 | 2007-01-10 | 陶氏环球技术公司 | Periodic antimicrobial peptides |
-
2005
- 2005-02-28 CA CA002557668A patent/CA2557668A1/en not_active Abandoned
- 2005-02-28 EP EP05756363A patent/EP1720990A4/en not_active Withdrawn
- 2005-02-28 JP JP2007500784A patent/JP2007528727A/en active Pending
- 2005-02-28 CN CNA2005800063090A patent/CN1926238A/en active Pending
- 2005-02-28 US US11/069,601 patent/US7928290B2/en active Active
- 2005-02-28 AU AU2005220734A patent/AU2005220734A1/en not_active Abandoned
- 2005-02-28 WO PCT/US2005/006342 patent/WO2005086667A2/en active Application Filing
- 2005-02-28 EP EP18173991.3A patent/EP3388521A1/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660500B2 (en) * | 1988-02-26 | 2003-12-09 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
US5874087A (en) * | 1991-04-19 | 1999-02-23 | Axis Genetics Plc | Modified plant viruses as vectors |
US5677274A (en) * | 1993-02-12 | 1997-10-14 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Anthrax toxin fusion proteins and related methods |
US5958422A (en) * | 1994-07-13 | 1999-09-28 | Axis Genetics Plc | Modified plant viruses as vectors of heterologous peptides |
US6232099B1 (en) * | 1994-10-18 | 2001-05-15 | Scottish Crop Research Institute | Method of producing a chimeric protein |
US6042832A (en) * | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
US6730306B1 (en) * | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
US20030018557A1 (en) * | 2001-07-18 | 2003-01-23 | Gilbert James A. | Financial processing gateway structure |
US20050214321A1 (en) * | 2003-12-01 | 2005-09-29 | Dow Global Technologies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090215179A1 (en) * | 2001-07-20 | 2009-08-27 | Transalgae | Transgenically preventing establishment and spread of transgenic algae in natural ecosystems |
US20090117144A1 (en) * | 2005-07-19 | 2009-05-07 | Lada Rasochova | Recombinant flu vaccines |
WO2009019693A3 (en) * | 2007-08-07 | 2010-03-04 | Sepal Pharma Sa | Analgesic effect of jasmonate derivatives |
WO2009019693A2 (en) * | 2007-08-07 | 2009-02-12 | Sepal Pharma Sa | Analgesic effect of jasmonate derivatives |
US20100081177A1 (en) * | 2008-09-05 | 2010-04-01 | TransAlgae Ltd | Decreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide |
WO2010027516A3 (en) * | 2008-09-05 | 2010-05-27 | Jonathan Gressel | Transgenically preventing establishment and spread of transgenic algae in natural ecosystems |
US8367392B2 (en) | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
US20120219579A1 (en) * | 2009-09-18 | 2012-08-30 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
WO2011046786A3 (en) * | 2009-10-16 | 2011-09-22 | Dow Agrosciences Llc | Use of dendrimer nanotechnology for delivery of biomolecules into plant cells |
CN102686733A (en) * | 2009-10-16 | 2012-09-19 | 陶氏益农公司 | Use of dendrimer nanotechnology for delivery of biomolecules into plant cells |
US20110093982A1 (en) * | 2009-10-16 | 2011-04-21 | Dow Agrosciences Llc | Use of dendrimer nanotechnology for delivery of biomolecules into plant cells |
US8686222B2 (en) | 2009-10-16 | 2014-04-01 | Dow Agrosciences, Llc. | Use of dendrimer nanotechnology for delivery of biomolecules into plant cells |
US9181531B2 (en) | 2011-12-21 | 2015-11-10 | Apse, Llc | Process for purifying VLPs |
WO2014204667A1 (en) * | 2013-06-19 | 2014-12-24 | Apse, Llc | Compositions and methods using capsids resistant to hydrolases |
US9822361B2 (en) | 2013-06-19 | 2017-11-21 | Apse, Inc. | Compositions and methods using capsids resistant to hydrolases |
WO2016061149A1 (en) * | 2014-10-14 | 2016-04-21 | Medgenics Medical Israel Ltd. | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2005086667A2 (en) | 2005-09-22 |
CA2557668A1 (en) | 2005-09-22 |
AU2005220734A1 (en) | 2005-09-22 |
CN1926238A (en) | 2007-03-07 |
JP2007528727A (en) | 2007-10-18 |
EP1720990A4 (en) | 2008-04-30 |
US7928290B2 (en) | 2011-04-19 |
EP3388521A1 (en) | 2018-10-17 |
EP1720990A2 (en) | 2006-11-15 |
WO2005086667A3 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7928290B2 (en) | Viral capsid fusion peptide expressing plant cells | |
Mason et al. | Transgenic plants as vaccine production systems | |
Porta et al. | Cowpea mosaic virus-based chimaeras: Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses | |
AU747647B2 (en) | A process for isolating and purifying viruses, soluble proteins and peptides from plant sources | |
US6020169A (en) | Production of secreted foreign polypeptides in plant cell culture | |
DK2610345T3 (en) | RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ | |
CN103031310B (en) | Protein is expressed in plant | |
KR101956910B1 (en) | RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES(VLPs) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ | |
AU2004313458B2 (en) | Recombinant icosahedral virus like particle production in pseudomonads | |
US20070041999A1 (en) | Production of multivalent virus like particles | |
US6232099B1 (en) | Method of producing a chimeric protein | |
US20090093019A1 (en) | Production and in vivo assembly of soluble recombinant icosahedral virus-like particles | |
EP1534834A2 (en) | Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof | |
EP1522585A1 (en) | Chimeric carrier molecules for the production of mucosal vaccines | |
JP4769977B2 (en) | Vaccine gene introduction rice | |
JP2003230379A (en) | Resistivity to virus and viroid in transgenic plant and animal host expressing double strand rna-binding protein | |
CZ20021303A3 (en) | Viral particles with exogenic epitopes inside a particle | |
Yusibov et al. | Plant viral expression vectors: history and new developments | |
Yusibov et al. | Chapter Four Expression of foreign sequences in virus-infected plants using alfalfa mosaic virus coat protein | |
Ahmad | Molecular Farming: Production of Pharmaceuticals in Transgenic Tobacco | |
Alli | The assembly of hepatitis B virus core particles in transgenic tobacco, carrot and rice plants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DOW GLOBAL TECHNOLOGIES INC., MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE DOW CHEMICAL COMPANY;REEL/FRAME:019482/0978 Effective date: 20070607 |
|
AS | Assignment |
Owner name: THE DOW CHEMICAL COMPANY, MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RASOCHOVA, LADA;DAO, PHILIP P.;REEL/FRAME:020172/0813 Effective date: 20040305 |
|
AS | Assignment |
Owner name: PFENEX, INC.,CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOW GLOBAL TECHNOLOGIES, INC.;THE DOW CHEMICAL COMPANY;REEL/FRAME:023922/0301 Effective date: 20091222 Owner name: PFENEX, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOW GLOBAL TECHNOLOGIES, INC.;THE DOW CHEMICAL COMPANY;REEL/FRAME:023922/0301 Effective date: 20091222 |
|
AS | Assignment |
Owner name: DOW GLOBAL TECHNOLOGIES, MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PFENEX INC.;REEL/FRAME:025162/0363 Effective date: 20100917 Owner name: DOW AGROSCIENCES LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOW GLOBAL TECHNOLOGIES INC.;REEL/FRAME:025302/0251 Effective date: 20100927 |
|
AS | Assignment |
Owner name: DOW GLOBAL TECHNOLOGIES LLC, MICHIGAN Free format text: CHANGE OF NAME;ASSIGNOR:DOW GLOBAL TECHNOLOGIES INC.;REEL/FRAME:026047/0372 Effective date: 20101231 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |